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FOCUS AREA I: SURVEILLANCE 
ACTION ITEM #1 
PROJECT TITLE: PUBLIC HEALTH SURVEILLANCE 
•	 Action Item(s): #1
•	 Project Type: Ongoing 
•	 Agency: CDC, FDA, DoD, VA 
•	 Description: Organisms currently under public health surveillance for antimicrobial 
resistance include: Campylobacter, E. coli O157:H7, Gram negative and Gram positive 
organisms causing health care associated infections, group A Streptococcus, group B 
Streptococcus, Haemophilis influenzae, Helicobacter pylori, HIV, Influenza, Malaria, 
Mycobacterium tuberculosis, Neisseria gonorrhoeae, Neisseria meningitidis, Salmonella, 
Shigella, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, 
Trichomonas vaginalis, and Vancomycin Resistant Enterococcus. Organisms are added 
to this list when resistance emerges as a public health problem, as tools are developed 
for detecting resistance, and when there is capacity at the appropriate level. 
•	 2008 Update: In 2008, CDC’s Active Bacterial Core surveillance, part of the Emerging
Infections Program Network, tracked MRSA as well as serious infections caused by
resistant strains of groups A and B streptococcus, H. Influenzae, N. meningitidis, S. 
pneumoniae, and Clostridium difficile. Surveillance summaries are available at 
http://www.cdc.gov/ncidod/dbmd/abcs/survreports.htm. CDC’s National Healthcare 
Safety Network (NHSN) published a report 
(http://www.cdc.gov/nhsn/PDFs/AR_report2008.pdf) to describe the frequency of 
selected antimicrobial resistance patterns among pathogens causing device-associated 
and procedure-associated healthcare-associated infections (HAIs). As many as 16% of 
all HAIs were associated with the following multidrug-resistant pathogens: methicillin-
resistant S. aureus (8% of HAIs), vancomycin-resistant Enterococcus faecium (4%), 
carbapenem-resistant P. aeruginosa (2%), extended-spectrum cephalosporin-resistant 
Klebsiella pneumoniae (1%), extended-spectrum cephalosporin-resistant E. coli (0.5%), 
and carbapenem-resistant A. baumannii, K. pneumoniae, K. oxytoca, and E. coli (0.5%). 
Continuing service activity providing testing and advice for treatment of resistant
trichomoniasis. Collation of 2002-2008 data suggests successful treatment of > 80% of 
patient who had failed at least 2 rounds of standard therapy. In regards to Trichomonas 
vaginalis, over 100 testing kits were distributed to 84 clinics/physicians with patients who 
had failed standard therapy for trichomoniasis. In 2008 several new tests were cleared by 
FDA to enhance surveillance efforts of multi-drug resistance organisms. On September 
24, 2008, FDA cleared a new nucleic acid amplification test (NAAT) for detection of 
Methicillin Resistant Staphylococcus aureus (MRSA) in patients with skin and soft tissue 
infection and on September 29, a similar NAAT for detection of MRSA in blood cultures of 
febrile patients. Also cleared in 2008, (December 19) was the first NAAT for the detection
of Clostridium difficile toxin B in liquid or soft stool specimens from patients suspected of 
having Clostridium difficile – associated disease.  
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PROJECT TITLE: BURDEN OF DISEASE DUE TO ANTIMICROBIAL RESISTANT NOCARDIA 
SPECIES (2007-2009) 
•	 Action item(s): #1 
•	 Project Type: New 
•	 Agency: CDC 
•	 Description: This is a collaborative project with 10 states to detect and monitor trends in 
emerging antimicrobial resistance among disease-causing Nocardia species. Sites collect
and send to CDC Nocardia isolates for work-up and antimicrobial susceptibility testing.  
Clinical and epidemiologic data is collected and forwarded to CDC using a standard 
surveillance tool, including information on recent antimicrobial agent use and previous 
diagnostic cultures or susceptibility profiles for each patient from the cachement area.  
CDC will evaluate Nocardia data to estimate US burden of illness due to Nocardia, 
susceptible/resistant species, estimate cost per illness, and antimicrobial use patterns.    
•	 2008 Update: CDC collected isolates and clinical data from the participating state health 
departments. 226 viable Nocardia isolates were collected from the states in 2008.  
Antimicrobial susceptibility panels were completed on all isolates.   
PROJECT TITLE: ISOLATION AND CHARACTERIZATION OF FLUOROQUINOLONE­
RESISTANT BACTERIA FROM IMPORTED SHRIMP 
•	 Action Item(s): #1 
•	 Project Type: New 
•	 Agency: FDA 
•	 Description: A collaborative research project with Centers for Veterinary Medicine 
(CVM/FDA) and Office of Regulatory Affairs (ORA/FDA) was initiated. Numerous
fluoroquinolone-resistant, pathogenic bacteria such as Vibrio spp., Salmonella and E. coli 
have been isolated from imported shrimp purchased from retail stores. These isolates are 
currently being characterized at the molecular level by PCR, RFLP, PFGE, Southern 
hybridization and DNA sequencing. The molecular mechanism of fluoroquinolone­
resistance in these food borne pathogens will also be investigated. 
•	 2008 Update: Antibiograms of these bacteria indicate that many display resistance to 
multiple antimicrobials of public health significance.
ACTION ITEM #2 
PROJECT TITLE: EXPANSION AND ENHANCEMENT OF THE NATIONAL ANTIMICROBIAL 
RESISTANCE MONITORING SYSTEM (NARMS) FOR ENTERIC BACTERIA
•	 Action Item(s): #2
•	 Project Type: Ongoing
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•	 Agency: CDC, FDA, USDA
•	 Description: NARMS is a collaboration among FDA (Center for Veterinary Medicine), 
CDC and U.S. Department of Agriculture. The NARMS program has three components or 
“arms” (human, retail, and animal) from which select foodborne bacteria are 
characterized from human clinical cases, retail meats, and food animals at federally 
inspected slaughter and processing plants. Additionally, ten state laboratories, who also 
participate in FoodNet, submit a proportion of Campylobacter isolates to the CDC 
NARMS laboratory. Currently, ten participating FoodNet states plus Pennsylvania test 
grocery store meat products for the presence of select enteric bacteria and 
corresponding antimicrobial susceptibility profiles. Salmonella slaughter isolates
recovered from chickens, turkeys, cattle, and swine were submitted to the NARMS 
animal program through the USDA Food Safety and Inspection Service (FSIS) 
Salmonella HACCP, Verification Testing baseline, and risk-based sampling programs. 
•	 2008 Update: NARMS now includes all 50 states, providing national surveillance for 
antimicrobial resistance among select foodborne pathogens. Campylobacter sampling in 
the ten FoodNet states has been changed to allow for burden estimates and a plan is 
underway for further expanding to more sites. One site sends generic E. coli and three 
sites send Enterococcus sp isolated from outpatient stools to CDC NARMS for 
antimicrobial susceptibility testing. FDA, CDC, and USDA NARMS staff also met in 
Athens, GA, September 10-12, 2008 for a laboratory methods and strategic planning 
conference to discuss progress and future plans related to implementation of the 
recommendations put forward in the FDA Science Board Summary report. Additional 
funds and partnerships were sought to extend surveillance to include additional 
antimicrobial agents (beta-lactams and macrolides) and pathogens (clostridia and 
methicillin-resistant Staphylococcus aureus in retail foods). Developed a DNA microarray 
to identify and track 775 resistance and virulence genes in a variety of bacteria 
simultaneously. Resistance and virulence genes in Campylobacter, Salmonella, E. coli, 
Enterococcus, Staphylococcus (including MRSA), Listeria and Clostridium have been 
identified using the microarray. Analysis of bacteria collected on-farm with this technique 
has identified common genes in different species of bacteria co-cultured from the same 
animal.
PROJECT TITLE: COORDINATION OF SURVEILLANCE EFFORTS
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC, FDA
•	 Description: Coordinate surveillance activities.  
•	 2008 Update: In 2007 the NARMS program was subjected to an extensive review by the 
FDA Science Board, focusing on 4 major areas: sampling strategies, data reporting and 
harmonization, coordinated research, and international surveillance activities. FDA 
responded to the Board’s recommendations, and is prioritizing recommendations for 
improving the program. Strategic planning and methods harmonization meetings were 
held in September 2007 and September 2008 focusing on progress and future plans to 
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implement the Science Board recommendations where appropriate. These meetings 
have been and will continue to be held annually. As of the end of calendar year 2008, 
NARMS published two executive summaries of food animal, retail meat and human 
isolate susceptibility data collected by USDA, FDA-CVM and CDC, respectively, for 
calendar years 2003 and 2004. The three NARMS partner agencies began to explore 
business practices and electronic infrastructure that would facilitate efficient data sharing 
and presentation. NARMS does not currently screen for MRSA but has been working with 
partners at the University of Maryland to conduct a pilot study looking for MRSA in retail 
meats in the Washington, DC metro area. NARMS scientists from FDA, CDC, and USDA, 
were appointed in 2008 to serve on the steering committee of the newly established 
WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (WHO­
AGISAR). The primary focus of AGISAR will be to exchange information and expertise in 
all matters relating to antimicrobial resistance surveillance programs globally. 
PROJECT TITLE: ENHANCED SURVEILLANCE FOR MULTIDRUG-RESISTANT (MDR TB) 
AND EXTENSIVELY DRUG RESISTANT TUBERCULOSIS (XDR TB) IN THE UNITED 
STATES. SUPPLEMENTAL FUNDED PROJECT FOR 4 TB PROGRAMS
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The purpose of this pilot exercise is to provide additional surveillance data 
for TB cases reported as MDR or XDR. Data not currently collected on the Report of a 
Verified Case of TB (RVCT), such as additional drug susceptibility test results, culture 
results, treatment and outcome data and information about hospitalization, are requested 
from 4 TB programs (CA, NYC, FL, TX), which provide about 55% of the reported MDR 
TB cases in the U.S. The results of this pilot will provide important additional clinical and 
diagnostic information on MDR TB. It will also inform CDC on how a nationwide 
supplemental registry for MDR/XDR TB would work, what information we can expect to 
collect, and the usefulness and reliability of that information.  
•	 2008 Update: Data collection was completed in August 2008, and data cleaning was 
completed in April 2009. Data analysis and report writing are ongoing, with an expected 
date of completion of September 2009. 
PROJECT TITLE: TREATMENT PRACTICES, OUTCOMES AND COST OF MULTIDRUG­
RESISTANT (MDR TB) AND EXTENSIVELY DRUG RESISTANT TUBERCULOSIS (XDR TB) 
IN THE UNITED STATES
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The purpose of this descriptive study is to provide detailed observational 
data on the diagnosis, treatment and management practices, outcomes, and costs of 
MDR and XDR TB patients in the United States. The study aims to collect data from 
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multiple sites that are generalizable to the U.S. population of MDR and XDR TB cases.   
Inpatient, outpatient, laboratory, and public health clinic records will be abstracted from 
approximately 134 patients reported to the Centers for Disease Control and Prevention 
(CDC) for the study period of 2005-2007. Costs will be collected or estimated to calculate 
inpatient, outpatient, and total costs per patient. 
•	 2008 Update: Project was awarded to three sites (the Departments of Health for 
California, Texas, and New York City) in November 2008. The study protocol and data 
collection instruments were drafted by June 2009 and are under CDC Institutional
Review, after which the awarded sites will seek local IRB approval to begin data 
collection.
PROJECT TITLE: FEDERAL TB TASK FORCE RESPONSE TO EXTENSIVELY DRUG­
RESISTANT (XDR) TB 
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC, NIH, FDA, HRSA, USAID, DoD, DOHS, VA 
•	 Description: In November of 2006, the Federal TB TF convened to discuss the possible 
U.S. government response to the global threat of XDR TB. It was decided that the TB TF 
would draft an action plan describing the potential U.S. government (USG) response to 
XDR domestically and internationally. The TB TF divided into 8 workgroups to draft each 
section (Surveillance, epidemiology and outbreak investigation; laboratory; infection 
control; clinical and programmatic; research; communications and education; 
partnerships; and cost analysis). The 1992 National Action Plan to Combat MDR TB was 
used as a model. In April 2007, an initial draft was completed and is undergoing review. 
•	 2008 Update: The action plan was completed, cleared and submitted for publication in 
2008.
PROJECT TITLE: AN ANALYSIS OF MOLECULAR EPIDEMIOLOGY OF MULTI-DRUG 
RESISTANT M. TUBERCULOSIS IN THE UNITED STATES
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The purpose of this research project is to develop a comprehensive 
national tuberculosis (TB) genotyping registry for TB case-patients with multidrug­
resistant M. tuberculosis (MDR-TB) and to assess the molecular epidemiology of MDR­
TB in the United States (U.S.). Through this investigation, the Division of TB Elimination 
(DTBE) at the Centers for Disease Control and Prevention (CDC) will work with 14 
selected U.S. TB Epidemiologic Studies Consortium (TBESC) sites to collect
epidemiologic and genotyping data from all MDR-TB case-patients in the U.S. This will be 
a five-year cross-sectional population based study design where recruitment and data 
collection are handled prospectively starting on October 1, 2005 through 2010.   
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•	 2008 Update: Project has enrolled 79 patients at 9 consortium sites. Data cleaning and 
preliminary analyses are underway. Abstracts to be presented at the International Union 
Against TB and Lung Disease Annual Conference in December 2009. 
PROJECT TITLE: NATIONAL TUBERCULOSIS SURVEILLANCE SYSTEM (NTSS) 
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Ongoing collection, analysis, and communication of national tuberculosis
surveillance information; expanded in 1993 to include the frequency and type of
antimicrobial resistance, enabling strategically focused tuberculosis control and 
elimination efforts. The expanded national TB surveillance system has proven its 
usefulness in assisting in the evaluation of the success of TB control efforts and 
monitoring the status of the epidemic, particularly through the collection of data on initial 
drug susceptibility. Information on the use of initial regimens of four first-line drugs, 
directly observed therapy, and completion of therapy in one year or less have been used 
as measures to evaluate program success. As future efforts towards TB elimination 
increase, both existing and new surveillance systems at the national, state, and local 
levels will become even more critical to monitor the burden and impact of TB, evaluate 
the success of control and prevention efforts, and direct planning and policy 
development. 
•	 2008 Update: Data collection and analysis are conducted on a continuous basis. The 
proportion of patients with primary MDR TB decreased from 2.5% in 1993 to 1.0% in 
2001. From 2001 to 2008, the most recent year for which data are available, the 
proportion has remained between 1.0% – 1.2% (all cases were culture positive with initial 
drug susceptibility testing performed). MDR TB differed by country of origin. In 2008, the 
percentage of U.S.-born persons with MDR was 0.6 %. The percentage of foreign-born 
persons with MDR was greater, at 1.2%. Of the total number of reported MDR TB cases, 
the proportion occurring in foreign-born persons increased from 25% in 1993 to 77% in 
2008. The CDC annual TB surveillance report, Reported Tuberculosis in the United 
States, 2008, will provide detailed summaries of anti-TB drug resistance from the national 
surveillance data. This report and other publications and recommendations based on 
these data are available on the internet: http://www.cdc.gov/tb/statistics/default.htm. 
PROJECT TITLE: GONOCOCCAL ISOLATE SURVEILLANCE PROJECT (GISP) 
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC, DoD
•	 Description: Sentinel surveillance system for monitoring antimicrobial resistance of 
Neisseria gonorrhoeae in the US was established in 1986. Male urethral gonococcal 
isolates are submitted for susceptibility testing together with clinical and demographic 
patient data each month from STD clinics in 25-30 cities in the US. GISP data are 
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published in an annual report, periodically in the MMWR, and other peer-reviewed 
journals. GISP annual reports from 1998-2007 can be found at 
http://www.cdc.gov/std/gisp. GISP data have demonstrated the ongoing and increasing
spread of fluoroquinolone-resistance N. gonorrhoeae and the emergence of N. 
gonorrhoeae with decreased susceptibility to azithromycin in the U.S. Currently, there is 
only one class of antibiotics that is recommended and available for treatment of all 
gonococcal infections in the US. With the continued decrease in the capacity for 
local/state public health laboratories to maintain culture capacity and to perform local 
antimicrobial susceptibility testing, GISP data have become even more important. 
•	 2008 Update: In 2007, 27% of all GISP isolates were resistant to penicillin, tetracycline, 
ciprofloxacin, or some combination of those antibiotics. Prevalence of ciprofloxacin­
resistant gonococcal isolates remains high at 14.8%. No isolates had decreased
susceptibility to ceftriaxone. There is a steady increase in isolates that show decreased 
susceptibility to azithromycin. Similar trends continued in 2008. The DoD Global
Emerging Infections Surveillance and Response System (DoD-GEIS) is currently trying to 
re-invigorate the military labs participating in GISP to include Trippler Army Medical 
Center Hawaii, the Navy lab in Peru as well the Army lab in Kenya. 
PROJECT TITLE: ENHANCEMENT OF INTERNATIONAL SURVEILLANCE FOR 
ANTIMICROBIAL RESISTANCE IN NEISSERIA GONORRHOEAE TO PREDICT POTENTIAL 
EMERGENCE OF CEPHALOSPORIN RESISTANCE IN THE UNITED STATES
•	 Action Item(s): #2
•	 Project Type: New
•	 Agency: CDC
•	 Description: CDC/DSTDP will collaborate with WHO via financial and technical support 
to maintain its regional GC-resistance surveillance programs and to strengthen the 
laboratory/epidemiological capacity of countries, particularly in the Far East, to monitor 
the potential emergence of Ceph-resistant GC. The project will obtain early alerts of 
cephalosporin treatment failures detected in WHO member countries and establish a 
system for expedited sharing with CDC of information, research findings and gonococcal 
strains for laboratory studies. In addition, CDC with WHO will organize an international 
forum to share information on emerging problems of antimicrobial resistance in N. 
gonorrhoeae and formalize international approaches to respond to this significant public 
health problem. Domestically, to complement these international efforts, the project will 
expand susceptibility testing in Hawaii and build gonococcal culture and susceptibility 
testing capacity in Guam in order to provide a domestic “early warning system” for Ceph­
resistant GC.
•	 2008 Update: Collaboration with WHO established and project planning initiated.  
PROJECT TITLE: FORMULATION OF A CEPHALOSPORIN-RESISTANT (CEPH-R) 
NEISSERIA GONORRHOEAE NATIONAL OUTBREAK RESPONSE PLAN 
•	 Action Item(s): #2 
•	 Project Type: New
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•	 Agency: CDC
•	 Description: CDC/DSTDP will formulate a comprehensive national and state-level public
health response plan to ensure the early detection of emerging cephalosporin-resistant 
N. gonorrhoeae cases and to prevent rapid spread of these strains through 
implementation of public health containment strategies in the United States. The project 
components include promoting awareness of clinicians of the threat of cephalosporin-
resistant N. gonorrhoeae and to increase vigilance of cephalosporin treatment failures, 
development and pilot implementation of the outbreak response plan in a selective 
domestic sites and step-wise expansions to develop State-specific response plan. 
•	 2008 Update: Project planning initiated.
PROJECT TITLE: AZITHROMYCIN RESISTANCE IN SYPHILIS IN THE UNITED STATES
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: This sentinel surveillance project for monitoring azithromycin-resistant 
syphilis in the United States was initiated in early 2008. Residual clinical specimens from
genital ulcers and other moist lesions from men and women, along with demographic 
data, are submitted to CDC from STD clinic sites in 11 cities. Specimens are tested by 
PCR for Treponema pallidum. When positive, the DNA is screened for mutations in 23S 
RNA associated with resistance to azithromycin. The objectives are to monitor and track 
the epidemiology of azithromycin-resistant syphilis for each participating geographic 
locale. 
•	 2008 Update: At the end of 2008, CDC had received and tested a total of 494 samples 
from participating sites: 21% were positive for T. pallidum, of which 54% carried the 23S 
mutation. Notably, samples carrying the 23S mutation came from 9 of 11 sites. 
Preliminary analysis indicated that samples carrying the 23S mutation more likely came 
from men having sex with men than from heterosexual men or women. 
PROJECT TITLE: SURVEILLANCE FOR HIV DRUG RESISTANCE 
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: CDC maintains a national surveillance system that provides data for 
national, state, and local public health HIV prevention program planning and evaluation.  
The variant, atypical, and resistant HIV surveillance (VARHS) system is an extension of 
CDC’s HIV/AIDS reporting system in select surveillance areas. It uses remnant HIV 
diagnostic sera or plasma to amplify and sequence relevant genes of the HIV pol region 
and collects electronic amino acid sequence data from private laboratories performing 
genotyping to evaluate HIV-1 drug resistance and HIV-1 subtypes and associated factors 
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among persons newly diagnosed and reported with HIV. Data will be useful for future 
evaluations of trends associated with the transmission of HIV drug resistant mutations 
and subtype distribution. Ongoing data collection and analyses through routine
surveillance also will inform HIV prevention and treatment program planning and vaccine 
development efforts and alert to the spread or clustering of atypical strains.  
•	 2008 Update: National surveillance for HIV drug resistance is ongoing. Currently (2008), 
eleven (11) surveillance areas (8 states, 2 cities, and 1 county) are funded to participate.
PROJECT TITLE: HIV RESISTANCE NETWORK (HIVRESNET, INTERNATIONAL 
LABORATORY BRANCH, DIVISION OF GLOBAL AIDS, NCHHSTP)
•	 Action Item(s): #2 
•	 Project Type: Ongoing
•	 Agency: CDC, WHO, Academic institutions
•	 Description: HIVResNet have developed a global strategy for HIV drug resistance 
prevention, surveillance and monitoring. The strategy aims to build evidence on the scale 
of HIV drug resistance and equip and prepare countries with knowledge, skills and 
systems to respond should HIV drug resistance epidemics emerge.
•	 2008 Update: HIVResNet has developed laboratory guidelines on HIV drug resistance 
using dried blood spot samples. In the process of developing laboratory networks at 
different levels to meet the need of HIV drug resistance surveillance and monitoring 
around the world. A DBS protocol development update meeting was held by WHO in 
December 2008 and based on the recent publications at the time, the protocol was 
further modified. Discussions were held to identify urgently needed research and data. 
Based on the discussions, WHO, Uganda, and CDC ILB will collaborate and conduct a 
comprehensive study on DBS and the SDRL will conduct in-house assay validation using 
DBS. The DBS evaluation project is on going and the in-house assay validation using 
DBS is going to start in September. 
PROJECT TITLE: TRICHOMONAS VAGINALIS ANTIMICROBIAL SUSCEPTIBILITY IN THE 
UNITED STATES, STD SURVEILLANCE NETWORK (SSuN)
•	 Action Item(s): #2 
•	 Project Type: New
•	 Agency: CDC
•	 Description: This sentinel surveillance activity was designed to evaluate the prevalence 
of T. vaginalis susceptibility to 5-nitroimidazoles, the only class of antimicrobial agents 
currently recommended for treatment of trichomoniasis in the US. The activity is 
conducted as part of the STD Surveillance Network (SSuN), a multi-site sentinel
surveillance system. The T. vaginalis susceptibility activity was initiated in 2009 and is 
projected to continue through 2010. STD clinics in 6 cities transmit clinical and 
demographic data and submit female vaginal T. vaginalis isolates to CDC for 
susceptibility testing. Isolates are tested for antimicrobial susceptibility to metronidazole 
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and tinidazole. These data will be used to assess national and regional prevalence of 
drug resistance and evaluate the epidemiology of drug resistance at participating sites. 
•	 2008 Update: Specimen and data collection are ongoing.
PROJECT TITLE: SURVEILLANCE FOR EMERGING ANTIMICROBIAL RESISTANCE 
CONNECTED TO HEALTHCARE (SEARCH)
•	 Action Item(s): #2
•	 Project Type: Ongoing 
•	 Agency: CDC
•	 Description: The SEARCH program started as a network of voluntary participants (i.e., 
hospitals, private industries, professional organizations, and state health departments) to 
enhance detection and reporting of vancomycin-resistant Staphylococcus aureus
(VRSA). All U.S. healthcare organizations and practitioners are encouraged to report 
such isolates to CDC through SEARCH and, after notifying their state health department, 
to send the isolates to CDC for confirmatory testing.
•	 2008 Update: As of August 2009, CDC has confirmed 9 VRSAs in the U.S. 
PROJECT TITLE: ENHANCED COLLECTION AND ELECTRONIC TRANSFER OF DATA ON 
ANTIMICROBIAL USE AND RESISTANCE (AUR)
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: A cooperative study of enhanced collection, compilation, and transmission 
of data on antimicrobial use and resistance from automated laboratory instrumentation 
systems in healthcare settings to CDC and other public health systems using architecture 
fully compatible with the Public Health Information Network (PHIN). This will create a 
database that will facilitate benchmarking and performance feedback to promote local AR 
improvement efforts; development of regional, state, and national data about patterns of 
use and resistance; and evaluation of prevention programs. 
•	 2008 Update: During 2008, microbiology, pharmacy and admission/discharge/transfer 
(ADT) data in the electronic HL7 Version 2.5 message format were received from pilot 
healthcare facilities. The validation of these data in the medications-associated module of 
the National Healthcare Safety Network continues. Expansion to additional hospitals has 
begun. 
PROJECT TITLE: SURVEILLANCE FOR INVASIVE METHICILLIN-RESISTANT 
STAPHYLOCOCCUS AUREUS THROUGH THE ACTIVE BACTERIAL CORE SURVEILLANCE 
(ABCS), EMERGING INFECTIONS PROGRAM
•	 Action Item(s): #2
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•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: ABCs, part of CDC's Emerging Infections Program, conducts ongoing, 
active, population-based surveillance for invasive pathogens, including MRSA, in 
selected areas of the United States. Population-based surveillance occurs at 9 ABCs 
sites (California, Colorado, Georgia, Maryland, Minnesota, New York, Oregon and 
Tennessee) for both community-associated and healthcare-associated invasive MRSA 
disease. Data collected are used to determine incidence rates for invasive MRSA 
disease, detect at-risk populations, and explore strain characteristics through collection of 
MRSA isolates. A convenience sample of isolates collected as part of this activity 
(approx. 1000/ year) are submitted to CDC for confirmation, typing and characterization.
•	 2008 Update: In 2008, two surveillance sites expanded. Maryland now includes the 
Baltimore metro area and Minnesota includes 2 counties for a total population under 
surveillance of approximately 18 million persons. All cases of invasive MRSA reported 
during 2005-2007 were analyzed, population based incidence rates were calculated and 
annual summaries were completed 
(http://www.cdc.gov/ncidod/dbmd/abcs/survreports.htm). A preliminary analysis of trends 
in invasive disease between 2005 through 2007 were performed and demonstrate a 20% 
decrease in incidence among hospitalized patients, and a more modest decrease among 
other types of patients. A survey of 80% of participating facilities identified a variety of 
MRSA prevention programs in place. Analysis of 1984 isolates collected during 2005­
2006 as part of the  ABCs MRSA activity was completed, including PFGE typing, PCR for 
toxin genes, antimicrobial susceptibility testing. Ref: J Clin Microbiol. 2009
May;47(5):1344-51..
PROJECT TITLE: SURVEILLANCE OF MULTI-DRUG RESISTANT INFECTIONS THROUGH 
NATIONAL HEALTHCARE SAFETY NETWORK (NHSN)
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Surveillance of healthcare associated infections and their antimicrobial 
resistance patterns.
•	 2008 Update: The first NHSN Antimicrobial Resistance Report was published in
November, 2008 in infection control and hospital epidemiology. Analysis of trends 
includes incidence of MRSA central line bloodstream infection published in August in 
JAMA demonstrated an overall annual 8% decrease in the incidence of MRSA central-
line associated bloodstream infections over the past decade. Development and
implementation of a new module to monitor multi-drug resistant pathogens was 
developed, tested, and launched for use in 2009 for use by the CMS QIO network in a 
national MRSA prevention effort.  
PROJECT TITLE: ASSESSING PREVENTION MEASURES FOR ANTIMICROBIAL 
RESISTANT INVASIVE PNEUMOCOCCAL DISEASE
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•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Streptococcus pneumoniae is a common cause of pneumonia, meningitis, 
and otitis media in the U.S. Incidence of drug-resistant S. pneumoniae increased steadily 
during the 1990s but then decreased after the introduction of pneumococcal conjugate 
vaccine (PCV7) in 2000. CDC's Active Bacterial Core surveillance (ABCs) has followed
trends in invasive pneumococcal disease (IPD) to evaluate the impact of PCV7
introduction. This project has five goals: 1. Assess and improve use of pneumococcal 
conjugate vaccines; 2. Evaluate trends in outpatient antibiotic use for drugs likely to 
select for DRSP; 3. Monitor trends in DRSP using conventional and molecular means to 
inform the development of new pneumococcal vaccines and monitor effect of prevention 
measures; 4. Develop PCR-based approaches for detecting antibiotic resistant 
pneumococci; 5. Provide ABCs data to partners developing or evaluating prevention 
measures.
•	 2008 Update: Held monthly conference calls with ACIP Pneumococcal Working Group to 
identify key areas of existing pneumococcal vaccine recommendations in need of
updating; 2. Used ABCs data to evaluate the potential usefulness of new pneumococcal 
vaccines with varying activity against pneumococcal colonization vs. disease; 3. 
Estimated that since conjugate vaccine was introduced, over 210,000 cases of invasive 
disease and 14,000 deaths were prevented; 4. Determined that effects on hospitalized 
pneumonia are a key driver of the cost-effectiveness of conjugate vaccine and that, when 
such effects are incorporated, conjugate vaccine may be cost-saving; 5. Used ABCs data 
to evaluate different strategies for using pneumococcal polysaccharide vaccine among 
persons with underlying illnesses and determined that current vaccination policies are 
appropriate.   
PROJECT TITLE: NATIONAL MOLECULAR SURVEILLANCE OF ANTIBIOTIC-RESISTANT 
STREPTOCOCCUS PNEUMONIAE
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The Respiratory Diseases Branch (RDB) and our collaborators at the 
Emory Rollins School of Public health will establish a national laboratory for the molecular 
surveillance of invasive Streptococcus pneumoniae (Spn). We will provide front-line 
information concerning established and newly emerging antibiotic resistance 
mechanisms, clonal types, and serotypes of ABCs Spn isolates. We will monitor effects 
of currently used vaccines and antibiotics on the emergence and distribution of antibiotic-
resistant strains.
•	 2008 Update: Since introduction of the 7 valent conjugate vaccine (PCV7), serotype 19A 
has become the predominant invasive serotype and the primary source of antibiotic 
resistance; multilocus sequence typing (MLST) indicates that this is due to the 
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emergence of new resistant 19 A variants and that serotype switching has played an 
important role (1). The proportion of beta-lactam resistant strains within serotype 19A
continues to increase, and this is due to continued preferential expansion of recently 
identified 19A strains (1, manuscript in preparation). We have also noted increases in 
antibiotic-nonsusceptible strains of additional serotypes not targeted by PCV7 and are 
completing MLST analysis of these strains. The newly discovered serotype 6C is of 
concern since it is not targeted by PCV7 and is increasing in resistance (2,3). We 
characterized (identification of resistance-conferring chromosomal alterations and MLST) 
current ABCs strains resistant to existing cephalosporins and found that ceftaroline (a 
new cephalosporin in development) was highly potent against these strains (4).
1. Moore MR et al. J. Infect. Dis. 2008. 197:1016-27.      
2. Park IH et al. J. Infect. Dis. 2008. 198: 1818-22.      
3. Carvalho Mda G et al. J. Clin. Microbiol. 2009. 47:554-9.        
4. McGee L et al. Antimicrob. Agents Chemother. 2009. 552-6.  
PROJECT TITLE: NATIONAL SURVEILLANCE FOR THE IMPACT OF PNEUMOCOCCAL 
CONJUGATE VACCINE USE AND APPROPRIATE ANTIBIOTIC USE CAMPAIGNS ON
DRUG-RESISTANT STREPTOCOCCUS PNEUMONIAE
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: CDC's Active Bacterial Core surveillance (ABCs) is a high-quality, active, 
population-based system operating in 10 states with a population of over 20 million 
persons under surveillance. ABCs has tracked drug-resistant S. pneumoniae since 1995, 
collecting approximately 3000 invasive disease strains yearly for susceptibility testing and 
serotyping. Data analyses by serotype can evaluate the ongoing impact of conjugate 
vaccine use on resistance; by linking to data on antibiotic use inferences can also be 
made about a possible impact of appropriate use measures. ABCs is CDC's main system 
for tracking drug-resistant pneumococcus and the impact of interventions.
•	 2008 Update: In 2008, approximately 3000 cases of invasive disease were identified 
through ABCs and serotyping and susceptibility testing of isolates is nearing completion.  
In addition, during 2008, multiple presentations of 2007 ABCs data were made at national 
and international meetings including CDC’s Advisory Committee on Immunization 
Practices, ICAAC, ASM, IDSA, and the International Symposium on Pneumococci and 
Pneumococcal Diseases (ISPPD). 
PROJECT TITLE: CHARACTERIZATION OF MUTATIONS IN GROUPS A AND B
STREPTOCOCCI CAUSING DECREASED SUSCEPTIBILITY TO PENICILLIN 
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
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•	 Description: Our primary objective is to screen invasive GAS and GBS isolates collected 
by the Active Bacterial Core surveillance (ABCs), a multistate population-based 
surveillance system, for susceptibility to beta-lactam agents and to characterize isolates
that express unusually high MICs. These organisms could be accumulating combinations
of mutations required for full resistance to penicillin. In S. pneumoniae, changes within 3 
key penicillin binding protein (PBP) genes, pbp1a, pbp2x, and pbp2b lead to resistance to 
beta-lactam agents. Our immediate objective is to examine key PBP gene sequences 
from 41 national surveillance isolates (40 GBS, 1 GAS) identified so far with elevated 
MICs to identify the molecular genetic basis of these phenotypes and to prospectively 
monitor for potential emergence of this phenotype among invasive GAS and GBS in the 
United States. 
•	 2008 Update: We identified three different penicillin binding protein (PBP) gene 
mutations in invasive GBS isolates recovered during 1999-2005 that were putatively 
responsible for elevated MICs to beta lactam antibiotics. With one key pbp2X mutation, 
seen to occur within multiple invasive isolates, wild type MICs were restored after gene 
replacement with the wild type allele and after expression of the wild type allele in-trans 
on a multicopy plasmid (1). Interestingly, this mutation exactly corresponds to a well-
characterized pneumococcal mutation that confers beta lactam resistance. Similar 
experiments are ongoing with a second nonconservative (Gly406 change to Asp) pbp2X
mutation identified within multiple isolates and a potential resistance-conferring pbp1A
allele. We red-flagged 32 invasive GBS and 6 GAS recovered during 2006-present using 
beta lactam MIC criteria and retested penicillin MICs. Of these 32, 2 were group D, and 
for 14 the penicillin retests showed MICs below the red flag levels. Sequencing is
ongoing of the 3 key PBP genes from the 16 verified GBS strains and 3 new causative 
mutations have been putatively identified. Of 6 red-flagged GAS, 5 penicillin MIC repeats 
were below red flag level and 1 was not S. pyogenes.
1. Dahesh S. et al. 2008. Antimicrob Agents Chemother. 52:2915-8.
PROJECT TITLE: SURVEILLANCE AND DETECTION OF ANTIMICROBIAL RESISTANT 
INVASIVE FUNGAL INFECTIONS AMONG STEM CELL AND LUNG TRANSPLANT 
RECIPIENTS
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Goals of this project are to detect and monitor trends in emerging 
antimicrobial resistance among invasive fungal infections, and develop a collection of 
such strains for applied research by CDC and other researchers. There are currently six 
transplant centers involved in a sentinel network collecting surveillance data and fungal 
isolates, related to invasive fungal infections among persons who have received stem cell 
or lung transplants. This population is at highest risk for anti-fungal resistant Candida
spp. and mold infections. There is no current system to track emerging anti-fungal 
resistance among fungal infections nationally.  
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•	 2008 Update: University of Pittsburgh, Washington University, Cleveland Clinic, 
University of Alabama, University of Michigan, and the University of Pennsylvania are 
currently contributing to surveillance. Patient enrollment into the cohort began in April 
2006 and ended December 31, 2008. Patients are being followed for 30 months after 
enrollment. A total of 676 patients have been enrolled (386 stem cell and 290 lung
transplants). There have been a total of 55 invasive fungal infections in 49 patients (29 
IFIs in stem cell transplants; 26 in lung transplants). Antifungal susceptibility analysis is
ongoing.
PROJECT TITLE: MRSA DISEASE IN ALASKA 
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Laboratory surveillance was established to collect isolates from the first 5 
MRSA infections each month in two sites: rural southwest where MRSA comprises 85% 
of all S. aureus infections and at the Alaska Native Medical Center in- and outpatient 
services, where 50% of S. aureus infections are due to MRSA.  
•	 2008 Update: Isolates of MRSA from southwest Alaska are predominantly ST1 or 
USA400. This differs from the predominant strain in the rest of the US and in Anchorage 
which is ST8 or USA300. Ref. Emerg Infect Dis. 2008 Nov;14(11):1693-9.
PROJECT TITLE: ALASKA SENTINEL SURVEILLANCE FOR ANTIMICROBIAL 
RESISTANCE IN HELICOBACTER PYLORI ISOLATES FROM ALASKA NATIVES
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC 
•	 Description: The Alaska H. pylori surveillance is a sentinel lab-based system that serves
hospitals located in five regions of Alaska. Gastric biopsies are obtained from patients 
undergoing routine diagnostic esophagogastroduodenoscopy (EGD), and sent to the 
CDC Arctic Investigations Program (AIP) laboratory for H. pylori culture and antimicrobial 
susceptibility testing. Among Alaska Natives, 80% of adults have H. pylori infection and 
gastric cancer mortality is 2-4 times higher than the general US population. 
•	 2008 Update: Ongoing specimen collection and analysis. Metronidazole resistance was 
found in 44% of persons, clarithromycin resistance in 31%, and amoxicillin resistance in 
2% persons. The proportion of resistant isolates has been stable over this time period. In 
2006, we added levofloxacin susceptibility testing and found 10% of isolates resistant, 
with resistance associated with prior fluoroquinolone use. 
PROJECT TITLE: ENHANCED SURVEILLANCE OF INFLUENZA VIRUSES FOR 
RESISTANCE TO LICENSED DRUGS AND DEVELOPMENT OF TESTS FOR RAPID 
DETECTION OF DRUG-RESISTANT STRAINS WITH PANDEMIC POTENTIAL 
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•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: In the United States, two classes of antiviral drugs are approved by the 
Food and Drug Administration for managing influenza virus infections: neuraminidase 
inhibitors (oseltamivir and zanamivir) and adamantanes (amantadine and rimantidine). 
Extensive heterogeneity of influenza viruses necessitates resistance monitoring to be 
conducted on a basis of antigenic type (A or B) and subtype (H1N1, H3N2, and H5N1). 
The 2007 influenza season was marked by the global prevalence of H3N2 viruses 
resistant to adamantanes. In addition, adamantane-resistant viruses were also detected 
among H1N1 viruses and highly virulent avian H5N1 viruses. These events have 
highlighted the need for the close monitoring of virus susceptibility to the newer class of 
drugs, neuraminidase inhibitors. This project focuses on the improvement of pandemic 
preparedness and interpandemic control of influenza via 1) development of molecular 
tests for rapid, reliable and high throughput detection of viruses resistant to both classes 
of drugs; 2) enhancement of viruses sampling for antiviral susceptibility testing; and 3) 
enhancement of reporting and sharing of antiviral susceptibility data.  
•	 2008 Update: The influenza season of 2008 was marked with the sudden and 
unprecedented emergence of oseltamivir resistance in seasonal influenza H1N1 viruses. 
It was first detected in the United States (U.S.), Australia, and Europe, particularly in 
countries where oseltamivir was not previously prescribed. All the H1N1 oseltamivir­
resistant viruses shared a single genetic mutation (H274Y) in the neuraminidase that 
confers oseltamivir resistance. In response to this event, Influenza Division, CDC, 
developed and employed a pyrosequencing assay that allowed for the detection of 
H274Y mutants directly in clinical specimens thus facilitating the testing and reporting of 
the drug susceptibility data. In addition, a restriction fragment length polymorphism 
(RFLP) protocol was developed which also allowed the detection of H274Y mutants in 
original clinical respiratory specimens. Prevalence of oseltamivir resistance varied
substantially, from 0% to 100%, among individual countries and states. Overall, 4,116 
influenza A (n=2,844) and B (n=1,272) viruses collected in the U.S. (n=2,511) and abroad 
(n=1,605) were tested at CDC during FY 2008. Oseltamivir-resistance was detected in 
12.8% of influenza H1N1 viruses collected in the U.S., which constitutes a substantial 
increase compared to the previous influenza season when the level of resistance was 
only 0.7%. No resistance to oseltamivir was identified among the 444 influenza H3N2 or 
305 influenza B viruses collected in the U.S. during the FY 2008. All tested viruses were 
sensitive to zanamivir. The results of the drug susceptibility tests were posted on the 
CDC website (FluView) and updates on oseltamivir resistance in U.S. and abroad were 
also submitted to the WHO on a weekly basis. In addition, detailed phylogenetic analysis
of the entire genome of H1N1 viruses was performed to elucidate molecular mechanisms
underlying the unexpected fitness (wide transmissibility) of the oseltamivir resistant 
viruses. The fitness as well as unchanged virulence of oseltamivir resistant viruses was 
also established in epidemiological study conducted by CDC (Dharan, NJ et al, 2009).  
Continuous testing of H5N1 viruses revealed the presence of variants with reduced 
susceptibility to either oseltamivir and/or zanamivir. These results emphasized the need 
for detailed analysis of the detected variation on clinical efficacy of the available drugs. A 














Last revised: December 29, 2009 
series of new molecular methods to detect resistance in seasonal A and B as well as
avian influenza viruses was developed at CDC and their protocols were shared with other 
virus surveillance laboratories and published in professional journals.  
In 2008, adamantane resistance continued to be high (99.8%) among the 525 influenza 
H3N2 viruses tested. Adamantane resistance among H1N1 viruses was detected at a 
lower level in the U.S. Of the 918 H1N1 viruses collected in the U.S., 98 (10.7%) were 
resistant to the adamantanes. However, adamantane-resistance remained high in some 
countries of Southeast Asia (e.g., China). None of the oseltamivir-resistant influenza 
H1N1 viruses collected in the U.S. during the 2008 season were resistant to 
adamantanes. Noteworthy, it was recognized that prevalence of adamantane resistance 
in avian H5N1 viruses varied significantly (~1% to 100%) among genetically distinct viral 
lineages circulating in different geographic regions.  
Based on the virus surveillance data, in 2008 CDC continued to recommend the use of 
oseltamivir and zanamivir for the treatment and prevention of influenza while amantadine
or rimantidine were not recommended.
PROJECT TITLE: ENHANCED SURVEILLANCE OF ANTIMICROBIAL SUSCEPTIBILITY OF 
NEISSERIA MENINGITIDIS IN THE UNITED STATES AND CHARACTERIZATION OF 
EMERGING STRAINS WITH REDUCED SUSCEPTIBLITY TO ANTIMICROBIALS   
•	 Action Item(s): #2
•	 Project Type: New
•	 Agency: CDC
•	 Description: Neisseria meningitidis (Nm) is a leading cause of meningitis and severe 
sepsis in the U.S. and prompt treatment of patients and chemoprophylaxis of close 
contacts is vital to the management of meningococcal disease. Surveillance has recently 
detected new Nm strains with reduced susceptibility to commonly employed 
antimicrobials; spread of these strains or emergence of similar strains would require 
modifications to current recommendations for chemoprophylaxis and treatment, 
increased activities to conduct susceptibility testing and the possibility of both break­
through cases (not prevented by prophylaxis) and suboptimal patient response to 
treatment. Increasing the population area covered by surveillance would enhance early 
detection of the emergence or spread of strains of Nm with reduced susceptibility to 
antimicrobials. Rapid detection and dissemination of susceptibility information is vital for 
effective surveillance.
•	 2008 Update: Funding from a previous ARWG grant allowed initiation of a surveillance 
program in 2007-2008. The Meningitis Laboratory receives all Nm isolates from the 
population-based Active Bacterial Core Surveillance (ABCs) covering 13% of the U.S. 
population and screens all incoming isolates for susceptibility to 6 antimicrobials by Etest.  
Isolates with resistant/non-susceptible MICs are confirmed by broth microdilution and the 
molecular mechanism of resistance is determined. That program made it possible for 
CDC to effectively and rapidly respond to and characterize the emergence of 
ciprofloxacin-resistant (cip-R) Nm in North America. In addition, the emergence of cip-R 
Nm in Minnesota and North Dakota changed chemoprophylaxis recommendations for 
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that area. To date the surveillance program has detected cip-R, penicillin-resistant, and 
azithromycin non-susceptible isolates of Nm, the latter not previously seen in the U.S. To 
expand detection, which is critical for a condition with low incidence such as
meningococcal disease, MeningNet, an enhanced surveillance system, was created in 
late 2008. MeningNet and ABCs together can provide surveillance for reduced 
susceptibility in Nm in 68% of the population.  
PROJECT TITLE: IMPROVING MEASUREMENT OF C. DIFFICILE-ASSOCIATED 
INFECTIONS (CDI)
•	 Action Item(s): #2 and # 75
•	 Project Type: New
•	 Agency: CDC/ Prevention Epi Center CoAg 
•	 Description: Multicenter Project (Harvard, Chicago, Ohio, Utah) evaluating the 
accuracy/efficiency of two emerging surveillance methods for CDI and comparing with 
traditional surveillance methods - 4 hospitals. 
•	 2008 Update: 1) Extracted demographic data on patients admitted from 2000 through 
2006 who had been given the diagnosis of CDI by ICD-9 discharge code or laboratory 
test 2) Conducted medical record review 3) Data collection complete and analyses is 
ongoing 4) One manuscript near completion 4 in progress 5) Participated in design and 
implementation of the Ohio program 6) Correlated antimicrobial  use rates with C. difficile 
and other antimicrobial resistance 7) Data collection is complete and data analysis is 
being finalized. 
PROJECT TITLE: DEVELOPMENT OF A DOD AR SURVEILLANCE PLAN CONSISTENT 
WITH THE NATIONAL AR SURVEILLANCE PLAN
•	 Action Item(s): #2
•	 Project Type: Ongoing
•	 Agency: DoD
•	 Description: Establish an overarching framework for facilitating the implementation, 
operation, and evaluation of activities in AR surveillance within DoD. 
•	 2008 Update: In February 2007 DoD and CDC sponsored a US Medicine Institute for 
Health Studies (USMI) roundtable meeting entitled, "Addressing Antimicrobial 
Resistance"; an executive summary, transcript and speaker presentations are available 
on the USMI website at http://www.usminstitute.org/index.html (from the home page, click 
on the tab "Roundtable" and scroll down to this date). New ways to capture 
microbiological (including resistance) clinical lab data from military treatment facilities' 
electronic medical records, standardization of Acinetobacter PFGE techniques with 
improved specimen sharing among certain medical centers, and a significant research 
effort by DoD and NIAID focusing on infections (e.g., wounds, burns, etc) with multidrug 
resistant organisms at collaborating medical centers  are areas of progress in 2007.  
DOD-GEIS has also started projects at the Navy Marine Corps Public Health Center in 
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Norfolk to use HL-7 data to monitor antimicrobial resistance in military facilities and is 
currently validating their electronic surveillance methodology. GEIS is also soliciting new 
proposals that specifically address MDR organisms, especially TB. 
PROJECT TITLE: EMERGING PATHOGENS INITIATIVE (EPI)   
•	 Action Item(s): #2, #6, and #24
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: The Veterans Health Administration (VHA) currently has an ongoing and 
well-defined AR surveillance plan (the EPI, a laboratory-based automated surveillance 
system). Resistance data are being gathered in the EPI at the reporting site level and can 
be used for comparisons based on geographic areas and can be linked to ICD-9-CM 
diagnostic codes. In addition, drug use data can be linked to laboratory testing and 
diagnoses for a significant emerging disease. The VHA uses standardized definitions and 
methods to set local parameters for surveillance in the EPI system. EPI data regarding 
some AR organisms have been returned to the Veterans Integrated Service Networks 
with reporting station specific data included. Confidentiality is a key element in any 
activity undertaken by the VHA. Great effort has been put forth to maintain confidentiality 
of the Emerging Pathogens Initiative surveillance data set. Access is strictly limited for 
any data with unique identifiers. 
•	 2008 Update: Currently over 153 VHA facilities across the country transmit data to the 
EPI monthly. The data collected by the EPI are being reviewed by the Infectious
Diseases Program Office and reported to VHA Central Office and the Veterans Integrated 
Service Networks (VISNs = VA regional offices). Enhancements that acquire additional 
information on antimicrobial resistance of specified organisms were distributed to 
reporting stations in July 2004 and continue to function as requested with ongoing
enhancements to acquire even more information have been requested and are currently 
in process. Request for enhancements to capture ICD-9-CM coding from outpatient 
encounters associated with presence of antimicrobial resistance has been submitted, as 
has request for ability to delineate differences of data from sites that have consolidated 
administrative services and reporting mechanisms. 
PROJECT TITLE: REVIEW OF COMMERCIALLY AVAILABLE COMPUTER SOFTWARE TO 
BE USED FOR INFECTION PREVENTION, CONTROL AND CONTAINMENT    
•	 Action Item(s): #2, #6, and #24
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: VA is actively engaged in cooperative development of computer off-the­
shelf software products to assist in infection control processes for prevention and control 
of infectious diseases including antimicrobial resistant organisms; computer-assisted 
decision support systems will be a key element in VA's final product.   
















Last revised: December 29, 2009 
•	 2008 Update: At this time, one vendor product has been selected for further 
development nationwide that will include antibiogram monitoring and possibly decision 
support regarding antibiotic choices. Provided successful pilot and beta-site testing, 
systemwide implementation would be anticipated within 3 years. Design specification and 
pilot testing ongoing during 2008.  
PROJECT TITLE: PARTNERSHIP WITH CDC PREVENTION EPICENTERS—EVALUATING 
DATA SOURCES AND DETECTION
•	 Action Item(s): #2 and #6
•	 Project Type: New
•	 Agency: VA
•	 Description: VHA is partnering with CDC Prevention Epicenters on several projects 
related to antimicrobial resistance.
•	 2008 Update: Funded Surveillance Prevention Epicenters/VA Collaboration to: i) 
Evaluate the use of electronic data sources to (e.g., Detect central-line associated 
bloodstream infections, detect MRSA outbreaks, evaluate impact of MRSA prevention 
programs by using clinical microbiology information to create incidence measures, 
demonstrate impact of current VA MRSA prevention activities using data from Veteran's 
Integrated Service Network [VISN]), and ii) Evaluate additional ways to detect HAIs (e.g., 
Surrogate inpatient surveillance measures for surgical site infections [SSI], Medicare 
claims to identify hospitals with high SSI rates, ICD9 codes for ascertaining device-days 
of use and related adverse events, Surveillance methods for Clostridium difficile infection, 
Measuring variability and appropriateness of antimicrobial utilization). 
ACTION ITEM #3 
PROJECT TITLE: REFINING AND VALIDATING USE OF ADMINISTRATIVE CODING DATA 
TO ESTIMATE BURDEN OF MRSA
•	 Action Item(s): #3 
•	 Project Type: New
•	 Agency: CDC
•	 Description: The objective of this project is to develop and validate measures to
determine the burden of overall S. aureus and MRSA infection using electronic 
administrative coding data. The project is being conducted via an inter-agency agreement 
with the Salt Lake City VA Medical Center and in collaboration with the University of Utah 
and Intermountain Healthcare Systems. Correlation between administrative coding data 
and clinical microbiology will be analyzed. Medical records will be reviewed on a subset 
of records, focusing primarily on those records in which there is discrepancy between 
administrative coding and microbiology data. Potential reasons for discordance will be 
explored. Results will be used to refine coding algorithms used to estimate MRSA burden 
nationally. 
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•	 2008 Update: In 2008, administrative coding data and clinical microbiology records were 
analyzed for a total of 494,604 inpatients discharged between 2004 and 2007 and 
correlation between administrative coding data and microbiology culture data was 
analyzed on multiple levels - presence or absence of S. aureus, classification of infection 
type, and classification of S. aureus as methicillin-susceptible or methicillin-resistant 
given that S. aureus was present. 
PROJECT TITLE: ANALYTICAL METHODS DEVELOPMENT FOR ECOLOGICALLY 
RELEVANT PHARMACEUTICALS AND METABOLITES 
•	 Action Item(s): #3
•	 Project Type: Ongoing
•	 Agency: EPA 
•	 Description: Evaluate sample volumes, sample preservation options, and extraction 
techniques for LC/MS/MS analyses in order to achieve the detection limits necessary to 
measure environmentally relevant or informatically predicted levels of the 65 
pharmaceuticals in water, sediment, and tissues.
•	 2008 Update: Manuscript on LC/MS/MS and water extraction methods published in 
March 2008 for the measurement of 54 human prescription pharmaceuticals. A second 
water method using SPE and LC/MS/MS is being developed, which focuses on 
antibiotics and steroids of both human and veterinary use. Work will begin on the fish 
tissue extraction method in early FY09. Future method development plans exist for a 
subset of pharmaceuticals in sediments (possible FY11).     
PROJECT TITLE: DEVELOPMENT AND SINGLE LAB VALIDATION OF METHODS FOR 
PHARMACEUTICALS AND PERSONAL CARE PRODUCTS
•	 Action Item(s): #3
•	 Project Type: Ongoing
•	 Agency: EPA 
•	 Description: Project designed to develop and refine methods of detection for 
pharmaceuticals, pesticides, steroids and hormones. Several antibiotics are included in 
the most recently published method.  Ultimately the goal is to produce refined methods 
with high accuracy and precision.
•	 2008 Update: Concluded: "Method 1694: Pharmaceuticals and Personal Care Products 
in Water, Soil, Sediment, and Biosolids by HPLC/MS/MS" was published in December of 
2007. This publication includes methods for numerous antibiotics. 
PROJECT TITLE: ANTIMICROBIAL SUSCEPTIBILITY TESTING FOR LISTERIA
•	 Action Item(s): #3
•	 Project Type: Ongoing
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•	 Agency: USDA 
•	 Description: Methodologies and standards for antimicrobial susceptibility testing of 
Listeria are being developed and implemented. 
•	 2008 Update: A new Listeria broth microdilution plate was constructed and tested in 
2007. Research determined the antimicrobial resistance of L. monocytogenes isolates 
detected in a poultry further processing facility. This large group of isolates is unique 
because they had been collected during one year in a commercial plant. Most of the L. 
monocytogenes isolates were susceptible to all antimicrobials. However, some were 
resistant to ceftriaxone, oxacillin, ciprofloxacin, clindamicin, tetracycline or some
combination of these.
ACTION ITEM #4 
PROJECT TITLE: ESTIMATING THE PUBLIC HEALTH AND ECONOMIC BURDEN OF 
DISEASE CAUSED BY DRUG RESISTANT GROUP A STREPTOCOCCUS
•	 Action Item(s): #4
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The goal of this project is to estimate the burden of disease caused by 
Drug-Resistant Group A streptococcus (GAS). The project will draw from estimates of the 
prevalence of resistance among GAS isolates from CDC's Active Bacterial Core 
surveillance as well as the scientific literature on resistance. Burden of disease will be 
estimated from national databases of health care visits and hospitalizations as well as 
ABCs data on disease rates.   
•	 2008 Update: During 2008 antibiotic susceptibility testing of 907 invasive GAS isolates 
obtained from ABCs during 2006 was completed. Among these isolates, testing of all 
macrolide-resistant strains both for genetic determinants of resistance (mef and erm) and 
for inducible clindamycin resistance has also been completed. Results show that
resistance to erythromycin has increased among ABCs sites from an average of
approximately 8% during 2001 and 2003 to 11.8% in 2006. Tetracycline resistance 
among GAS isolates also increased from <1.0% to 14.9% during the same time periods. 
During 2007 and 2008 approximately 1800 GAS isolates were sent to CDC from the 
ABCs sites. Antibiotic susceptibility testing of these has recently been completed. 
Preliminary estimates of the burden of noninvasive GAS infections (e.g., skin infections
such as cellulitis and impetigo, pharyngitis) obtained from two national databases
(National Ambulatory Medical Care Survey or NAMCS and the National Hospital 
Ambulatory Medical Care Survey or NHAMCS) have been calculated: annual visits for 
GAS cellulitis=1.4-5.0 million; GAS pharyngitis=4.4-9.0 million. Next steps: analyze 
antibiotic susceptibility testing results of ABCs 2007 and 2008 GAS isolates; finalize 
national estimates of noninvasive GAS disease; calculate annual burden of macrolide 
resistant invasive GAS infections as identified through ABCs and use sensitivity 
estimates to generate high and low estimates of the total annual number of resistant 
noninvasive GAS infections. 
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PROJECT TITLE: NATIONAL BURDEN OF ANTIMICROBIAL RESISTANT NEONATAL 
SEPSIS
•	 Action Item(s): #4
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Neonatal sepsis, including bloodstream infections, meningitis, pneumonia 
and clinical sepsis, is a leading cause of illness in early life that can result in long-term 
disability and death. The emergence of antimicrobial resistance among common neonatal 
pathogens, particularly Escherichia coli and Staphylococcus aureus, threatens successful 
treatment of these infections and has raised concerns about overuse of intrapartum 
antibiotics. Recent studies have detected vaginal MRSA colonization in up to 11% of 
pregnant women late in pregnancy. However, there are no precise estimates of the 
overall burden of disease caused by drug-resistant neonatal pathogens upon which to 
base clinical guidelines and policy decisions. This project is a collaboration between 3 
CDC centers, Emory University, and the National Institute of Child Health and 
Development’s (NICHD) neonatal network. Through CDC’s Active Bacterial Core 
surveillance (ABCs) and NICHD’s neonatal network, we will conduct active surveillance 
for early-onset neonatal sepsis from 2007-2009.
•	 2008 Update: A full year of active surveillance for invasive neonatal sepsis was 
conducted in ABCs and in the NICHD neonatal network. In ABCs, in 2008, 175 neonatal 
sepsis cases were identified.  Overall neonatal sepsis incidence was 0.75 cases /1000 
live births; GBS was the leading cause (0.28/1000 live births). E coli sepsis was the 
leading cause after GBS (24% of cases). From 2006-8, the incidence of nonGBS sepsis
was stable among term infants but increased among preterm from 2.10 to 2.48 
cases/1000 live births; 83% of E coli infections among preterm were ampicillin resistant in 
2008 compared to 56% among term infants. From 2005-8 there is still only 1 case of 
invasive early-onset MRSA infection detected in the ABCs neonatal sepsis catchment. 
The NICHD 2008 data are not finalized; from 2006-first 6 months of 2008 NICHD 
identified 381 early-onset sepsis cases; 108 were deemed contaminants and 273 were 
diagnosed with early onset sepsis or meningitis. GBS was the leading cause (38%) 
followed by E. coli (26%). Among the E coli cases, 96% were symptomatic, 91% were 
admitted to intensive care and 33% died. The NICHD data were presented at the 2009 
Pediatric Academic Society Meetings. Both the ABCs and NICHD data were presented at 
a meeting in June 2009 to revise the US perinatal GBS disease prevention guidelines. 
These data were evaluated to determine whether unintended consequences of 
intrapartum prophylaxis for GBS prevention had reached a tipping point and all the 
guidelines partners agreed that IAP continues to cause benefit and that there are not yet 
evidence of an adverse impact on nonGBS sepsis. A preliminary estimate of the national 
burden of invasive neonatal sepsis suggests approximately 3100 cases occur annually in 
infants less than 72 hours of age. Further refinement and finalization of this estimate 
needs to occur in 2009. 
PROJECT TITLE: BURDEN OF ANTIMICROBIAL RESISTANT STREPTOCOCCUS 
PNEUMONIAE 
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•	 Action Item(s): #4
•	 Project Type: New
•	 Agency: CDC
•	 Description: Streptococcus pneumoniae, or pneumococcus, is a common cause of otitis, 
meningitis, pneumonia, and blood stream infections. In the U.S., antibiotic resistance 
among pneumococcal strains increased during the 1990s, decreased during the first few 
years after 7-valent pneumococcal conjugate vaccine (PCV7) was introduced, and then 
began to increase again after non-PCV7 serotypes began to emerge. Multiple studies
have attempted to estimate the national burden of individual pneumococcal syndromes 
(e.g., otitis cases, pneumonia hospitalizations) but there is not a single national estimate 
of disease burden or economic costs associated with pneumococcal disease, not to 
mention antibiotic resistant disease. Such estimates are critical for policy makers to assist
them in prioritizing various options for public health interventions. This project aimed to 
estimate the total national burden of pneumococcal disease, including that portion 
associated with antibiotic resistance and the economic costs associated with those 
cases.
•	 2008 Update: In 2008, collaborators at the Harvard School of public health and CDC 
arrived at multiple estimates of the burden of antibiotic resistant pneumococcal disease. 
There are over 4.3 million episodes of pneumococcal disease in the U.S. each year. Of 
those, about 1.7 million are associated with penicillin resistance. Estimates of cases 
resistant to other agents are being finalized and are expected to be available this fall. 
After considering direct medical costs and costs associated with lost productivity, 
pneumococcal disease costs about $8 billion annually. These findings have been 
accepted for presentation at the 2009 Annual Meeting of the Infectious Diseases Society 
of America and a manuscript outlining all of the findings associated with this project is in 
preparation.
PROJECT TITLE: POPULATION-BASED SURVEILLANCE FOR ANTIMICROBIAL 
RESISTANCE AMONG CANDIDA BLOODSTREAM INFECTIONS   
•	 Action Item(s): #4
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Conduct population-based surveillance for antimicrobial resistance among 
Candida bloodstream infections in metropolitan Baltimore MD and Atlanta GA (limited by 
funding to two sites). Sites are collecting epidemiologic data and submitting Candida
isolates to CDC for identification and susceptibility results. Surveillance will be conducted 
for two years and compared with previous surveillance data from the same areas in order 
to assess changing trends. There are no national surveillance programs for monitoring 
susceptibility in Candida infections.
•	 2008 Update: Approximately 100 isolates have been received to date from Atlanta 
metropolitan area sites. Demographic and detailed clinical data collection for case 
patients is also underway in the Atlanta area. Of 70 cases for which data have been 
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received, 50% have candidemia due to C. albicans, and 30% have candidemia due to C. 
glabrata (12% of candidemia cases were due to C. glabrata in 1992-1993 Atlanta 
metropolitan area candidemia surveillance). Species confirmation is underway at CDC, 
and susceptibility testing will be performed. Isolate collection has recently begun in 
Baltimore City and Baltimore County. More funding is being sought in order to expand the 
surveillance network.
PROJECT TITLE: CLINICAL OUTCOMES IN MULTI-DRUG RESISTANT NON-TYPHI 
SALMONELLA SEROTYPES 
•	 Action Item(s): #4
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Enhanced surveillance for non-Typhi Salmonella to investigate the impact 
of multi-drug resistance on clinical outcomes.
•	 2008 Update: All 10 participating sites completed 2 years of data/isolate collection.  
Participants submitted approximately 2600 isolates for susceptibility testing to NARMS 
lab at CDC as of the end of CY2008. Participants and CDC epidemiologists conducted 
teleconferences to finalize analysis scheme. The results of the interim analysis were 
presented at the 2008 FoodNet Vision Meeting held in Denver, CO.  
PROJECT TITLE: PARTICIPATION IN THE REGIONAL DAIRY QUALITY MANAGEMENT
ALLIANCE (RDQMA) 
•	 Action Item(s): #4
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: RDQMA is a 4 state university-based program partially supported by
USDA. The mission of the RDQMA is to assure a healthful and safe food supply by 
advocating the adoption of best management practices (BMPs), which promote animal 
health and welfare, improve productivity and profitability of dairy farms and encourages 
environmental stewardship. The RDQMA utilizes the New York State Cattle Health 
Assurance Program (NYSCHAP) herd risk assessment model and this model has been 
adopted for use in all participating states. The USDA is responsible for addressing
research into specific issues such as Johne's Disease, salmonellosis, antimicrobial 
resistance and mastitis/milk quality.
•	 2008 Update: Ongoing. Blood, manure, weekly bulk milk tank samples, environmental 
samples, management data surveys, economic data, nutrient management data and 
carcass data are being gathered from 2 farms in the northeastern US. Samples are being
analyzed for the presence of Mycobacterium avium spp. paratuberculosis, Salmonella 
spp., E. coli 0157:H7 and generic E. coli, Listeria monocytogenes, Campylobacter, and 
Enterococci. In 2008, only 2 of 117 Salmonella isolates were resistant to any of the 
antimicrobials tested. Both isolates were identified as serotype Heidelberg and were 
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resistant to kanamycin, streptomycin, sulfizoxale and tetracycline. Of the E.coli isolates
tested, 91.2% were susceptible to all antimicrobials tested, 4.9% were resistant to a 
single drug, and 3.9% were resistant to multiple drugs. Of the Campylobacter species, 
32.4% were susceptible to all while 67.6% showed resistance to a single drug, 
tetracycline. Among enterococcus, 84.8% were multi-drug resistant and 13.5% were 
resistant to a single drug. 
PROJECT TITLE: IMPLEMENTATION OF USDA VETNET
•	 Action Item(s): #4
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: USDA VetNet was established in 2003 and was modeled after PulseNet 
USA, the national molecular subtyping network for food-borne disease surveillance. The 
objectives of USDA VetNet are to use PFGE to subtype zoonotic pathogens submitted to 
the animal arm of the National Antimicrobial Resistance Monitoring System (NARMS), 
compare USDA VetNet and PulseNet PFGE patterns, and to use the comparative data 
for surveillance and investigation of food-borne illness outbreaks. Whereas PulseNet 
subtypes seven food borne disease-causing bacteria: E. coli O157:H7, nontyphoidal 
Salmonella, Shigella, Listeria monocytogenes, Campylobacter, Yersinia pestis, and Vibrio 
cholerae, VetNet, at present, subtypes nontyphoidal Salmonella serotypes and 
Campylobacter from animals including diagnostic specimens, healthy farm animals, and 
carcasses of food-producing animals at slaughter. 
•	 2008 Update: Ongoing. VetNet has two functioning databases including the NARMS 
Salmonella and Campylobacter databases. The Salmonella database contains over 
17,000 Salmonella isolates, while the Campylobacter database contains over 900 
Campylobacter isolates. Over 2000 Salmonella isolates submitted to the animal arm of 
NARMS were submitted to VetNet in FY09. VetNet has been used by FSIS and CDC to 
assist in the investigation of several Salmonella-related foodborne outbreaks including 
those from fresh produce and meat. Both databases contain the PFGE Tagged Image 
File Format (TIFF) images, demographic information, and the antimicrobial resistance 
profiles assigned by NARMS. VetNet is a major component of the FSIS’s risk-based
sampling approach, and samples have been submitted to VetNet from FSIS’s baseline 
studies. VetNet training on the methods have been conducted for investigators at the 
University College of Dublin, Ireland, and the Dept of Agriculture and Food Safety in 
Dublin so that they could pattern a PFGE system after VetNet. 
PROJECT TITLE: CHARACTERIZATION AND REPORTING OF ANTIMICROBIAL
RESISTANCE AMONG ENTERIC BACTERIAL ISOLATES FROM SWINE ON FARMS
•	 Action Item(s): #4
•	 Project Type: New
•	 Agency: USDA 
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•	 Description: Collection of feces to be cultured for Salmonella, Campylobacter, 
Enterococcus and E coli as part of the USDA:APHIS National Animal Health Monitoring
System study. 
•	 2008 Update: Overall 7.2% of samples were positive for Salmonella. Resistance was 
most common for tetracycline, sulfisoxazole and streptomycin. For Campylobacter, 51.6 
percent of samples were culture positive. Very few of the isolates were Campylobacter 
jejuni. Sixty nine percent of the samples were culture positive for Enterococcus, most
commonly E. hirae or E. faecalis. Resistance was most common to lincomycin and 
tetracycline. Among the samples cultured for E coli, 94.9% were positive. Resistance was 
most common to tetracycline. Info sheets on the study results have been made available 
on the NAHMS website.
PROJECT TITLE: CHARACTERIZATION AND REPORTING OF ANTIMICROBIAL
RESISTANCE AMONG ENTERIC BACTERIAL ISOLATES FROM DAIRY COWS ON FARMS
•	 Action Item(s): #4
•	 Project Type: New
•	 Agency: USDA 
•	 Description: Collection of feces to be cultured for Salmonella, Campylobacter, 
Enterococcus and E coli as part of the USDA:APHIS National Animal Health Monitoring
System study. 
•	 2008 Update: Overall, 13.7 percent of samples were culture positive for Salmonella and 
92.8% of the isolates were sensitive to all the antimicrobials tested in the panel. For 
Campylobacter, 33.7% of the samples were culture positive. For the C. jejuni isolates, 
36.6% were susceptible to all antimicrobials in the panel and 61.2% were resistant to a 
single antimicrobial drug, almost always tetracycline.   
PROJECT TITLE: CHARACTERIZATION AND REPORTING OF ANTIMICROBIAL
RESISTANCE AMONG ENTERIC BACTERIAL ISOLATES FROM BEEF COWS ON FARMS
•	 Action Item(s): #4
•	 Project Type: New
•	 Agency: USDA 
•	 Description: Collection of feces to be cultured for Salmonella, Campylobacter, 
Enterococcus and E coli as part of the USDA:APHIS National Animal Health Monitoring
System study. 
•	 2008 Update: Overall, 0.5% of samples were culture positive for Salmonella and all of 
these isolates were sensitive to all antimicrobials in the panel. For Campylobacter jejuni, 
8.4% of samples were positive. Among the C. jejuni isolates 56.2% were sensitive to all 
antimicrobials in the panel and 38.9% were resistant only to tetracycline. Nearly 80% of 
the samples were positive for Enterococcus but these were most commonly E. 
casseliflavus and E. hirae. 
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PROJECT TITLE: CHARACTERIZATION OF ANTIMICROBIAL DRUG USE ON SWINE, 
DAIRY AND COW-CALF OPERATIONS
•	 Action Item(s): #4
•	 Project Type: New
•	 Agency: USDA 
•	 Description: As part of the National Animal Health Monitoring System data are collected
from a representative sample of livestock operations in the U.S.  During in-person 
interviews with the farm managers, data are collected on antimicrobial use as well as 
other management practices.
•	 2008 Update: Data have been collected on swine, dairy and cow-calf operations.   
Results for the swine and dairy operations have been published and posted to the 
website at http://nahms.aphis.usda.gov./. 
PROJECT TITLE: DETECTION AND CHARACTERIZATION OF EMERGING CLOSTRIDIUM
DIFFICILE STRAINS
•	 Action Item(s): #4 
•	 Project Type: New
•	 Agency: CDC
•	 Description: C. difficile isolates associated with outbreaks, or from states or geographic 
regions that have not yet documented the presence of the NAP1 epidemic strain, will be 
typed and characterized to document the spread of the current epidemic strain. At the 
same time, we will request new C. difficile strains associated with clinical infection for 
characterization, and to ensure that we are able to recognize changing trends in the 
molecular epidemiology of C. difficile. 
•	 2008 Update: The NAP1 C. difficile epidemic strain has been documented and confirmed 
in 40 US states. We have also documented the emergence of a new strain. Ref. Emerg 
Infect Dis. 2008 Jul;14(7):1039-45.
PROJECT TITLE: CHARACTERIZE C. DIFFICILE STRAINS FROM COMMUNITY­
ASSOCIATED INFECTIONS  
•	 Action Item(s): #4 
•	 Project Type: New
•	 Agency: CDC
•	 Description: The epidemiology of C. difficile infection (CDI) appears to be changing, with 
emergence in the community and among persons without traditional risk factors for 
development of CDI. We sought to investigate the strains from confirmed community-
associated CDI (CA-CDI) cases from two separate investigations. Chart review and 
patient interviews were performed to document CA-CDI cases, then stool specimens 
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positive for C. difficile toxin were forwarded to CDC for culture. C. difficile isolates
recovered were characterized by PFGE, characterization of the pathogenicity locus, PCR 
for binary toxin, and antimicrobial susceptibility testing.  
•	 2008 Update: Organism recovery and isolate characterization is complete. Manuscript 
preparation is in progress.   
PROJECT TITLE:  DEVELOPMENT OF MULTI-CENTER TRIAL TO DETERMINE 
PREVALENCE OF RESISTANT T. VAGINALIS
•	 Action Item(s): #4 
•	 Project Type: New
•	 Agency: CDC
•	 Description: Point prevalence studies have suggested that up to 10% of T. vaginalis
infections are resistant to treatment. However, the available data are not sufficient to 
warrant changes in treatment policy. DPD worked with DSTDP to develop a 6-site 
surveillance study to obtain a more accurate estimate for trichomoniasis AR in the US. 
•	 2008 Update: Sample collection and testing began in 2009. Related publications:
Helms, D. J., D. J. Mosure, W. E. Secor, and K. A. Workowski. 2008. Management of 
Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am. J.
Obstet. Gynecol. 198:370.e1-7.
Kissinger, P., W. E. Secor, J. S. Leichliter, R. A. Clark, N. Schmidt, E. Curtin, and D. H. 
Martin. 2008. Early repeated infections with Trichomonas vaginalis among HIV positive 
and negative women.  Clin. Infect. Dis. 46:994-999.
PROJECT TITLE:  MOLECULAR AND IN-VITRO SURVEILLANCE FOR MONITORING 
ANTIMALARIAL DRUG RESISTANCE 
•	 Action Item: #4
•	 Project Type: New
•	 Agency: CDC
•	 Description: Establish an active surveillance program for early detection of resistance to 
newly used artemisinin based combination therapy (ACT) by using an in vitro drug 
susceptibility test and molecular characterization of gene targets involved in drug
resistance in selected countries in Africa, Asia and South America. Conduct population 
based studies to detect changes in the drug resistant genotypes as new drug policies 
were implemented. Develop methods to understand the origin and spread of drug 
resistant genotypes in the population. Provide training to country partners in genotyping 
methodologies and in vitro drug susceptibility test. 
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•	 2008 Update: Training and capability to conduct in vitro drug susceptibility was 
established in Kenya, Tanzania and Peru. Sulphadoxine-pyrimethamine resistant 
genotypes declined in Peru five years after this drug use policy was changed to ACT. On 
the contrary, in Venezuela sulphadoxine-pyrimethamine resistant genotypes did not 
decline but reached fixation five years after the policy change. Copy number variation in 
the MDR-1 gene is associated with mefloquine resistance (one of the partner drug used 
in ACT in many countries). In Cambodia (where resistance to ACT is emerging), copy 
number variation in the mdr-1 gene was found to have multiple genetic origins. The 
pyrimethamine resistant genetic marker dhfr in both East and West African parasite 
isolates were found to be related to Southeast Asian parasite isolates implying their 
spread from Southeast Asia to Africa. Attempts to identify new genetic markers to predict 
the resistance to ACT is in progress. Provided training to scientists from Tanzania, Peru, 
Brazil and Pakistan in in vitro drug susceptibility testing and genotyping of drug resistant 
mutations.  
ACTION ITEM #5 
PROJECT TITLE: COMPREHENSIVE DEMONSTRATION PROJECT: BUILDING REGIONAL 
COALITIONS TO PREVENT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN 
HEALTHCARE FACILITIES 
•	 Action Item(s): #5 and #63
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: This project continues to support the development and implementation of 
comprehensive programs to reduce the incidence of MRSA infections in states and/or 
large regional networks. Continued work stems from an initial MRSA prevention project in 
collaboration with the Pittsburgh VA Medical Center. 
•	 2008 Update: 2008 milestones include: 1) National Veteran’s Health Affairs MRSA 
Prevention Initiative-building on the work at VA Pittsburgh, a national pilot program was 
initiated in August 2006 to determine if results could be replicated in 17 other VA
hospitals; CDC’s NHSN is being used to  measure the impact. Data collection is ongoing 
and an additional interim analysis will occur in 2009. In January 2007 plans were 
announced to initiate MRSA prevention programs in all VA hospitals. CDC continues to 
actively participate in that national task force. 2)  Plexus Institute Initiative (funded by 
Robert Woods Johnson Foundation-another expansion of Pittsburgh VA work, this project 
examines use of a social/cultural change improvement model (“positive deviance’) 
applied to MRSA prevention. CDC is providing in-kind support and assistance, including 
analysis of impact using electronic data submission through NHSN. Preliminary results of 
this multicenter study were presented at SHEA 2009, demonstrating significant 
reductions in both the incidence of MRSA and in methicillin-susceptibility among all S. 
aureus isolates. 3) Maryland Patient Safety Center Initiative continues a regional
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voluntary MRSA prevention program of >20 Maryland Hospitals that have implemented 
MRSA prevention initiatives using the “positive deviance” change model. CDC is
providing in-kind support and assistance in analyzing electronically data submitted 
through NHSN as the outcome measurement tool. 
PROJECT TITLE: NATIONAL AMBULATORY MEDICAL CARE SURVEY (NAMCS) AND 
NATIONAL HOSPITAL AMBULATORY MEDICAL CARE SURVEY (NHAMCS) 
•	 Action Item(s): #5
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: NAMCS is an annual national survey that collects data on the utilization of 
ambulatory medical care services provided by office-based physicians in the United 
States. Findings are based on a sample of visits to nonfederally employed office-based 
physicians who are primarily engaged in direct patient care. NAMCS monitors trends in 
prescription of antimicrobial drugs in the physician office setting. NHAMCS is an annual 
national survey that collects data on the utilization of ambulatory medical care services 
provided by hospital emergency and outpatient departments in the United States. 
Findings are based on a sample of visits to emergency departments and outpatient 
clinics. NHAMCS monitors trends in prescription of antimicrobial drugs in hospital 
emergency and outpatient departments. 
•	 2008 Update: During 2008, an abstract was accepted to present at the 2009 Annual 
Meeting of the Infectious Diseases Society of America that will discuss changes in 
antimicrobial prescribing in ambulatory care and emergency department visits in the U.S. 
from 1997-2006 using NAMCS and NHAMCS data. Preliminary analyses revealed that 
while there has been a decrease in prescribing for upper respiratory infections in 
outpatient, primary care settings, there has been a concurrent increase in prescribing for 
these conditions in emergency department settings. In addition, a publication is in 
process that will describe findings from both NAMCS and NHAMCS and current trends in 
the prescribing of antimicrobial drugs in physician offices, hospital emergency rooms and 
outpatient facilities. 
PROJECT TITLE: DEVELOPING MEASUREMENT AND BENCHMARK STRATEGIES FOR 
ANTIMICROBIAL USE IN ACUTE CARE SETTINGS  
•	 Action Item(s): #5, #26, and #63
•	 Project Type: New
•	 Agency: CDC/ Prevention Epi Center CoAg 
•	 Description: Multicenter project (Ohio, Utah, Washington) in which electronically 
extracted data are used to construct unit-specific measures of antimicrobial prescribing 
for the purpose of describing variability in use across units and facilities as a means for 
optimizing antimicrobial use. 
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•	 2008 Update: 1) Antimicrobial use data have been compiled from 15 ICUs in four 
hospitals 2)Data have been validated by three separate methods 3) Data collected to 
date demonstrate substantial variation between months and between attending physician 
rotation periods within ICUs, without evident time trends in aggregate ICU antimicrobial 
use. 4) Currently comparing pharmacy charge data and electronic MAR data 4) Data 
collection for measuring use by antimicrobial days is complete-additional measures still 
being collected 5) Completed retrospective and prospective data collection and submitted 
data set for analysis 6) Completed prospective observation of antimicrobial administration 
7) Currently completing manuscript on the project barriers 8) Two abstracts presented at 
national meetings.
PROJECT TITLE: IMPROVING ANTIMICROBIAL USE IN ICUS 
•	 Action Item(s): #5, #26, and #63
•	 Project Type: New
•	 Agency: CDC/ Prevention Epi Center CoAg 
•	 Description: Multicenter project (Ohio, Utah, Washington) Evaluate efficacy of a 
multidisciplinary antimicrobial stewardship program and evaluate computer expert system 
- 4 ICUs.
•	 2008 Update: 1) Completed retrospective and prospective data collection and submitted 
data set for analysis 2) Completed prospective observation of antimicrobial administration 
3) Currently completing manuscript on the project barriers.
PROJECT TITLE: COLLECTION AND CHARACTERIZATION OF CLOSTRIDIUM DIFFICILE
FROM FOOD AND FOOD-PRODUCING ANIMALS  
•	 Action Item(s): #5 
•	 Project Type: New
•	 Agency: CDC
•	 Description: The epidemiology of C. difficile infection (CDI) appears to be changing, with 
emergence in the community and among persons without traditional risk factors for 
development of CDI. At the same time, C. difficile is causing epidemic disease in food-
producing animals. One potential link between these might be the food supply, and 
specifically retail meat products. We have previously collaborated with investigators in 
Canada and the United States to characterize C. difficile isolated from retail meats, and 
we are now working to develop an optimized method for detection and recovery of C. 
difficile from food products.
•	 2008 Update: Experts meeting convened at CDC in conjunction with FoodNet group, 
research gaps identified, and plan developed for study to define best recovery methods.  
PROJECT TITLE: ANTIBIOTIC RESISTANCE- SHIGELLA SURVEILLANCE PROJECT (PART 
OF BIDS- BORDER INFECTIOUS DISEASE SURVEILLANCE PROJECT) 
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•	 Action Item(s): #5
•	 Project Type: New
•	 Agency: CDC
•	 Description: Studies suggest that levels of antimicrobial resistance (AMR) for some 
pathogens may be higher in US states bordering Mexico, compared to national levels. In 
the US, shigellosis is among the most commonly reported enteric bacterial infections, 
with the highest incidence occurring in regions bordering Mexico. High levels of AMR 
have been observed in Shigella nationally, with 78% resistance to Ampicillin (AMP), 51% 
resistance to Trimethoprim-sulfamethoxazole (SXT) and 0% resistance to Ceftriaxone 
(CRO) and Ciprofloxacin (CIP) in 2004. To date no studies describe AMR in Shigella in 
the US-Mexico border region.  Available isolates from all sporadic Shigella cases
reported in San Diego County (SDC) beginning October 1, 2008 were submitted to the 
SDC Public Health Laboratory for serotype confirmation, antibiotic susceptibility testing 
(AST) by disc diffusion, and genetic characterization by pulsed field gel electrophoresis
(PFGE). Cases were also administered a supplemental risk history questionnaire to 
further characterize risk factors such as travel history, antibiotic use, food consumption, 
severity of illness, management, and outcome.  
•	 2008 Update: From October 1st, 2008 through December 31st, 2008, 36 sporadic 
Shigella cases have been reported to SDC; 29 (81%) were identified as sonnei, 6 (17%) 
flexneri, 1 (3%) boydii, and 0 (0%) dysenteria. Of 25 Shigella sonnei isolates available for 
AST, all were resistant to SXT, 3 were resistant to AMP, and 0 were resistant to CRO 
and CIP. All of 6 Shigella flexneri isolates available for AST were resistant to AMP, 5 
were resistant to SXT, 0 were resistant to CIP, and all were sensitive to CRO. PFGE 
typing has been completed for 31 isolates, although not yet compared to national
databases. Supplemental epidemiologic risk data has been collected for 21 cases.  
Conclusions: Interim AST data suggest the patterns of resistance occurring along the US-
Mexico border may differ from those seen nationally. These data suggest that differing 
selective pressures of the region may result in a unique AMR profile. Epidemiologic data 
will be reconciled with laboratory findings. 
PROJECT TITLE: ASSESSMENT OF ANTIMICROBIAL RESISTANCE AMONG CLINICAL 
CULTURES IN U.S. – MEXICO BORDER HOSPITALS (PART OF BIDS- BORDER 
INFECTIOUS DISEASE SURVEILLANCE PROJECT)
•	 Action Item(s): #5 
•	 Project Type: New
•	 Agency: CDC 
•	 Description: Antimicrobial resistance (AR) and reduced efficacy of antibiotics is a 
growing problem globally associated with increased morbidity and costs. Antibiotic 
resistance data are lacking on the U.S. – Mexico border, while increased access to 
prescription antimicrobials in this region with high cross-border mobility and commerce 
may predispose to high rates of resistance in the region. To describe AR in the U.S. - 
Mexico border region, we obtained all bacterial cultures and antimicrobial sensitivities for 
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the period January 2000 to December 2005 from 4 major hospitals on the border in CA, 
Arizona and Texas. We analyzed trend data for well recognized important pathogen-
antibiotic combinations, methicillin-resistant Staphylococcus aureus (Sa), vancomycin-
resistant enterococcus, penicillin-resistant Streptococcus pneumoniae (Sp), and 
sensitivities of E. coli to third generation cephalosporins, quinolones, and 
trimethoprim/sulfa. 
•	 2008 Update: Data was cleaned, and analyzed and presented at the Border 
Epidemiology and Surveillance Annual Meeting in El Paso in December 2008. Forty-three 
percent of Sa cultures were resistant to methicillin overall with a significant trend of 
increasing resistance over time. Almost eighteen percent of enterococcus cultures overall 
were resistant to vancomycin, and 23% of Sp cultures overall were resistant to penicillin.  
Thirteen percent of E. coli cultures overall were resistant to quinolones with a significant 
increasing trend over time. Border hospital pooled proportions of resistant organisms 
were at the high end of the range of such proportions or higher than proportions in
National Nosocomial Infectious Surveillance pooled data from 1998-2004. Conclusions: 
Resistance to common antibiotics appears to have increased between 2000-2005 in the 
US-Mexico border region, with increasing trend in resistance to antibiotics used to treat 
Staph aureus and E. coli most salient. Further studies and analysis of border 
antimicrobial resistance patterns are needed, as well as linkage with ongoing 
antimicrobial resistance prevention campaigns.   
PROJECT TITLE: PRESCRIPTION DATABASES
•	 Action Item(s): #5
•	 Project Type: Ongoing
•	 Agency: DoD
•	 Description: Use of the prescription database (PDTS) is being piloted for gastrointestinal 
and respiratory outbreak detections.
•	 2008 Update: Ongoing. 17 additional VA hospitals nationwide are now participating in a 
pilot program to evaluate the reproducibility of the initial results, and the group has 
elected to use CDC’s National Healthcare Safety Network (NHSN) for data collection. 
Data submission is underway in those hospitals.  
ACTION ITEM #6 
PROJECT TITLE: MONITORING TRENDS IN PRESCRIPTIONS OF ANTIMICROBIALS IN THE 
ALASKA NATIVE HEALTH CARE SYSTEM 
•	 Action Item(s): #6
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The Alaska Native Health System is an integrated population-based health 
delivery system serving 220 village-based clinics, 8 regional hospitals and a tertiary 
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medical facility. In this system little is known antibiotic prescribing rates. We have 
developed a method to use electronic prescription and clinic visitation data to measure 
rates of antimicrobial prescriptions over time and compare with national trends.
•	 2008 Update: Prescription data for 3 Alaska regions have been analyzed. The overall 
visit-based prescribing rate of oral antimicrobials in <18 year-olds was lower than rates 
reported from similar ages in the general US population, but the decrease in prescribing 
rates seen in other regions of the US since the mid-1990's have not been seen in Alaska.    
PROJECT TITLE: NATIONAL COMPREHENSIVE ASSESSMENT OF AVAILABLE TB 
LABORATORY SERVICES TO FILL GAPS IN KNOWLEDGE ABOUT THE CAPABILITIES 
AND CAPACITIES OF JURISDICTIONAL LABORATORY NETWORKS TO PERFORM RAPID 
AND RELIABLE DRUG SUSCEPTIBILITY TESTING 
•	 Action Item(s):  # 6
•	 Project Type: New
•	 Agency: CDC
•	 Description: DTBE/ MLB will collaborate with the APHL to develop a comprehensive 
laboratory services survey instrument. The survey will collect data on available services
in each laboratory, including test methods and volumes, turnaround time, reporting 
processes, and integration with public health and TB Control programs. The survey will 
be developed for electronic dissemination and data collection via the MR Interview survey 
platform. In year one, APHL will compile a list of laboratories to be surveyed through 
multiple sources. Pilot testing will be conducted among a subset of public health and 
clinical laboratories after consultation with the ADS office of NCHHSTP regarding OMB 
limitations. Once data from the pilot are analyzed and the instrument is finalized, we will 
submit an application for OMB approval. Once OMB clearance is obtained, additional 
funds will be necessary to support conducting the survey and analyzing data in future 
years.
•	 2008 Update: Project planning initiated.
ACTION ITEM #7 
PROJECT TITLE: GET SMART: KNOW WHEN ANTIBIOTICS WORK-DEVELOPMENT AND 
TESTING OF HEALTH PLAN EMPLOYER DATA AND INFORMATION SET (HEDIS) 
MEASURES FOR APPROPRIATE ANTIBIOTIC USE
•	 Action Item(s): #7
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: HEDIS is a performance measurement tool used by purchasers and 
consumers to compare many of the nation’s leading health plans. In this project, CDC 
epidemiologists collaborated with experts in the development and testing of HEDIS 
measures to create measures of appropriate antimicrobial use in children and adults.  
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Child measures include rate of prescribing antimicrobial drugs for acute upper respiratory 
infections and bronchitis; rate of prescribing antimicrobial drugs for pharyngitis where no 
throat culture or rapid streptococcal antigen test was performed; and episodes of otitis 
media treated with a recommended first-line agent. Two adult measures were included in 
the HEDIS set beginning in 2006. The 2006 pilot year of the acute bronchitis measure 
showed that on average, both Commercial and Medicaid plans showed high rates of 
inappropriate antibiotic use (66% and 70%, respectively). The antibiotic utilization
measure was not originally approved for public reporting because of the type of 
information collected (e.g. total number of antibiotics prescribed not broken down by 
diagnosis); the committee approved this measure for 2008.




PROJECT TITLE: SURGICAL SITE INFECTION ANTIBIOTIC PROPHYLAXIS PLAN IN 
CONJUNCTION WITH THE JOINT COMMISSION ORYX AGGREGATE
•	 Action Item(s): #7, #22, and #32
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: VHA has introduced surgical site antibiotic prophylaxis (including both 
timing and appropriateness of choices, as well as timely cessation) as a performance 
measure for VHA systems nationwide. These performance measures constitute 50% of 
the annual evaluation for Executive Career Field (ECF) performance plans for VHA 
regional directors and individual medical center directors. The particular performance 
measures relative to surgical site infection antibiotic prophylaxis include percent of the 
cases the drug began timely, percent of the cases the appropriate drug was given, and 
percent of the cases the drug was discontinued timely.  
•	 2008 Update: In Federal Fiscal Year 2005, VHA introduced surgical site antibiotic 
prophylaxis as a performance measure for VHA systems nationwide--ongoing into FY 
2008 (considered a "mission critical" measure). Data from VHA's Office of Quality and 
Performance reveal that for Performance Measures SIP1a (Prophylactic antibiotic started 
timely) comparing national numbers from the third and 4th quarters from FY 2005, FY 
2006, and FY 2007,and FY 2008 the percent starting timely was 78.7%, 88.6%, 90.6%, 
and 96%,respectively. Additionally, for the measure of SIP10a (Correct Antibiotics ALL 
surgeries) comparing national numbers from fourth quarter FY 2006, FY 2007, and FY 
2008, percent with correct antibiotics was 93.7%, 95.8%, and 97%, respectively. An 
additional Performance Measure of SIP3an (Prophylactic antibiotic discontinued timely) 
was introduced, and comparison of third and fourth quarters of FY 2007 to FY 2008 
reveals results of 87% and 91%, respectively. 
PROJECT TITLE: COMMUNITY-ACQUIRED PNEUMONIA PERFORMANCE MEASURES IN 
CONJUNCTION WITH THE JOINT COMMISSION ORYX AGGREGATE
•	 Action Item(s): #7 and #22
•	 Project Type: Ongoing
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•	 Agency: VA
•	 Description: VHA Office of Quality and Performance has initiated quality measures for 
timing, diagnostics and treatment of community-acquired pneumonia.     
•	 2008 Update: Data from VHA's Office of Quality and Performance reveal that for 
Performance Measures CAP 11 (Initial antibiotic started within 8 hours of presentation) 
comparing national numbers from 2005, 2006 and 2007, percent of community-acquired 
pneumonia cases admitted to inpatient status received initial antibiotics within 8 hours of 
presentation for 73.5%, 88.9%, and 94.4% of the time respectively. For CAP12 (Initial 
antibiotic started within 4 hours), the numbers are 44.4%, 68.7%, and 80.9%, respectively 
for FY 2005, 2006, and 2007. For FY 2008, CAP11 and 12 transitioned to CAP23j (Initial 
antibiotic given within 6 hours of arrival) where this occurred 92% of the time (during the 
course of the year, this improved from 91% in first quarter to 95% in fourth quarter).   
CAP 14 (Appropriate initial antibiotic for immunocompromised, non-ICU admission) was 
69.7%, 82.2%, 89%, and 92%, respectively for FY 2005, 2006, 2007, and 2008.  And, 
CAP10 (Blood culture obtained before initial dose of antibiotic) for community-acquired 
pneumonia admitted, quarters 2, 3 and 4 for FY 2005, 2006, and 2007, respectively, 
revealed rates of 87.5%, 90.3%, and 92.7%, respectively. During FY 2008 the measure 
was transitioned to CAP18 (Blood cultures performed in Emergency Department prior to 
first antibiotic dosing) where the performance was 97%. During FY 2008, a new measure 
of CAP13 (Appropriate initial antibiotic for immunocompromised, ICU admission) was 
added for baseline measurement.  
PROJECT TITLE: TRANSFORMATIONAL MEASURES FOR VHA-INFECTION RATE 
REDUCTION 
•	 Action Item(s): #7 and #22
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: VHA Office of Quality and Performance has espoused as Transformational 
Measure 1, Infection Rate Reduction which included central line-associated bloodstream 
infections, ventilator-associated pneumonias and methicillin-resistant Staphylococcus 
aureus prevention. Transformational measures are incremental measures designed to 
support long term strategic goals. They are visionary and identify areas of significant 
system impact, but may not be attainable in a single performance year.   
•	 2008 Update: Formally adopted as transformational measures for FY 2008.  Ventilator-
associated pneumonia and central-line-associated bloodstream infections in the ICUs 
have been in effect since FY 2006 through the VA Inpatient Evaluation Center (IPEC). 
MRSA Prevention Initiative started in FY 2007. All are ongoing. Transformational
measures indicates that no definitive measures have been selected, but the issue is of 
such significance to the organization that individual ones are being reviewed for inclusion 
in the next set of performance measures. 
PROJECT TITLE: PARTICIPATION IN THE INSTITUTE FOR HEALTHCARE 
IMPROVEMENT'S 5 MILLION LIVES CAMPAIGN 
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•	 Action Item(s): #7
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: Relative to antibiotic resistance the individual campaigns 'Reduce 
Methicillin-Resistant Staphylococcus aureus (MRSA) Infection,' 'Prevent Surgical Site 
Infections,' 'Prevent Central Line-Associated Bloodstream Infections,' and 'Prevent 
Ventilator-Associated Pneumonia' have been espoused. 
•	 2008 Update: Ongoing. Establishment of performance measures as part of the annual 
evaluation for the Executive Career Field (ECF) performance plans for VHA regional 
directors and individual medical center directors.  These will be transformational 
measures for the organization.  Transformational measures indicates that no definitive 
measures have been selected, but the issue is of such significance to the organization 
that individual ones are being reviewed for inclusion in the next set of performance 
measures.
ACTION ITEM #8 
PROJECT TITLE: QUALITY HIV DRUG RESISTANCE GENOTYPING SERVICES TO PEPFAR 
COUNTRIES (INTERNATIONAL LABORATORY BRANCH, DIVISION OF GLOBAL AIDS, 
NCHHSTP) 
•	 Action Item(s): #8
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Purpose of this ongoing project is to provide the best possible quality data 
and services to PEPFAR countries on HIV drug resistance surveillance and monitoring.
•	 2008 Update: Ongoing. Our laboratory is the only laboratory within CDC which has been 
accredited by College of American Pathologists (CAP) and one of only 6 laboratories in 
the world that has been accredited by WHO ResNet as a specialized drug resistance 
laboratory (SDRL). Any data we provide to PEPFAR countries have been generated by 
certified technologists or scientists and the assays we use have been validated in our lab 
based on CAP standards. We routinely participate in CAP, WHO and AccuTest PT 
programs for our assays. For the past two years, we have provided genotyping and 
analytic services for the surveillance of transmitted HIV DR in recently-HIV-infected 
populations in Tanzania, Malawi, Kenya, China and Botswana. The results indicate that 
transmitted HIV DR in recently-infected populations are low, less than 5%. Results from 
two of the surveys, Tanzania and Malawi, have been published in peer-reviewed
scientific journal (Antiviral Therapy, 2008). A manuscript describing the transmitted HIV 
DR results from China has been submitted to a peer-reviewed journal for review and 
manuscripts are currently in preparation describing results from Botswana and Kenya. In 
2008, we also expanded HIV drug resistance surveillance to include HIV-infected patients 
on ARV treatment. The pilot projects for monitoring patients on ART were implemented in 
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2 sites in Nigeria and 3 sites in Malawi. Analyses on baseline samples from Nigeria 
indicated that patients infected with CRF06-cpx viruses from harbored high proportion of 
MDR and 6 patients with primary DR. These results suggest treatment outcomes from 
these patients should be closely monitored. 
PROJECT TITLE: DEVELOPMENT OF STANDARDIZED HIV DR TRAINING PACKAGE AND
PILOT OF THE TRAINING IN AFRICA 
•	 Action Item(s): #8 
•	 Project Type: New
•	 Agency: CDC
•	 Description: In order to generate quality-assured genotyping data and to make 
sustainability of HIV DR genotyping a reality in resource-limited countries, in collaboration 
with WHO ResNet and acting as a member of the ResNet laboratory group, the 
International Laboratory Branch (ILB)  has been closely working with WHO in 2008 to 
develop a standardized HIV DR training package.  
•	 2008 Update: In 2008, a framework for a standardized HIV DR laboratory training
package was established in collaboration with WHO ResNet group. The training package 
was developed according to the 12 essential of quality management systems of CLSI. 
Thirteen modules were developed and a pilot training session was conducted in April 
2009. Thirty-four trainees from 13 African countries attended the training. Current plan is 
to develop additional modules and to plan a 2nd training. 
PROJECT TITLE: PERTINENT TRAINING
•	 Action Item(s): #8
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Continue to ensure validity of antimicrobial susceptibility information 
derived from NARMS.
•	 2008 Update: NARMS laboratories continue to participate in the WHO-Global Salm-Surv 
External Quality Assurance System (EQAS). The EQAS supports the assessment of the 
quality of serotyping and antimicrobial susceptibility testing of Salmonella in all 
participating laboratories. The NARMS program has developed two secondary 
antimicrobial testing plates for Salmonella and E. coli; a fluoroquinolone panel and 
extended-spectrum cephalosporin panel, which are now in use in all three NARMS 
laboratories.
ACTION ITEM #10 
PROJECT TITLE: ADOPTATION AND IMPLEMENTATION OF WHO METHODOLOGIES ON
HIV DRUG RESISTANCE IN PEPFAR COUNTRIES (INTERNATIONAL LABORATORY 
BRANCH, DIVISION OF GLOBAL AIDS, NCHHSTP)
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•	 Action Item(s): #10
•	 Project Type: Ongoing
•	 Agency: CDC 
•	 Description: Aim of the project is to harmonize the CDC-supported HIV drug resistance 
surveillance in PEPFAR countries is in line with the WHO recommended methodologies. 
To ensure the data generated can be compared and analyzed. 
•	 2008 Update: By adopting the WHO methodologies for transmitted HIV drug resistance 
survey, termed Threshold Survey (TS). We have shared data generated from 3 countries 
with WHO and make data analysis from different countries a reality. With the close 
collaboration on protocol developments and harmonization with WHO ResNet, data 
generated from CDC from PEPFAR countries have become part of the HIV drug 
resistance database at WHO. We have submitted data from Tanzania, Malawi and 
Kenya. For the first time in HIV DR surveillance history, all the data generated from
PEPFAR and WHO-supported countries can be analyzed and compared which make a 
global HIV DR surveillance database a reality. In 2008, the surveillance of transmitted 
HIV DR in recently HIV-infected populations has been expanded to Botswana and China. 
PROJECT TITLE: POPULATION-BASED, NATIONAL/REGIONAL SURVEY FOR TB DRUG 
RESISTANCE 
•	 Action Item(s): #10
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: In 2008, the fourth report of ongoing population-based, national/regional 
survey for TB drug resistance sponsored by the WHO and the International Union 
Against TB and Lung Disease (IUATLD) will be issued, representing up to 85 countries 
and >50,000 patients. The Division of TB Elimination, via both the Mycobacteriology 
Laboratory Branch and the International Research and Programs Branch, has contributed 
substantially to this massive, sustained surveillance effort by: 1) providing scientific and 
technical leadership, quality assurance, and training to national and regional TB labs; 2)  
conducting surveys and surveillance programs in several countries which contribute data 
to the WHO/IUATLD program; and 3) leading in the development of international
standard case and outcome definitions and surveillance procedures for MDR TB. 
•	 2008 Update: Results remain the same as for 2007. Ongoing, data on new cases were 
available for 72 countries and 2 special administrative regions (SARs) of China. DST 
results were available for 62, 746 patients. The proportion of resistance to at least one 
antituberculosis drug (any resistance) ranged from 0% in two Western European 
countries to 56.3% in Baku, Azerbaijan. The proportion of MDR ranged from 0% in eight 
countries to 22.3% in Baku, Azerbaijan and 19.4% in the Republic of Moldova. Data on 
previously treated cases were available for 66 countries and 2 SARs of China. In total, 
DST results were available for 12,977 patients. Resistance to at least one anti­
tuberculosis drug (any resistance) ranged from 0% in three European countries to 85.9%, 
in Tashkent, Uzbekistan. The highest proportions of MDR were reported in Tashkent, 
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Uzbekistan (60.0%), and Baku, Azerbaijan (55.8%). Thirty five countries and two SARs 
were able to report data on XDR-TB either through routine surveillance data or through 
drug resistance surveys. In total, data were reported on 4, 012 MDR-TB cases, and 
among those 301 or 7.0% XDR-TB cases were detected. 
PROJECT TITLE: PRESERVING EFFECTIVE TB TREATMENT STUDY (PETTS) 
•	 Action Item(s): #10
•	 Project Type: Ongoing
•	 Agency: CDC 
•	 Description: Prospective, multinational cohort study of MDR TB treatment to determine 
the extent to which the "Green Light Committee" mechanism prevents acquired 
resistance to 2nd-line drugs. The Green Light Committee is an international committee of 
experts on MDR TB that enables TB control programs to purchase quality-assured 2nd­
line anti-TB drugs at substantially reduced costs through WHO and the Global Drug
Facility's pooled procurement program. To receive Green Light Committee approval, 
programs must demonstrate their readiness to manage MDR TB in accordance to
published WHO guidelines. 
•	 2008 Update: Enrollment was completed in June 2008 with a total of 1,785 patients 
entered into the database. From these patients, approximately 4,710 culture isolates of 
M. tuberculosis were received at CDC's mycobacteriology laboratory, including 1617 
baseline isolates and 3,093 follow-up isolates. Baseline drug susceptibility test results to 
date indicate resistance to 2nd-line drugs in 10% to 20% (depending on which drug) of 
MDR TB patients at the start of treatment with ~5% having extensively drug resistant 
(XDR) TB with a broad range across countries. Follow-up will continue until June 2010.  
This study demonstrated that large, multinational clinical and epidemiological studies of 
MDR TB with long-term follow-up are indeed possible and affordable and provided the 
first substantial data on the baseline prevalence and distribution of 2nd-line drug
resistance and genotypes among MDR TB cases in several countries. The Division of TB 
Elimination has also implemented programmatic and clinical research projects to address 
principal issues during several international outbreaks of MDR TB. 
PROJECT TITLE: DEVELOPMENT OF A NOVEL, RAPID VIABILITY BASED ASSAY FOR 
YEAST ANTIFUNGAL SUSCEPTIBILITY TESTING 
•	 Action Item(s): #10
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The goals of this project: (1) Development of a yeast antifungal 
susceptibility testing method (AFST) using the viability dye FUN1in a flow cytometry 
based assay to generate objective results in under 6 hours. Results of conventional 
AFST methods are available in 24 hours and are often subjective. (2) To adapt the flow 
cytometry based system to a fluorescent plate reader format for AFST. This will allow 
routine clinical microbiology including state health laboratories to use this methodology in 
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a cost-efficient, objective and user-friendly fashion. (3) To perform a multi-center study to 
evaluate the inter-laboratory reproducibility of this novel AFST assay 
•	 2008 Update: Assay parameters including dye concentrations, appropriate incubation 
temperature/ time, interpretation and analyses of results for representative Candida and 
Cryptococcus isolates have been established. Several domestic and international 
laboratories identified to participate in the multi-center study. Antifungal susceptibilities of 
20 C. albicans and 10 C. neoformans isolates to amphotericin B and fluconazole have 
been generated using the new flow cytometry based assay. Results were comparable 
with the established CLSI AFST method.  
PROJECT TITLE: DEVICES CONTAINING ANTIMICROBIALS GUIDANCE
•	 Action Item(s): #10
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Draft guidance document for industry: how the Center for Devices and 
Radiologic Health (CDRH) intends to regulate devices containing antimicrobial agents, 
and what information regarding efficacy and resistance CDRH wants to see in premarket 
applications.
•	 2008 Update: Draft guidance published in July 2007 with comments due by October 
2007. Comments received and reviewed with final guidance to issue soon.  
ACTION ITEM #13 
PROJECT TITLE: MONITORING DRUG RESISTANCE IN LYMPHATIC FILARIASIS 
ELIMINATION PROGRAMS 
•	 Action Item(s): #13
•	 Project Type: New
•	 Agency:  CDC
•	 Description: Annual mass treatment with antifilarial drugs (albendazole plus either 
ivermectin or diethylcarbamazine) is the cornerstone of the global program to eliminate 
lymphatic filariasis (LF). Although the primary goal of the program is to interrupt 
transmission of LF, additional benefits also are expected because of the known 
anthelminthic properties of these drugs. Substantial reductions in the prevalence of 
intestinal helminth infections are associated with mass treatment for LF. Though
encouraging, the results also raise questions about the intensity of selection for 
albendazole resistance. Genes for resistance to benzimidazoles are known to occur at a 
low frequency in all nematodes studied to date. Monitoring for drug resistance has not 
been done as part of the LF elimination program. We are monitoring the development of 
albendazole resistance in the context of the LF elimination efforts in Haiti.   
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•	 2008 Update: Samples were collected pre- and post-MDA from 4 sites. These samples 
are being analyzed by colleagues at McGill University with pyrosequencing techniques to 
detect changes in the frequency of alleles for benzimidazole resistance.   
ACTION ITEM #15 
PROJECT TITLE:  SENTINEL SURVEILLANCE FOR HUMAN AFRICAN TRYPANOSOMIASIS 
TREATMENT FAILURE AND DRUG RESISTANCE 
•	 Action Item(s): #15
•	 Project Type: New
•	 Agency: CDC
•	 Description: A sentinel surveillance network (HATSENTINEL) has operated since 2002 
to monitor geographical and temporal trends in efficacy of treatment for human African 
trypanosomiasis, identify risk factors for treatment failure, and perform limited drug 
susceptibility testing. During 2008, the network operated at 8 sites in 5 countries (Angola, 
Democratic Republic of Congo, Sudan, Tanzania, and Uganda). 
•	 2008 Update: Despite high rates (61-98%) of melarsoprol treatment failure documented 
in parts of Angola and Democratic Republic of Congo, eflornithine remains fully effective 
at all sentinel sites treating Trypanosoma brucei gambiense infection. Melarsoprol 
efficacy remains high for treatment of T. b. rhodesiense. Drug susceptibility data are 
being collected for specimens from areas of melarsoprol-refractory T. b. gambiense in 
central Democratic Republic of Congo. 
PROJECT TITLE: SURVEILLANCE FOR STREPTOCOCCUS PYOGENES AMONG MILITARY 
TRAINEES 
•	 Action Item(s): #15
•	 Project Type: Ongoing
•	 Agency: DoD
•	 Description: Increasing resistance of S. pyogenes to macrolide antibiotics is a concern.  
Furthermore, during military-recruit training exercises, penicillin-allergic patients are often 
given erythromycin when mass prophylaxis is recommended.  If resistant organisms are 
present or develop in this population, S. pyogenes infections (latent or overt) may not be 
treated effectively. Recruits could be reservoirs of resistant pathogens for military 
populations.   This project conducts antimicrobial susceptibility and gene typing on S. 
pyogenes isolates collected from recruits at 9 military training centers and monitors for S. 
pyogenes resistance rates.
•	 2008 Update: Ongoing. Reports of susceptibility test results and summary statements 
are being provided to primary care facilities, are accessible to DoD staff at  
www.geis.fhp.osd.mil. Generated data show moderate antibiotic resistance through 2007.  
National DoD surveillance data for antibiotic resistance and emm gene type of group A 
streptococcal isolates from eight basic-training military sites was published in the Journal 
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of Clinical Microbiology, Vol 48, October 2003.  All isolates remain susceptible to 
penicillin, and macrolide resistance remained steady at approximately 10%. NHRC 
assisted in S. pyogenes outbreak investigations at 3 recruit training centers in 2006-07. 
Data from this surveillance was presented to the Defense Health Board (formerly the 
Armed Forces Epidemiology Board) in December 2006 and September 2007.  Additional 
publication: Crum NF, Russell KL, Kaplan EL, Wallace MR, Wu J, Ashtari P, Morris DJ, 
Hale BR. Pneumonia outbreak associated with group a Streptococcus species at a 
military training facility. Clin Infect Dis. 2005 Feb 15;40(4):511-8. This project is a core 
part of the Navy Health Research Center funding by GEIS. 
PROJECT TITLE: MULTILOCUS SEQUENCE ANALYSIS OF STREPTOCOCCUS 
PNEUMONIAE ISOLATES 
•	 Action Item(s): #15
•	 Project Type: Ongoing
•	 Agency: DoD 
•	 Description: DoD data from 1981 to 1991 suggest that S. pneumoniae may cause about 
12% of military pneumonia hospitalizations.  Multilocus sequence typing characterizes 
isolates of bacterial species using the sequences of internal fragments of 7 house­
keeping genes.  This highly discriminatory molecular typing method is used to track the 
global spread of virulence, to provide a direct comparison of isolates of multidrug­
resistant S. pneumoniae, to define serotypes of isolates, estimate recombinational 
parameters, and identify discrete clonal complexes.
•	 2008 Update: A pneumococcal isolate from a fatal case of meningitis was investigated 
using this technique, allowing the discovery of a non-vaccine serotype not commonly 
found among meningitis cases. During 2003 a conjunctivitis outbreak of S. pneumoniae
was identified and analyzed. This work enabled the identification of a novel strain 
responsible for the outbreak and provided epidemiologic information on the causative 
isolate's resistance pattern. Further analyses of pneumococcal strains from Egypt is in 
process in hopes of providing valuable epidemiologic data for prevention and treatment 
options. Publications: Wasfy MO, et. al. Antimicrobial susceptibility and serotype 
distribution of Streptococcus pneumoniae causing meningitis in Egypt, 1998-2003. J 
Antimicrob Chemother. 2005 Jun;55(6):958-64. Crum NF, Barrozo CP, Chapman FA, 
Ryan MA, Russell KL. An outbreak of conjunctivitis due to a novel unencapsulated
Streptococcus pneumoniae among military trainees. This project is a core part of the 
Navy Health Research Center funding by GEIS. 
PROJECT TITLE: INVESTIGATIONS OF METHICILLIN-RESISTANT STAPHYLOCOCCUS 
AUREUS (MRSA) OUTBREAKS OCCURRING ON MILITARY BASES   
•	 Action Item(s): #15
•	 Project Type: Ongoing
•	 Agency: DoD
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•	 Description: Hospital acquired MRSA outbreaks are well known, but recent reports have 
caused concern about community acquired MRSA infections. Investigations into this 
recent trend have been conducted at several military bases. Laboratory work has 
involved culture identification followed by antibiotic resistance testing. The presence of 
the panton valentine leukocidin gene which is a known virulence factor has been shown 
in many of these investigations. The multilocus sequence typing method has also been 
used to identify global virulent clones by characterizing the isolates with the sequencing 
of 7 house-keeping genes. Further molecular analyses have been utilized to discover the 
specific SCCmec type of these MRSAs, which is the mobile genetic element that 
mediates the methicillin resistance.
•	 2008 Update: BAMC investigators have conducted a randomized trial to look at 
mupirocin intranasal treatment and reduced MRSA carriage. Unfortunately, there was no 
reduction in carriage within the treated group.  BAMC has also been collecting and 
characterizing MRSA isolates from across the MHS.NHRC has been testing MRSA 
isolates for over 15 years within military populations in the San Diego area. Molecular 
characterization has shown the emergence of distinct community-acquired MRSA strains 
that were genetically unrelated to nosocomial MRSA isolates from the same community. 
This is a core project funded yearly by GEIS at BAMC. 
PROJECT TITLE: INVESTIGATION OF MULTI-DRUG RESISTANT ACINETOBACTER
BAUMANNI IN US SERVICE MEMBERS 
•	 Action Item(s): #15
•	 Project Type: Ongoing
•	 Agency: DoD
•	 Description: Acinetobacter baumannii is an opportunist, with pathogenicity usually 
associated with high infectious doses or contamination of deep or necrotic wounds. Its 
importance as a nosocomial agent is due to its high rate of multi-antibiotic resistance.  A 
review of A. baumannii infection in wounded US service persons is underway to 
determine 1) the number and location of patients involved, 2) what risk factors are 
common to the patients (e.g., military unit or geographic proximity before injury, type and 
site of wound causing hospitalization, specimen source, type and location of all medical 
and surgical treatment, exposure to other patients with A. baumannii infection), 3) the 
phenotypic strain(s) of A. baumannii involved, 4) genotyping of strains currently involved 
in hospitals at NNMC and WRAMC, and 5) sequencing isolates to conduct molecular 
epidemiology study with the Naval Medical Research Center.
•	 2008 Update: DoD GEIS has established a strategic initiative to monitor changes in 
Acinetobacter isolates recovered from large medical centers. The medical centers that 
are participating are WRAMC, BAMC, LRMC and NNMC. WRAIR is coordinating the 
effort and serving as a focal point for sharing data.  An epidemiologist is reviewing the 
data and providing monthly reports to critical MHS responsible officials to help raise 
awareness and augment infection control. SOPs and quality control procedures have 
been established and data exchange has been initiated. The goal is to have regular 
reports generated by this project and disseminated to the military health system. This 
system will expand to other MDROs in the future. GEIS is also funding an in theater study 
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at a combat support hospital to try to identify the common source of Acinetobacter 
infections. 
PROJECT TITLE: ELECTRONIC DATA CAPTURE OF CLINICAL MICROBIOLOGICAL AND
AR DATA IN EXISTING MILITARY TREATMENT FACILITY MEDICAL RECORDS, USING HL7 
MESSAGE DATA, FOR SURVEILLANCE OF ANTIMICROBIAL RESISTANCE (NEW EFFORT) 
•	 Action Item(s): #15
•	 Project Type: Ongoing
•	 Agency: DoD
•	 Description: Surveillance of antimicrobial resistance and monitoring trends in emerging 
AR are important to military and public health. Empirical treatment guided by validated 
sensitivity and resistance data can lead to improved patient outcomes and a reduction in 
the emergence of resistance. However, it is difficult to establish this capability effectively 
across a spectrum of military medical facilities located in the US and in many foreign 
countries. A prior approach to developing such a system has been tried through a 
partnership with TSN (described in another part of this report); this was successful but 
has not expanded beyond four medical centers. 
•	 2008 Update: Ongoing. The Navy and Marine Corps Public Health Center, Portsmouth, 
VA, is testing a newer approach using Health Level 7 (HL7) data generated from the 
military health system. HL7 microbiology data were restructured for analysis using 
WHONET© to produce detailed reports characterizing antibiotic resistance in 
beneficiaries served by four military treatment facility (MTF) laboratories. A total of 32,264 
isolates were identified from clinical specimens collected from July 2005 to October 2007.  
The efficiency and scope of DoD-level electronic surveillance, using this approach, will 
augment existing institutional-level surveillance techniques. This method can be 
expanded to include many more military centers and clinics - it is the first methodology to 
provide the possibility of timely AR surveillance and analysis of clinical microbiology 
laboratory data in the military population; this approach can lead to improvements in 
health outcomes, reduced healthcare costs and earlier recognition of adverse trends in 
antibiotic sensitivity. Electronic methodologies are currently being validated with 
laboratory result data. 
ACTION ITEM #17 
PROJECT TITLE: FDA SCIENCE BOARD REVIEW OF THE NARMS PROGRAM
•	 Action Item(s): #17
•	 Project Type: Ongoing
•	 Agency: CDC, FDA, USDA
•	 Description: A scientific review designed to help the program identify how it can 
enhance the coordination among the three arms to provide a more comprehensive look 
at drug resistance in enteric bacteria was initiated.
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•	 2008 Update: In 2007, the NARMS program underwent an extensive review by the FDA 
Science Board, focusing on 4 major areas: sampling strategies, data reporting and 
harmonization, coordinated research, and international surveillance activities. FDA 
responded to the Board’s recommendations, and is prioritizing recommendations for 
improving the program. Strategic planning and methods harmonization meetings were 
held September 17-18, 2007 and September 10-12, 2008 focusing on progress and plans 
to continue implementing the Science Board recommendations where appropriate. 
Sampling strategies have since focused on alternate approaches to food animal 
slaughter surveillance and extension of retail monitoring to capture additional pathogens 
of interest such as Clostridium difficile and methicillin-resistant Staphylococcus aureus. 
Data reporting and harmonization goals have been furthered by publication of executive 
summaries of NARMS food animal, retail meat and human isolate data for CY2004 and 
2005, and resources have been sought to improve business practices and electronic 
infrastructure to better share and present combined NARMS data. Plans for joint NARMS 
projects/publications were developed in CY2008. The three NARMS agencies have 
engaged in international activities such as participating in AGISAR (the WHO Advisory 
Group on Integrated Surveillance of Antimicrobial Resistance), the Codex Alimentarius 
ad hoc Task Force on Antimicrobial Resistance as well as expanding support for 
international capacity building in surveillance of antimicrobial resistance in foodborne 
pathogens through WHO. 
PROJECT TITLE: INTEGRATED (HUMAN, ANIMAL, RETAIL) NATIONAL ANTIBIOTIC
RESISTANCE MONITORING SYSTEM FOR ENTERIC BACTERIA (NARMS) REPORT 
•	 Action Item(s): #17 
•	 Project Type: Ongoing
•	 Agency: CDC, FDA, USDA
•	 Description: An integrated summary of human, animal, and retail meat NARMS data for 
annual publication.  
•	 2008 Update: Center for Veterinary Medicine (CVM) released the CY 2003 executive 
report, which summarizes data on Salmonella and Campylobacter isolates from all three 
components of the program in an integrated format, on CVM’s website on February 5, 
2007. The joint FDA, CDC and USDA CY 2004 Executive Summary of NARMS data 
became available Summer 2007. The fourth annual NARMS retail meat report provides
2005 data on the prevalence of antimicrobial resistant foodborne pathogens and 
commensal bacteria among retail meat and poultry samples, comprising results from 
nearly 4,800 samples; the report was released in December, 2007. As of the end of CY 
2008, NARMS published two executive summaries of food animal, retail meat and human 
isolate susceptibility data collected by USDA, FDA-CVM and CDC, respectively, for 
calendar years 2003 and 2004. The three NARMS partner agencies began to explore 
business practices and electronic infrastructure that would facilitate efficient data sharing 
and presentation in a more timely fashion, and sought additional resources and 
partnerships to further these goals. Center for Veterinary Medicine (CVM) released the 
CY 2004 executive report on CVM’s Website July 2008. The fifth annual NARMS Retail 
Meat Annual Report was released in October 2008 and provides 2006 data on the 
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prevalence of antimicrobial resistant foodborne pathogens and commensal bacteria 
among retail meat and poultry samples, comprising results from nearly 4,800 samples.  
PROJECT TITLE: ANTIMICROBIAL RESISTANT BACTERIA IN FEED INGREDIENTS
•	 Action Item(s): #17 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Assess the prevalence of antimicrobial resistant bacteria in feed 
ingredients, primarily rendered product. This work is being done in conjunction with FDA 
field personnel. Results will be coordinated with NARMS. 
•	 2008 Update: Initial surveys of rendered products and plant based proteins completed. 
CVM continues to screen feeds and feed commodities for the presence of antimicrobial 
resistant Enterococcus and E. coli. 
ACTION ITEM #18 
PROJECT TITLE: NARMS ENTEROCOCCI AND E. COLI SURVEILLANCE STUDY
•	 Action Item(s): #18 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Determine the susceptibility patterns for isolates of Enterococci and E. coli
isolated from stool samples of healthy persons or outpatients from the community. 
Determine the risk factors associated with resistant and susceptible bacteria.    
•	 2008 Update: In CY2008, three states sent isolates of enterococci and one state
submitted generic E. coli to the NARMS CDC lab collected from stool of healthy
volunteers or outpatients who report no hospitalization. Interviews were conducted to 
determine specific environmental, medical, and food exposures previous to the culture. 
The three NARMS agencies explored comparability and reporting options for food animal, 
retail meat, and human Enterococcus and generic E. coli isolates. 
PROJECT TITLE: ANTIMICROBIAL RESISTANT BACTERIA IN SENTINEL HUMAN 
POPULATIONS 
•	 Action Item(s): #18 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Evaluate abattoir workers for carriage of antimicrobial resistant bacterial 
pathogens. 
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•	 2008 Update: CVM funded a cooperative research agreement to academic investigators 
at the University of Maryland to characterize antimicrobial resistance and genetic 
relatedness among enterococcal isolates from retail poultry, and healthy and ill humans.  
The study has concluded and data analysis is complete. CVM scientists continue to 
partner with scientists in the Mexican Resist-Vet surveillance program to determine the 
prevalence of Salmonella species and quinolone-resistant non-type specific E .coli from 
human clinical cases, asymptomatic children, and raw retail meats. 
ACTION ITEM #19 
PROJECT TITLE: INVESTIGATING ENVIRONMENTAL SINKS OF MACROLIDE 
ANTIBIOTICS, AND ILLICIT DRUGS, WITH ANALYTICAL CHEMISTRY 
•	 Action Item(s): #19 
•	 Project Type: Ongoing
•	 Agency: EPA 
•	 Description: Research to determine what, if any, environmental sinks the macrolide 
antibiotics and illicit drugs (e.g., methamphetamine, MDMA) apportion to. This will
include: source waters, wastewaters, biosolids, wetland plants, sediments, and possibly 
fish tissue. Antibiotics being analyzed include azithromycin, roxithromicin, and 
clarithromycin.  
•	 2008 Update: Ongoing. Preliminary data suggests that there are reservoirs of the 
macrolides other than wastewater and biosolids (i.e., wetland plant/roots and sediments). 
Some correlation between prescribed use of macrolides and environmental findings, but 
presence of Roxithromycin, which is not used in the U.S., suggests other means are used
for obtaining antibiotics. Thus far, four articles have been published in a direct response 
to this research.  
PROJECT TITLE: OCCURRENCE, TRANSPORT, AND FATE OF PHARMACEUTICALS AND 
OTHER EMERGING CONTAMINANTS PRESENT IN WASTEWATER 
•	 Action Item(s): #19 
•	 Project Type: Ongoing
•	 Agency: EPA 
•	 Description: At ten locations, samples were collected upstream and at two sites 
downstream from the wastewater treatment plant discharge, as well as from the effluent 
pipe. Of the 110 compounds investigated in effluents and surrounding surface waters, 78 
were detected at least once. Different chemicals exhibited diverse environmental
persistence.
•	 2008 Update: This project supplied information on the occurrence and fate of 
pharmaceuticals and other wastewater derived compounds. This information is being 
applied in other projects that are (1) evaluating the compounds for use as indicators of 
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human fecal contamination; and (2) ascertaining which chemicals are present in finished 
drinking water. 
PROJECT TITLE: PERSISTENCE OF CONTAMINANTS FROM WASTEWATER
DISCHARGES DURING DRINKING WATER TREATMENT:  IDENTIFICATION OF 
COMPOUNDS AND DEGRADATION/DISINFECTION BYPRODUCTS, EVALUATION OF 
REMOVAL, AND POTENTIAL EXPOSURE
•	 Action Item(s): #19 
•	 Project Type: Ongoing
•	 Agency: EPA 
•	 Description: Compounds in wastewater, including antibiotics, discharged from a 
treatment plant or septic system have the potential to end up in surface or groundwater 
that may ultimately be used as a source of drinking water. This project is being conducted 
in two phases. In Phase I (2007), source and finished water from nine drinking water 
treatment plants (DWTPs) were analyzed for 83 different chemicals. In Phase II (2009­
2010), both the number of DWTPs (20-30) and the number of analytes (~200) will be 
increased.
•	 2008 Update: Ongoing. This work will assist the USEPA's Office of Water in determining 
which compounds should be included in future Unregulated Contaminant Monitoring 
Regulation (UCMR) sampling plans. Knowledge of the occurrence and persistence of 
these compounds will become increasingly important in the future as the demands on 
potable water sources increase and communities turn to approaches such as water reuse 
to supplement their drinking water supply. 
PROJECT TITLE: MONITORING FOR RESISTANCE TO KASUGAMYCIN IN APPLE 
ORCHARDS PRIOR TO AND AFTER THE APPLICATION OF KASUGAMYCIN TO CONTROL 
FIRE BLIGHT
•	 Action Item(s): #19 
•	 Project Type: New
•	 Agency: EPA 
•	 Description: Project intended to examine bacterial resistance to kasugamycin in the 
blossom, leaf surface, and soil bacterial communities. In addition, it will identify any 
kasugamycin-resistant (KmR) bacterial isolates and determine the occurrence of KmR 
genes in these environmental isolates. 
•	 2008 Update: Planning for the study occurred in 2008 and research was initiated in 
Spring 2009. Data are expected to be submitted to the Agency in the Winter/Spring of 
2010.
PROJECT TITLE: HYDROLYTIC TRANSFORMATION OF EMERGING CONTAMINANTS 
•	 Action Item(s): #19 
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•	 Project Type: New
•	 Agency: EPA 
•	 Description: This project plans to assess the fate of emerging contaminants, with 
emphasis on pharmaceutically-active chemicals and their chemical transformations, at 
environmentally relevant conditions. The target list of chemicals to be studied includes 
antibiotics such as amoxicillin, azithromycin, clarithromycin, erythromycin, lincomycin, 
penicillin, and tylosin, which have the potential to undergo chemical transformation in the 
environment. The effect of environmental variables, which could include pH, temperature, 
dissolved metals, natural organic matter, and presence of solid media (sediments and 
soils) on the chemical transformation of such chemicals will be evaluated.
•	 2008 Update: Ongoing. Study scheduled to begin FY 2011.
PROJECT TITLE: ENHANCE OVERALL UNDERSTANDING OF PATHOGENS THAT POSE A 
FOOD-SAFETY RISK PARTICULARLY FROM THE ENVIRONMENT 
•	 Action Item(s): #19 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Pilot study to determine the contribution waterways play in movement of 
bacteria originating from animal production facilities in particular. 
•	 2008 Update: Sulfonamide antibacterial agents have been found in effluent from
wastewater treatment plants and waterways worldwide. Sulfamethazine (used in
veterinary medicine) and sulfamethoxazole (used in human medicine) are two 
sulfonamides of particular interest because of their extensive use. Immunoassays for 
sulfamethazine and sulfamethoxazole worked well in the analyses of wastewater from 
swine-rearing facilities and municipal wastewater treatment plants. The immunoassay 
results were confirmed by liquid chromatography-mass spectrometry-based analyses. 
New methods have been developed to look at levels of chemicals and bacteria in 
wastewater, lagoon pits, and wetlands. These methods and research may point to 
potential mediation. 
FOCUS AREA II: PREVENTION AND CONTROL 
ACTION ITEM #21 
PROJECT TITLE: RESEARCH PROJECTS (R01): 1. IMPROVING ANTIBIOTIC USE IN 
ACUTE CARE TREATMENT (IMPAACT) TRIAL.  2. IMPLEMENTING EVIDENCE-BASED
GUIDELINES FOR TREATING NHAP
•	 Action Item(s): #21 
•	 Project Type: Ongoing
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•	 Agency: AHRQ
•	 Description: 1. IMPAACT has examined patient, physician, and hospital factors relating 
to appropriate antimicrobial use and has tested different types of interventions to improve 
antimicrobial use in eight emergency departments located across the United States. 2.  
This quasi-experimental study is designed to test the translation of multidisciplinary 
guidelines on evaluating and treating nursing home-acquired pneumonia (NHAP) into 
practice in multiple nursing facilities.
•	 2008 Update: 1. To identify factors that influence community practitioners to prescribe 
antibiotics and examine how they differ from the recommendations of the Centers for 
Disease Control and Prevention (CDC) guideline for treatment of ARI, 101 community 
practitioners were asked to estimate how likely they would be to prescribe antibiotics in 
each of 20 hypothetical cases of ARI. Practitioners were compared with eight faculty 
physicians who evaluated the cases following the CDC guidelines rather than their own 
judgments. Practitioners prescribed antibiotics in 44.5% of cases, over twice the 
percentage treated by the faculty panel using the CDC guidelines (20%). Practitioners 
were most strongly influenced by duration of illness, particularly when accompanied by 
fever or productive cough (Wigton RS et al. J Gen Intern Med 2008;23:1615-20). 2. A 
prospective, chart-review study was conducted among residents of 16 nursing homes in 
three states with 2 signs and symptoms of pneumonia during the 2004–2005 influenza 
season. Mid and high certified nursing assistant (CNA) hours per resident per day were 
significantly associated with better pneumococcal and influenza vaccination rates. More 
than 1.2 licensed nurse hours per resident per day was significantly associated with 
appropriate hospitalization and guideline-recommended antibiotics. A >70% nurse 
turnover was inversely related to timely physician notification and appropriate 
hospitalization (Hutt E et al. J Gerontol A Biol Sci Med Sci 2008;63:1105-11).  
PROJECT TITLE: RESEARCH DEMONSTRATION AND DISSEMINATION PROJECT (R18): 
IMPROVING OTITIS MEDIA CARE WITH HER-BASED CLINICAL DECISION SUPPORT AND 
FEEDBACK 
•	 Action Item(s): #21 
•	 Project Type: Ongoing
•	 Agency: AHRQ
•	 Description: Otitis media is the second commonest disease in childhood and the most 
common reason for antibiotic prescriptions in the United States. Physicians tend to 
overuse antibiotics for otitis media because it can be hard to diagnose, medical care is 
often fragmented across multiple sites and clinicians, and some physicians are not aware 
of national guidelines that recommend more judicious use of these medicines. 
•	 2008 Update: The Children's Hospital of Philadelphia primary care network has been 
organized as a Pediatric Research Consortium with >180,000 children managed by >300 
practitioners from 28 practices in three states. The project will use the Children's Hospital 
electronic health record to integrate care across time and to supply physicians with the 
knowledge they need about how to treat a patient at the point of care. Randomly 
allocating practices into usual care, full intervention, and full intervention without 
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feedback, the project will assess the effects of intervention on quality, resource use, and 
clinician adoption of the technology. 
PROJECT TITLE: RESEARCH DEMONSTRATION (U18): CENTERS FOR EDUCATION AND 
RESEARCH ON THERAPEUTICS (CERTS) PROGRAM: A NATIONAL INITIATIVE TO 
INCREASE AWARENESS OF THE BENEFITS AND RISKS OF NEW, EXISTING, OR 
COMBINED USES OF THERAPEUTICS THROUGH EDUCATION AND RESEARCH 
•	 Action Item(s): #21 
•	 Project Type: Ongoing
•	 Agency: AHRQ
•	 Description: The University of Pennsylvania Center for Education and Research on 
Therapeutics has undertaken studies investigating the association between antibiotic use 
and antibiotic resistance, including the impact of different methods of categorizing prior 
antibiotic use. The Harvard Pilgrim Healthcare CERT supports nine collaborating systems 
within an HMO Research Network to study antibiotic use in children and has evaluated 
the impact of a 16-community trial to promote judicious antibiotic use in Massachusetts.
•	 2008 Update: To identify the prevalence of and risk factors for fluoroquinolone-resistant 
Escherichia coli (FQREC) colonization among hospitalized patients annual fecal 
surveillance studies were conducted in two large medical centers within an academic 
health system. Of the 774 subjects, 89 (11.5%) were colonized with FQREC. The 
association between prior FQ use and FQREC colonization varied significantly by study 
year, suggesting that the clinical epidemiology of resistant organisms may change over 
time (Lautenbach E et al. Infect Control Hosp Epidemiol 2009;30:18-24).
PROJECT TITLE: HIV DRUG RESISTANCE AND CLINICAL EPIDEMIOLOGY 
•	 Action Item(s): #21 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: DHAP’s Epidemiology Branch conducts a number of activities to assess the 
clinical relevance of HIV resistance. The Epidemiology Branch will continue collecting 
commercial HIV genotype and phenotype antiretroviral resistance testing results from the 
convenience sample of ca. 3,000 active adult participants enrolled in the HIV Outpatient 
Study (HOPS) and the Study to Understand the Natural History of HIV/AIDS in the Era of 
Effective Therapy (the "SUN" Study) and ca. 1,000 children and young adults in the 
Longitudinal Epidemiologic Study to Gain Insight into HIV and AIDS in Children and 
Youth (LEGACY). These data will be used to assess modifiable factors for reducing risk 
of developing clinically relevant antiretroviral resistance. 
•	 2008 Update: To summarize the data thus far:   
o	 Among the nearly 1,000 children enrolled in LEGACY, clinicians have ordered 
the following (and results available): 930 genotype tests from among 543 
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participants (1.71 test per participant); 329 phenotype tests from among 230 
participants (1.43 test per participant); and 85 virtual phenotype tests from 
among 68 participants (1.25 test per participant).
o	 In HOPS, which has observed over 8,000 patients in an open cohort since 1997, 
clinicians have ordered the following (and results available): 4,130 genotype tests 
from among 2,194 patients (1.88 tests per patient) and 1,633 phenotype tests 
from among 893 patients (1.83 tests per patient).
o	 In the SUN study which enrolled 700 patients in a closed cohort starting in March 
2004, clinicians have ordered the following (and results available): 346 genotype
tests have been completed among 235 participants (1.5 per patient) and 26 
phenotype tests have been completed among 20 participants (1.3 per patient). 
o	 Multiple guidelines recommend widespread use of antiretroviral resistance 
testing in the management of HIV-infected patients. Although intellectually 
compelling, these recommendations are based predominately on equivocal 
studies of its effect on short-term improvement suppressing HIV replication. It is 
unlikely that in the current environment, randomized controlled trials could be 
conducted to assess the benefit of antiretroviral resistance testing. Our research
indicates that use of both genotypic and phenotypic antiretroviral resistance 
testing is significantly associated with improved survival even after accounting for 
other factors known to affect survival and for potential confounding due to 
differential intensity or quality of care. Early disparities in the use of antiretroviral 
resistance testing observed when the technology became commercially available 
(i.e., less testing among non-Hispanic black and Hispanics, less testing among 
publicly insured patients) appear to have improved or resolved. Testing of 
patients prior to initiation of antiretroviral therapy has increased substantially 
following release of guidance recommending this practice. Initiating suppressive 
antiretroviral therapy at higher CD4 cell counts does not appear to increase the 
prevalence of clinically relevant resistance mutations when virologic failure 
develops.  
PROJECT TITLE: APPROPRIATE USE OF ANTIMICROBIALS
•	 Action Item(s): #21, #22, and #30
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: The VHA has a national formulary, develops and implements care 
guidelines, and provides extraordinary educational opportunities for staff to deal with 
questions concerning appropriate use of antibiotics.  This is an ongoing activity, but the 
effort will continue to be enhanced by further collaboration with federal agencies and 
other partners (including the private sector) since appropriate antibiotic usage involves 
many components such as physician education, education of the public, appropriate drug 
advertising, control of over-the-counter antibiotic use, and many other items that require 
intervention both inside and outside of the federal systems.  Local VA facilities pilot and 
use standardized computerized medical records,  templating and ordering for medication

















Last revised: December 29, 2009 
ordering (including antimicrobials) that incorporate use of clinical pathways for infectious
diseases processes (e.g., pneumonia, peri-operative antimicrobial use) ;  these all help to 
direct providers or care to preferred diagnostic and therapeutic strategies. 
•	 2008 Update: Infectious Diseases Field Advisory Committee has representation on the 
national Antimicrobial Medical Advisory Panel (MAP) for pharmacy.  Local sites update 
pathways and order sets based on local feedback from front line providers and as newer 
regional and national recommendations are available; also as formulary choices change 
(either local, regional or national) there updates also can occur. 
ACTION ITEM #24 
PROJECT TITLE: INPATIENT EVALUATION CENTER (IPEC)    
•	 Action Item(s): #24, #63, and #64
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: The IPEC is a national program to improve outcomes (risk adjusted 
mortality and length of stay) in VA ICUs and eventually in inpatient care through feedback 
of outcomes and implementation of evidenced-based practices. Currently two of the 
initiatives deal with issues related to infection prevention--catheter-related bloodstream 
infections and ventilator-associated pneumonias--both of which may involve resistant 
organisms. These data are reported back immediately to the local facilities who can track 
their rates over time and compliance with performance, as well as see the national mid­
range statistical analysis results. 
•	 2008 Update: IPEC program initiated nationwide during FY 2006 with results 
demonstrating a significant decrease in ventilator-associated pneumonias and central 
catheter related bloodstream infections nationwide since implementation of the program.  
Pilot testing for expansion of the IPEC process into non-ICU acute inpatient care was 
initiated. The IPEC intranet website provides numerous resources regarding evidence-
based practices and implementation strategies for the reduction of healthcare-associated 
events, including infections with antimicrobial-resistant organisms, for frontline healthcare 
personnel. Initial discussions on expansion to the Community Living Center (nursing 
home/long term care) component of VHA care also begun.
ACTION ITEM #25 
PROJECT TITLE: "GET SMART: KNOW WHEN ANTIBIOTICS WORK" NATIONAL MEDIA 
CAMPAIGN
•	 Action Item(s): #25 
•	 Project Type: Ongoing
•	 Agency: CDC, FDA
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•	 Description: This national media education campaign was developed to promote 
appropriate antimicrobial drug use in the community for upper respiratory infections, e.g., 
to decrease patient requests for antibiotics for illnesses for which they offer no benefit.  
Target audiences are the general public, primarily focusing on parents of young children, 
and healthcare providers. The campaign uses a variety of health communication 
materials based on concepts tested in focus groups, and its effectiveness will be 
evaluated when support is available. The first annual Get Smart About Antibiotics Week 
(GSW) was launched during the week of October 6th through 10th, 2008. GSW Goals 
included recruiting new partners and reinvigorating existing partners’ interest in the 
campaign. By creating a newsworthy activity, this goal would lead to expanding the reach 
of key messages by generating media interest regarding the judicious use of antibiotics. 
The observation week would be the basis for forming new partnerships and re-engaging 
past partners to collaborate on a particular project, thereby potentially revitalizing the 
year-round campaign. 
•	 2008 Update: To estimate GSW’s reach, data was collected by totaling the number of 
subscribers to publications that advertised GSW messages. The total number of 
healthcare providers who were estimated to be exposed to GSW messages was 510,000 
and the number of parents of young children estimated to be exposed was 3.8 million. 
Healthcare providers were primarily exposed to GSW messages through advertisements 
in professional publications and websites. Parents of young children were primarily 
exposed through parent newsletters and by the video PSA that played in 2,900 pediatric 
and obstetrician/gynecology waiting rooms. It was anticipated that a total of 500,000 
healthcare providers would be exposed to GSW messages through publications and 
websites. Because there was an estimated 510,000 healthcare providers exposed to 
GSW messages, the target was exceeded. The target of 1.5 million parents with young 
children exposed to GSW messages was also exceeded. To gauge the level of online 
media coverage, staff members used search engines like Google and Yahoo to search 
websites using the key terms “get smart week” and “get smart campaign” during the 
month of October. A total of 145 unique websites were found that contained GSW 
messages or advertised GSW. Eight miscellaneous websites sent out their own press 
releases about GSW. Staff members expected only 75 unique websites to reference 
GSW. This target was exceeded.   
PROJECT TITLE: GET SMART: KNOW WHEN ANTIBIOTICS WORK - PHARMACY 
INITIATIVE 
•	 Action Item(s): #25 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Several projects are in development or implementation stages to increase 
awareness among consumers about antibiotic adherence, and to educate pharmacists 
about counseling customers on appropriate antibiotic use.
2008 Update: In 2008, the Get Smart Team conducted a survey of local pharmacists 
about new trends in retail pharmacies. This information was used to recruit retail
pharmacy partners and develop pharmacy content for the Get Smart website and Get 
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Smart About Antibiotics Week. The primary audience for Get Smart About Antibiotics 
Week 2009 is pharmacists. Get Smart has developed a print ad and podcast to be 
distributed through partners such as the American Pharmacists Association and the 
National Alliance of State Pharmacy Associations. Get Smart staff worked in 
collaboration with the Infectious Diseases Society of America (IDSA) to respond, through 
letters and press releases, to pharmacies that offer free and low-cost antibiotics. This 
outreach led to opportunities to work with retail pharmacies to educate consumers about 
appropriate antibiotic use. CDC is currently inviting these retailers to CDC for a meeting 
to take place on October, 1, 2009. 
PROJECT TITLE: GET SMART: KNOW WHEN ANTIBIOTICS WORK ON THE FARM
•	 Action Item(s): #25 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Conduct a public health education campaign to promote appropriate 
antimicrobial use with the veterinary and agricultural settings as a national health priority, 
involving many partners.
•	 2008 Update: Completed. 7 funded state-based campaigns completed state-based 
projects addressing appropriate antimicrobial use in veterinary and agricultural settings. 
This work resulted in 10 peer-reviewed publications, 11 oral/poster presentations, 3 
behavioral surveys, and printed materials that were distributed to thousands of 
veterinarians and food animal producers. Two state partners, Michigan and Minnesota, 
are developing modules for an online AR veterinary curriculum.  
ACTION ITEM #26 
PROJECT TITLE: MENTORED CLINICAL SCIENTIST AWARD (K08): IMPROVING CARE 
FOR ACUTE RESPIRATORY INFECTION 
•	 Action Item(s): #26 
•	 Project Type: Ongoing
•	 Agency: AHRQ
•	 Description: The recipient is developing and implementing an electronic medical record-
based template for acute respiratory infection (ARI) visits, the ARI Smart Form. The ARI 
Smart Form will standardize documentation of care and give clinicians easy access to 
clinical information, patient-education materials, and clinical decision support with a goal 
of reducing inappropriate antibiotic prescribing.
•	 2008 Update: To determine whether publicly reporting hospital scores on antibiotic timing 
in pneumonia (percentage of patients with pneumonia receiving antibiotics within 4 hours) 
has led to unintended adverse consequences for patients retrospective analyses of 
13,042 emergency department (ED) visits by adult patients with respiratory symptoms in 
the National Hospital Ambulatory Medical Care Survey, 2001-2005, were carried out.  
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Public reporting of hospital antibiotic timing scores has not led to increased pneumonia 
diagnosis, antibiotic use, or a change in patient prioritization (Friedberg MW et al.  Am J 
Managed Care 2009;15:137-44). Linder JA. Editorial commentary: antibiotics for 
treatment of acute respiratory tract infections: decreasing benefit, increasing risk, and the 
irrelevance of antimicrobial resistance. Clin Infect Dis 2008;47:744-6. 
PROJECT TITLE: CAMPAIGN TO PREVENT ANTIMICROBIAL RESISTANCE IN 
HEALTHCARE SETTINGS 
•	 Action Item(s): #26 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The Campaign to Prevent Antimicrobial Resistance in Healthcare Settings 
(the Campaign) was launched in March 2002. The Campaign’s overall goal is to reduce 
antimicrobial resistance (AR) by decreasing inappropriate antimicrobial use and
improving adherence to proven infection control precautions. Five 12-step Programs with 
evidence-based action steps have been developed to target physicians who provide care 
to the following populations: hospitalized adults, dialysis patients, surgical patients, 
hospitalized children, and long-term care residents. Didactic tools and materials also 
have been developed and tested and accompany each of the 12-step Programs to 
promote the implementation of the recommended steps. In addition, materials have been 
developed that focus on the prevention of community-associated methicillin-resistant 
Staphylococcus aureus (CA-MRSA).
•	 2008 Update: The Campaign is currently undergoing an overhaul in an attempt to better 
focus the messages and action steps to enhance its impact. The Campaign now has a 
medical director and a dedicated public health advisor. Major 2008 activities included: 1) 
Finalizing IPA with ID pharmacist to help develop campaign 2) Hosted experts meeting in 
April to get input on the campaign 3) Conducted focused interviews with experts around 
the country to get input on how best to structure the campaign. 
PROJECT TITLE: GET SMART: KNOW WHEN ANTIBIOTICS WORK- STATE-BASED 
MULTIFACETED INTERVENTIONS FOR CLINICIANS AND PATIENTS TO PROMOTE THE
APPROPRIATE USE OF ANTIBIOTICS FOR OUTPATIENT UPPER RESPIRATORY 
INFECTIONS
•	 Action Item(s): #26 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The campaign assists states in implementing broad-based multi­
faceted health communication and behavioral interventions to promote appropriate 
antibiotic use for outpatient upper respiratory infections. State health departments 
develop broad-based coalitions (e.g., state medical societies, healthcare delivery 
organizations, healthcare purchasers, consumer groups), use CDC educational 
materials, develop materials of their own, launch campaigns targeting providers and the 
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general public, and evaluate various aspects of their local campaigns and/or appropriate 
antibiotic use knowledge, behaviors, and attitudes. Controlled trials have demonstrated 
success of this program in decreasing inappropriate prescribing; also, nationwide 
antibiotic prescribing rates for children are declining.  
•	 2008 Update: In FY08, 14 local programs were funded through CDC’s Epidemiology and 
Laboratory Capacity mechanism. The Get Smart campaign maintains a comprehensive 
website that funded sites can utilize to gain access to campaign resources and 
educational tools and to learn more about national campaign activities. The Get Smart 
campaign conducts regularly scheduled phone calls to provide technical assistance as
well as document ongoing activities of the programs. In addition, the funded programs 
assisted with the planning and promotion of Get Smart Week within their states and local 
communities.  
PROJECT TITLE: GET SMART: KNOW WHEN ANTIBIOTICS WORK-MEDICAL 
PROFESSIONAL CURRICULA PROMOTING APPROPRIATE USE OF ANTIBIOTICS
•	 Action Item(s): #26 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Developing and promoting four appropriate antibiotic use curricula for 
medical professionals:
1.	 Curriculum for medical students regarding appropriate antibiotic use. Topics 
include extent of antibiotic resistance, diagnostic techniques, and appropriate 
antibiotic use. Case studies focus on diagnosis, treatment, and provider-patient
communication. This course is designed to meet the needs of a variety of 
medical schools with components that can be used separately or as a whole.
2.	 Curriculum for family practice and pediatric residents for diagnosing otitis media. 
3/4. Two Continuing Education courses for MDs, PAs, and NPs 
•	 2008 Update: 1) Medical school curriculum, ongoing: The curriculum is intended to be 
distributed nationally in FY2010. CDC is working in collaboration with Wake Forest 
University to complete the curriculum.  2) Otitis media curriculum, completed. The 
Children’s Hospital of Pittsburgh has developed a curriculum for family practice and 
pediatric residents to improve training in the diagnosis and treatment of acute otitis 
media; available at: http://pedsed.pitt.edu/. 3) CDC funded the Colorado Get Smart 
campaign to develop and promote an online video-based continuing education course for 
acute respiratory infections; available at: http://www.getsmartcolorado.com/08course.htm. 
4) CDC has also funded the New Jersey Department of Health and Senior Services to 
develop a web-based continuing education course, which will highlight primary care 
provider communication techniques, to be available FY2009/2010. 
PROJECT TITLE: GET SMART: KNOW WHEN ANTIBIOTICS WORK- NEW MESSAGE 
DEVELOPMENT INVOLVING ADVERSE DRUG EVENTS AND HEALTHCARE QUALITY
PROMOTION 
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•	 Action Item(s): #26 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: In FY2007, Get Smart convened an External Review Panel to assess the 
progress of the Get Smart program.  While the expert panel stated that significant inroads 
had been made, they recommended that more should be done. They recommended to 
shift the focus of Get Smart’s messages to include patient safety and healthcare quality 
promotion.   
•	 2008 Update: Get Smart staff began conducting formative research to be able to 
develop, test and implement new messages that highlight quality promotion and patient 
safety (e.g. adverse drug events). Get Smart staff will work with the Oak Ridge Institute 
for Science and Education, which has been awarded a contract through in interagency 
agreement to develop materials and conduct formative research. In-depth-interviews with 
physicians were conducted in FY09 and focus groups with the general public are 
scheduled to be conducted in FY09. New materials should be available in early FY2010. 
CDC's Division of Healthcare Quality Promotion is a partner in this effort. 
PROJECT TITLE: GET SMART: KNOW WHEN ANTIBIOTICS WORK ON THE FARM: 
DEVELOPMENT OF A VETERINARY CURRICULUM AND COLLABORATIONS PROMOTING 
APPROPRIATE ANTIBIOTIC USE IN VETERINARY MEDICINE
•	 Action Item(s): #26 
•	 Project Type: New
•	 Agency: CDC
•	 Description: An antimicrobial resistance curriculum is being developed in partnership 
with two of our Get Smart on the Farm state partners, Michigan and Minnesota. When
completed, the Antimicrobial Resistance Learning Site (AMRLS) will house an online 
curriculum for veterinary students. The AMRLS utilizes multiple digital media to
innovatively deliver modular, fact-based and peer-reviewed scientific information 
regarding AR. 
•	 2008 Update: 5 new modules were developed for the AMRLS. Additionally, the 





PROJECT TITLE: NATIONAL METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS
EDUCATION INITIATIVE 
•	 Action Item: #26 and #43 
•	 Project Type: New
•	 Agency: CDC 
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•	 Description: Recent increases in methicillin-resistant Staphylococcus aureus (MRSA) 
skin infections in the community have resulted in millions of outpatient medical visits each 
year and intense demand for accurate MRSA information from the public, clinicians, and 
legislators. In response this Initiative provides both the public and clinicians with credible 
resources about MRSA skin infection recognition, prevention, clinical management and 
treatment. It targets both the general public – with specific outreach to at-risk groups 
including African Americans and people involved with caring for children (e.g., moms, 
parents, school personnel) – and first-line clinicians in emergency medicine, family 
practice, and pediatrics.   
•	 2008 Update: Within the first months, team members developed a communications plan. 
The planning and initial research phase consisted of developing a research protocol for 
focus groups and concept testing with target audiences, obtaining IRB approval, 
developing campaign concepts and content, conducting focus groups and interviews with 
target audiences, and assessing baseline knowledge among 5,000 individuals who 
revealed that only 25% knew the signs and symptoms for MRSA skin infections. With the 
first research phase complete, the team developed and tested a comprehensive set of 
education materials that addressed Spanish translation and other audience requests
including child care centers, and athletic community for both the general public and 
clinicians. Materials were posted to newly developed CDC Initiative Web pages prior to 
launch, and were printed and delivered to CDC Info and the Public Health Foundation.  
The team developed a media relations and communications strategy that employed 
traditional media methods (e.g., news media coverage, print advertisements, radio public
service announcements, web features, professional association newsletters, press 
releases) as well as electronic methods (e.g., Mom blog networks, online communities, 
listservs, Web sites), engaging both internal and external partners. The initiate launched 
on September 9 and active collaboration occurred with more than 25 partners following
the launch to ensure information is reaching target audiences. 
PROJECT TITLE: PERFORMANCE MEASURES FOR SURGICAL ANTIBIOTIC 
PROPHYLAXIS AND ANTIBIOTIC THERAPY FOR COMMUNITY-ACQUIRED PNEUMONIA 
HAVE BEEN ROLLED OUT WITHIN THE LAST YEAR OR ARE IN PROCESS  
•	 Action Item(s): #26 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: VHA Office of Quality and Performance has instituted nationwide measures 
related to antibiotic prescribing regarding timing of antibiotic prophylaxis relative to 
surgical procedures. Additionally, plans are in process to gather performance data on use 
of appropriate antibiotics relative to surgical prophylaxis, as well as with regard to 
treatment of hospitalized patients with community-acquired pneumonias. 
•	 2008 Update: Office of Quality and Performance measures began implementation in FY 
2005 and continue through FY 2008 with plans for additional measures in FY 2009. See 
Action Item #7 for more details.   
PROJECT TITLE: DEVELOPMENT OF NATIONAL ICU INPATIENT EVALUATION CENTER
(IPEC) 
•	 Action Item(s): #26 
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•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: The IPEC is a national program to improve outcomes (risk adjusted 
mortality and length of stay) in VA ICUs and eventually in inpatient care through feedback 
of outcomes and implementation of evidenced-based practices. Currently two of the 
initiatives deal with issues related to infection prevention--catheter-related bloodstream 
infections and ventilator-associated pneumonias--both of which may involve resistant 
organisms. These data are reported back immediately to the local facilities who can track 
their rates over time and compliance with performance, as well as see the national mid­
range statistical analysis results.  
•	 2008 Update: IPEC program initiated nationwide during FY 2006 with results 
demonstrating a significant decrease in ventilator-associated pneumonias and central 
catheter related bloodstream infections nationwide since implementation of the program.  
Pilot testing for expansion of the IPEC process into non-ICU acute inpatient care was 
initiated. The IPEC intranet website provides numerous resources regarding evidence-
based practices and implementation strategies for the reduction of healthcare-associated 
events, including infections with antimicrobial-resistant organisms, for frontline healthcare 
personnel.  
PROJECT TITLE: NATIONAL MRSA PREVENTION INITIATIVE 
•	 Action Item(s): #26, #43, #44, #63, and #64
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: In January 2007 VHA administration took strong directive action in plan to 
address infection with MRSA nationwide as a prototype agent for multidrug resistance 
issues; this national plan employs a bundle approach which includes hand hygiene, 
contact precautions, active surveillance culturing and cultural change. Seventeen VA 
medical centers ("beta-sites") across the country are also participating in a cooperative 
evaluation of this process with the Centers for Diseases Control and Prevention (CDC).
•	 2008 Update: Directive signed Jan 12, 2007 by Under Secretary for Health and all sites 
with acute care facilities have initiated at least one care unit (preferably an ICU) as of 
March 1, 2007. All acute care units in all VA medical centers nationally implemented 
initiative by December 31, 2007. All VHA community living centers (long term 
care/nursing home care) nationally implemented the initiative by December 31, 2008.   
National healthcare-associated MRSA infection rates in the ICU setting decreased by 
about 50% during the first year, while healthcare-associated MRSA infections in the non-
ICU setting decreased by about 30%. The prevention initiative was expanded to include 
VHA's Community Living Centers (nursing home care) during 2008, with full coverage 
completed by Dec 31, 2008. Dr. Rajiv Jain, Project for the National VHA MRSA 
Prevention Initiative awarded the 2008 Citizen Services-Service to America Medal from 
the Partnership for Public Service. 
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ACTION ITEM #30 
PROJECT TITLE: NATIONAL MRSA SUMMIT AND MRSA IMPLEMENTATION TASK FORCE 
•	 Action Item(s): #30 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: National MRSA Summit with VA and non-VA experts to come to consensus 
on implementation. This Summit was used to compliment much work done by the 
National MRSA Prevention Initiative Implementation Task Force; it also helped to
determine future issues for the Task Force and National Program Office. 
•	 2008 Update: MRSA Summit held May 2-3, 2007; work of Implementation Task Force 
will be ongoing. Subworkgroups for special patient populations of nursing home/long-term 
care/community living centers, spinal cord injury and polytrauma units have been formed, 
along with subworkgroups to address issues of patient education, employee education, 
decolonization and duration of contact precautions. Additional working groups for mental 
health and ambulatory care have been chartered. Task Force has continued providing 
guidance for the prevention initiative. Most planning for a second MRSA Summit (which 
was held in February 2009) was done during 2008.
ACTION ITEM #32 
PROJECT TITLE: COMMUNITY-ACQUIRED PNEUMONIA TREATMENT
•	 Action Item(s): #32 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: VHA Office of Quality and Performance has also added community-
acquired pneumonia treatment timing measures and in pursing appropriate antibiotic 
choice measures. 
•	 2008 Update: During FY 2006 these measures have been introduced and are being 
refined. Ongoing FY 2008. See action item #7 for more detail.
PROJECT TITLE: IMMUNIZATIONS-HEDIS 
•	 Action Item(s): #32 
•	 Project Type: New
•	 Agency: VA
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•	 Description: VHA Office of Quality and Performance has adopted measures of 
pneumococcal vaccination and influenza vaccination since introduction of national 
performance measures for VHA. 
•	 2008 Update: Rates of immunization in VHA-served population meets or exceeds other 
national comparative measures. In FY 2008, achieved 94% immunization for those for 
whom pneumococcal vaccination was indicated and achieved 84% immunization for 
those over age 65 for whom influenza vaccination was indicated, and 69% for those age 
50-64 for whom influenza vaccination was indicated. Ongoing into 2009.
ACTION ITEM #38 
PROJECT TITLE: LONG TERM CARE INFECTION SURVEILLANCE
•	 Action Item(s): #38 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: A national VA taskforce developed a prototype web-based point prevalence 
survey which was subsequently beta-tested and used for the actual survey. CDC-based 
definitions of infections were used. Long term plans are to develop and improve 
standardized infection surveillance of VHA nursing homes. Develop a nursing home care 
educational session for use with VHA nursing home care units.
•	 2008 Update: National nursing home survey was completed in Fall 2005. Data analysis
and review are ongoing, with report released by the Office of the Inspector General. 
Publication of article in Am J Infect Control. 2006 Mar;34(2):80-3. Ongoing evaluation of 
surveillance methodologies and standards are actively being pursued, along with 
development of education session(s) for use by personnel within VHA nursing home care 
units (e.g., conference which may be multi-purposed with development of web-based 
sessions/components from this). Results of first national point-prevalence survey of all 
VA long-term care facilities released by the Office of the Inspector General for VA; 
publication of article in Am J Infect Control 2008 Arp;36(3):173-179.  A second national 
point-prevalence survey was completed January 2008 and analysis is ongoing at this 
time. Also, first national VA conference on Infection Prevention and Control in Long Term 
Care completed January 2008.  A second conference is planned for 2009.
ACTION ITEM #39 
PROJECT TITLE: TASK ORDER: TESTING TECHNIQUES TO RADICALLY REDUCE 
ANTIBIOTIC-RESISTANT BACTERIA (METHICILLIN-RESISTANT) STAPHYLOCOCCUS 
AUREUS, OR MRSA
•	 Action Item(s): #39 
•	 Project Type: Ongoing
•	 Agency: AHRQ, CDC 
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•	 Description: The overall purpose of this task order is to measurably reduce hospital-
acquired MRSA infections in acute-care facilities or hospitals and document how this was 
done, in order to help others achieve success in similar settings.
•	 2008 Update: Indiana University has developed and implemented a novel approach to 
reduce MRSA in Intensive Care Units (ICUs) in hospital systems in Indianapolis.
Focusing on improved surveillance, hand hygiene, and contact isolation, participants in 
this Accelerating Change and Transformation in Organizations and Networks (ACTION) 
project have documented an average 60% reduction in MRSA infections in intervention 
units in comparison with a 20% reduction in control units. Other hospitals in the 
Indianapolis area and elsewhere are adopting this approach.
PROJECT TITLE: CENTERS OF EXCELLENCE IN HEALTHCARE EPIDEMIOLOGY 
(PREVENTION EPICENTERS) 
•	 Action Item(s): #39 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: Academic medical centers conduct research to improve infection control 
practices. Current projects address improving antimicrobial use in acute care facilities, 
the epidemiology of transmission of resistant organisms in the ICU setting, and exploring 
novel approaches to preventing transmission.   
•	 2008 Update: See descriptions below for projects titled: 1) randomized evaluation of 
decolonization vs. universal clearance to eliminate methicillin resistant Staphylococcus 
aureus (reduce mrsa trial) and reducing nosocomial infections with chlorhexidine
cleansing of icu patients 
PROJECT TITLE: REDUCING NOSOCOMIAL INFECTIONS WITH CHLORHEXIDINE 
CLEANSING OF ICU PATIENTS 
•	 Action Item(s): #39 and #75
•	 Project Type: New
•	 Agency: CDC/ Prevention Epi Center CoAg 
•	 Description: Cleansing patients with chlorhexidine to reduce rates of CVC BSIs and 
lower risk of acquiring antimicrobial resistant pathogens, including MRSA and VRE. 
•	 2008 Update: 1) Completed data analysis and presented data on chlorhexidine bathing 
study at SHEA 2008 national meeting 2) Examined the incidence of nosocomial 
bloodstream infections due to CA-MRSA strains 3) Published two review articles and 
prepared two editorials (one in press and one in preparation) on CA-MRSA 4)Preparing 
manuscripts for our studies of CA-MRSA in critically ill and HIV-infected individuals and 
additionally, we now are examining CA-MRSA among individuals with prior healthcare 
exposures.
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PROJECT TITLE: RANDOMIZED EVALUATION OF DECOLONIZATION VS. UNIVERSAL 
CLEARANCE TO ELIMINATE METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS 
(REDUCE MRSA TRIAL) 
•	 Action Item(s): #39
•	 Project Type: New
•	 Agency: CDC/ Prevention Epi Center CoAg 
•	 Project : Randomized Evaluation of Decolonization vs. Universal Clearance to 

Eliminate Methicillin Resistant Staphylococcus Aureus (REDUCE MRSA Trial) 

•	 Description: A Cluster Randomized Trial of Hospitals to Assess Impact of Targeted 
Versus Universal Strategies to Reduce Methicillin-Resistant Staphylococcus aureus in 
Intensive Care Units. Conducted in partnership with Hospital Corporation of America. 60 
hospitals will be randomized to one of three separate approaches to MRSA control. The 
study aims are as follows: 1) Compare the effectiveness of three strategies for the 
prevention of MRSA+ clinical cultures in intensive care units: a) screening followed by 
isolation of MRSA+ patients, b) screening followed by decolonization of MRSA+ patients, 
c) universal decolonization without screening.  The study will assess both decolonization 
vs. no decolonization, and selective vs. universal decolonization. 2) To assess the impact 
of the two decolonization strategies on bloodstream and urinary tract infections due to 
MRSA, as well as all pathogens 3) to assess the impact that targeted or universal 
decolonization regimens have on antimicrobial resistance to topical decolonizing agents 
4) To determine the intervention costs of each arm.
•	 2008 Update: 1) Protocol IRB approved, funding secured, and recruitment has begun. 2) 
Initiation of Study planned September 2009.
PROJECT TITLE: CDC EXPERTS MEETING ON STAPHYLCOCCAL DECOLONIZATION  
•	 Action Item(s): #39
•	 Project Type: New 
•	 Agency: CDC
•	 Description: in August 2008, CDC held an experts meeting for approximately 30
National and International Experts on Staphylococcal disease to discuss the role of 
decolonization in community and healthcare settings.
•	 2008 Update: The meeting was held in August 2008. Expert input was provided on a 
number of important topics. Experts felt that decolonization although it has shown 
promise in a number of settings its widespread implementation is not yet supported by 
the available data. Potential settings where decolonization may be reasonable in settings 
where rates of Staphylococcal infection continue to be above National averages despite 
use of standard infection control recommendations include perioperative for patients 
undergoing cardiac or orthopedic surgery (with implants) and potentially in some 
outbreak settings. A summary of the meeting is currently being produced. The meeting 
provided important input to CDC and has helped to solidify research needs in this area. 
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PROJECT TITLE: EVALUATING THE EFFECTIVENESS OF THE RECENT IL STATE LAW 
REQUIRING ALL HOSPITALS TO IMPLEMENT SPECIFIC MRSA INFECTION PREVENTION 
MEASURES 
•	 Action Item(s): #39 
•	 Project Type: New  
•	 Agency: CDC
•	 Description: Determine whether a legislative mandate to implement active surveillance 
testing for MRSA is associated with (1) a decreased prevalence of MRSA colonization 
among patient receiving care in an ICU, or (2) a decreased prevalence of MRSA  
bloodstream infection (BSIs) by an annual cross-sectional survey for colonized or 
infected patients over a three-year time period.  
•	 2008 Update: Initiation of a regional program involving >90% of Chicago area hospitals 
includes systematic periodic evaluation of all intensive care unit patients for carriage or 
infection with MRSA. Isolates have been processed by partner laboratories in Chicago, 
with 100% compliance in surveillance cultures at participating sites.  
PROJECT TITLE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS PATTERNS IN 
VA 
•	 Action Item(s): #39 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: MRSA laboratory data collected nationwide from VA medical facilities to 
identify antibiotic resistance patterns.  
•	 2008 Update: Abstracts presented at the Society for Healthcare Epidemiology of 
America Annual Scientific Conference April 2007, Baltimore MD  authors: G Roselle, R 
Jain, S Kralovic, L Simbartl about MRSA,  at the Society for Healthcare Epidemiology of 
America Annual Scientific Conference April 2006, Chicago, IL  authors: S Kralovic, L 
Danko, L Simbartl, G Roselle about MRSA, at the Society for Healthcare Epidemiology of 
America Annual Scientific Conference April 2005, Los Angeles, CA authors: S Kralovic, 
L Danko, L Simbartl, G Roselle about Clostridium difficile. Invited presentation of the VHA 
National MRSA Prevention Initiative at the annual meeting of the Association of
Professionals in Infection Control and Epidemiology for June 2008; with follow-up invited 
presentation scheduled for June 2009. Work continues through the MRSA Prevention 
Initiative. 
PROJECT TITLE: TOYOTA PRODUCTION SYSTEM (TPS) PROCESS TO REDUCE 
INFECTION 
•	 Action Item(s): #39 and #63
•	 Project Type: Ongoing
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•	 Agency: VA
•	 Description: Through a demonstration project sponsored by CDC, VA facilities in 
Pittsburgh along with other health care institutions in the region participated in evaluation 
of a methodology (Toyota Production System process) for implementing change in 
infection control practices.  
•	 2008 Update: Has demonstrated decrease with sustained success in resistant 
Staphylococcus aureus within facility. Abstract presented at the Society for Healthcare 
Epidemiology of America Annual Scientific Conference April 2006, Chicago, IL  authors 
R Muder, E McCray, C Cunningham, P Perreiah, C Squier, R Sinkowith-Cochran, J 
Jernigan. Ongoing and has led to both a further in depth evaluation process of 17 VHA 
medical centers nationwide and to nationwide implementation of a VHA MRSA 
Prevention Initiative. Publication: Infect Control Hosp Epidemiol 2008;29:702-708. 
PROJECT TITLE: PARTNERSHIP WITH CDC PREVENTION EPICENTERS—DEVELOPING 
INTERVENTIONS, EVALUATING EFFECTIVENESS OF INTERVENTIONS 
•	 Action Item(s): #39 
•	 Project Type: New
•	 Agency: VA
•	 Description: VHA is partnering with CDC Prevention Epicenters on several projects 
related to antimicrobial resistance.
•	 2008 Update: Funded Prevention Epicenters/VA Collaboration regarding developing 
interventions and evaluating effectiveness of interventions. These include MRSA focused 
prevention efforts such as cleansing of patients with chlorhexidine cloths, reducing 
transmission of MRSA and VRE (e.g., using electronic alerts to flag high risk patients, 
collection of nasal swab (PCR), Toyota Production System-based quality improvement 
program large VA multi-site study, evaluating effectiveness of screening and 
decolonization for MRSA control automated standing orders for routine ICU MRSA
surveillance cultures, and the impact on ICU and total hospital MRSA bacteremia), 
Urinary Tract Infections prevention (Implementing an intervention to electronically identify 
and flag patients for whom urinary catheters may no longer be needed), and evaluating 
impact of Clostridium difficile infections (CDI) prevention strategies. 
PROJECT TITLE: POSITIVE DEVIANCE 
•	 Action Item(s): #39 and #63
•	 Project Type: New
•	 Agency: VA
•	 Description: Use of Positive Deviance model to assist with national MRSA Prevention 
Initiative. VA has partnered with the Plexus Institute, an organization which has espoused 
the Positive Deviance Model for cultural change, on a number of projects related to 
MRSA. 
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•	 2008 Update: Abstracts demonstrating use of positive deviance for cultural change at the 
Pittsburgh VA as part of its successful MRSA reduction efforts presented at the Society 
for Healthcare Epidemiology of America Annual Scientific Conference April 2007, 
Baltimore, MD  authors R. Muder, C Cunningham, C Squier, E McCray, R Jain, R 
Sinkowitz-Cocharn, J Lloyd, J Jernigan on the first abstract and J Jacob, R Muder, C 
Cunighham, E McCray, C Squier, C Mehta, R Jain, R Sinkowitz-Cochran, J Lloyd and J 
Jernigan on the second abstract. VA MRSA experience highlighted on the Plexus 
Institute website; an MRSA blog is available on the Plexus Institute website also. 
Ongoing.   
ACTION ITEM #43 
PROJECT TITLE: INFECTION -DON'T PASS IT ON CAMPAIGN    
•	 Action Item(s): #43 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: The Veterans Administration campaign, “Infection: Don’t Pass It On” is a 
national campaign launched in the fall of 2004. The major focus of this ongoing campaign 
is hand hygiene, respiratory etiquette, and preparedness for infectious disease 
emergencies.
•	 2008 Update: Initiated Fall 2004 and ongoing. 2005 winner of Excellence in Public 
Health Award from the National Public Affairs Association. During Association of 
Professionals in Infection Control and Epidemiology National Conference June 2006 in 
Tampa, FL, presented as a general concurrent session. Remains active with annual 
publication of materials and user guide for field facilities across the nation. 
ACTION ITEM #44 
PROJECT TITLE: INFOMERCIALS TAPED AND AIRED ON VA KNOWLEDGE NETWORK.
VIEWED BY VHA EMPLOYEES
•	 Action Item(s): #44 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: 2-3 minute “infomercials” covering issues relating to influenza, PPD’s and 
bloodborne pathogens 
• 2008 Update: Completed. Airing of infomercials ongoing.
PROJECT TITLE: NATIONAL CENTER FOR HEALTH PROMOTION MONTHLY TOPICS   
•	 Action Item(s): #44 






















Last revised: December 29, 2009 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: Some of the monthly topics address specific diseases and some address 
specific infectious diseases preventive measures.     
•	 2008 Update: Information on the following, rotation of monthly disease prevention and 
health promotion which regularly include infectious diseases topics.  Dissemination point 
for annual influenza-pneumococcal vaccination toolkit information. 
PROJECT TITLE: PLANNED LONG TERM CARE CONFERENCE IN SEPTEMBER 2006 
•	 Action Item(s): #44 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: Issues of antibiotic resistance discussed.
•	 2008 Update: Completed January 2008. Conference provided for administrators, front 
line nursing personnel, infection control professionals for all VHA Community Living 
Centers (nursing home care/long term care) nationwide. A second conference is planned 
for Summer 2009 where infection prevention and control issues regarding antimicrobial 
resistant organisms such as MRSA will be discussed.
ACTION ITEM #45 
PROJECT TITLE: INNOVATIVE FS PROGRAM FOR LOW LITERACY FOOD HANDLERS 
•	 Action Item(s): #45 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Using enhanced and distance education programs
•	 2008 Update: Ongoing research. Funded by CSREES, National Integrated Food Safety 
Initiative (University of Connecticut). See CSREES website.
PROJECT TITLE: SCIENCE-TECHNOLOGY BASED FS EDUCATION PROGRAMS ON SAFE 
FOOD HANDLING 
•	 Action Item(s): #45 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Focused on consumers with use of collected data, databases 
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•	 2008 Update: Ongoing research. Funded by CSREES, National Integrated Food Safety 
Initiative (University of Missouri). See CSREES website. 
PROJECT TITLE: GOOD AGRICULTURAL PRACTICES ON LINE COURSE FOR PRODUCE 
SAFETY
•	 Action Item(s): #45 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Will also assess impact of training 
•	 2008 Update: Ongoing research. Funded by CSREES, National Integrated Food Safety 
Initiative (Cornell University). See CSREES website.
PROJECT TITLE: RISK ANALYSIS BASED FOOD DEFENSE CERTIFICATION PROGRAM
•	 Action Item(s): #45 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: For professional and academic programs
•	 2008 Update: Ongoing research. Funded by CSREES, National Integrated Food Safety 
Initiative (University of Maryland). See CSREES website. 
PROJECT TITLE: FOOD SAFETY TRAINING PROGRAMS FOR ETHNIC VENDORS
•	 Action Item(s): #45 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Evaluate programs and implement changes, particularly for Asian and 
Mexican foods
•	 2008 Update: Ongoing research. Funded by CSREES, National Integrated Food Safety 
Initiative (University of Florida). See CSREES website. 
PROJECT TITLE: FIGHT BAC!® CAMPAIGN
•	 Action Item: #45
•	 Project Type: Ongoing
•	 Agency: CDC, FDA, USDA
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•	 Description: This national program emphasizes the four basic safe handling behaviors: 
Clean, Separate, Cook, and Chill.   
•	 2008 Update: For over 10 years, USDA, FDA, and CDC, have served as the Federal 
liaisons to The Partnership for Food Safety Education, the public/private partnership that 
created the Fight BAC!® Campaign. Ongoing research funded by CSREES, National 
Integrated Food Safety Initiative (University of Georgia)-see CSREES website.  
PROJECT TITLE: USDA/FSIS SAFE FOOD HANDLING OUTREACH INITIATIVES
•	 Action Item(s): #45 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Examples of FSIS' efforts include media events, consumer brochures, 
public service announcements for keeping food safe during power outages, food safety 
camps for children, and development of 5 brochures on food safety for at-risk audiences: 
people with cancer, HIV/AIDS, diabetes, transplant recipients, and older adults. FSIS 
provides a toll-free telephone service, the USDA Meat and Poultry Hotline, to help 
prevent foodborne illness by answering consumer questions about the safe preparation 
and handling of food handling. The FSIS podcast and videocast series, “Food Safety at 
Home”, began in April 2008 and is available on the FSIS website in English and Spanish.
• 2008 Update: Ongoing.
PROJECT TITLE: BE FOOD SAFE INITIATIVE 
•	 Action Item(s): #45 
•	 Project Type: New
•	 Agency: USDA 
•	 Description: Launched in September 2006, this nationwide food safety educational 
campaign gives educators the tools to inform consumers about foodborne illness and 
raises awareness of the dangers associated with improper handling and undercooking of 
food. The toolkit includes: print media including a brochure, ads, an activity book and 
posters, broadcast media including public service announcements for radio and TV, and 
an extensive graphics library.  
• 2008 Update:  Ongoing. 
PROJECT TITLE: “ASK KAREN” A WEB-BASED COMMUNICATION TOOL
•	 Action Item(s): #45 
•	 Project Type: New
•	 Activity in 2008: yes 
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•	 Agency: USDA 
•	 Description: This “virtual representative” debuted in 2004 and is available 24/7. “Ask 
Karen” responds, from an extensive database of food safety information, to inquiries from 
the public about the safe handling, preparation, and storage of meat, poultry, and egg 
products. 
• 2008 Update: Ongoing.
PROJECT TITLE: SEPTEMBER IS NATIONAL FOOD SAFETY EDUCATION MONTH 
•	 Action Item(s): #45 
•	 Project Type: New
•	 Agency: USDA 
•	 Description: Provides educational materials as a resource for educators at the state, 
local and federal level.
•	 2008 Update: Distributed a DVD developed by USDA, FDA and the Partnership for Food 
Safety Education for use in current year’s food safety educational efforts.
ACTION ITEM #47 
PROJECT TITLE: ANNUAL INFLUENZA/PNEUMOCOCCAL VACCINE TOOLKIT 
•	 Action Item(s): #47 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: Influenza/Pneumococcal Vaccine Toolkits were developed to enhance local 
influenza/pneumococcal immunization programs throughout VA, and contain promotional 
items along with directive containing most recent influenza vaccine recommendations    
•	 2008 Update: Updated toolkits are sent to VA facilities nationwide in the fall of each year 
for 2003-2004 season, 2004-2005 season, 2005-2006 season, 2006-2007 season, 2007­
2008 season, and 2008-2009 season. Planning for the toolkit for the 2009-2010 season 
toolkit is underway.
PROJECT TITLE: ANNUAL INFLUENZA VACCINATION DIRECTIVE 
•	 Action Item(s): #47 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: Provide to the field facilities central direction for the consistent use of 
influenza vaccination and treatment strategies nationwide within VHA.  
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•	 2008 Update: Each year a Directive is signed and delivered to the local VA medical 
centers giving guidance and direction on each new years influenza vaccine and antiviral 
medications for the treatment of influenza disease including potential influenza viral 
resistance. This has been ongoing since 1992 and continues--most recent directive was 
released for 2008-2009 influenza season.  
PROJECT TITLE: PNEUMOCOCCAL AND INFLUENZA VACCINATION AS PERFORMANCE 
MEASURES 
•	 Action Item(s): #47 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: For many years VHA has included the delivery of both influenza vaccination 
and pneumococcal vaccination to at-risk populations (based on CDC recommendations) 
as a key performance measure for patient care.  Performance measures constitute 50% 
of the annual evaluation for Executive Career Field (ECF) performance plans for VHA 
regional directors and individual medical center directors. Directive measures each year 
are signed by VHA Under Secretary for Health regarding annual influenza immunizations 
for patients, and also encouraging healthcare worker participation.
•	 2008 Update: Ongoing.  Additional measures for missed opportunities with inpatient 
admissions currently admitted for high-risk illnesses, including pneumonia have been 
added to the performance measures for FY 2008 and achieved 97% for CAP2j 
(Inpatients with diagnosis of pneumonia screened for previous pneumococcal vaccination 
or received vaccination by time of discharge). See Action Item #7 for additional details.
ACTION ITEM #48 
PROJECT TITLE: H. INFLUENZAE TYPE B (HIB) VACCINE
•	 Action Item(s): #48 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Monitoring of polysaccharide conjugated vaccines, including regular 
inspections of the production facilities, review and conduct of Lot Release studies, and 
review of amendments to the current Biologic License Application. 
•	 2008 Update: Ongoing. Several licensed vaccines. Continued vaccine supply essential 
to maintaining the near elimination of resistant H. influenzae disease in the U.S.
PROJECT TITLE: PNEUMOCOCCAL VACCINE 
•	 Action Item(s): #48 
•	 Project Type: Ongoing
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•	 Agency: FDA 
•	 Description: Monitoring of polysaccharide and polysaccharide conjugate vaccines, 
including regulator inspections of the production facilities, review and conduct of Lot 
Release studies, and review of amendments to the current biologic License Application.
•	 2008 Update: Ongoing.  One licensed polysaccharide primarily for use in the elderly and 
one licensed seven valent conjugate vaccine for the prevention of invasive disease and 
acute otitis media. Studies suggest decrease in antimicrobial resistance among S. 
pneumonia isolates coincident with wide spread use of conjugate vaccine in infants. 
Continued vaccine supply essential for continued prevention of pneumococcal disease. 
PROJECT TITLE: INFLUENZA VACCINE 
•	 Action Item(s): #48 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Regulatory and research support of annual trivalent inactivated and live 
intranasal influenza vaccine development, production and licensure, including additional 
manufacturers and novel technologies. Facilitating expanding indication to additional age 
groups and select immunocompromised populations.
•	 2008 Update: Six seasonal influenza vaccines are currently licensed and distributed in 
the U.S. These vaccines include Medimmune (FluMist®), Sanofi (Fluzone®), Novartis
(Fluvrin®), ID Biomedical (FlulavalO), GSK (Fluarix®), and CSL Ltd (Afluria).  At the 
February 2008 ACIP meeting, there was discussion and vote to expand the pediatric 
recommendation to include children 6 months through 18 years of age. September 2008 
Vaccine and Related Products Advisory Committee meeting considered use of MDCK 
Cells for Manufacture of Live Attenuated Influenza Virus Vaccines. The VRPAC 
supported initiation of phase 1 clinical studies for LAIV manufactured in MDCK cells and 
provided recommendations for additional pre-clinical studies. 
PROJECT TITLE: IMPROVE USE OF VACCINES RELATED TO PRUDENT USE OF 
ANTIBIOTICS
•	 Action Item(s): #48 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: Dept. of Veterans Administration, VHA Directive 2001-053. Influenza 
Vaccine – Recommendations for 2001-2002. Published and placed on VA Intranet 
website 8/28/01. Infomercials were aired on VA Knowledge Network regarding influenza 
vaccine. Performance Measurement Program, 2001 and 2002 VHA Performance
Measurement System Technical Manuals list Influenza Immunization and Pneumococcal 
Immunization as Preventive Care Quality Performance Measures, with specific
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recommendations for these immunizations for Nursing Home Care Units within VHA 
system.
•	 2008 Update: The VHA is already in the forefront of immunization practices as is 
evidenced by the pneumococcal and influenza vaccine usage rates compared to the 
national averages. In addition, influenza vaccine use increases each year in the VHA as 
emphasis on this program continues. Therefore, this action item is already under way and 
will continue to be an area of emphasis area for the VA. For FY 2008, Performance 
Measurement monitors of p1 (persons at increased risk for pneumococcal vaccine have 
received vaccination) was 94%, while measurement p22h (persons between ages of 50­
64 have received influenza vaccination) was 69% and p25h (persons greater than age 65
and/or at increased risk for influenza have received influenza vaccination) was 84%.   
ACTION ITEM #49 
PROJECT TITLE: POTENTIAL PUBLIC HEALTH AND FOOD SAFETY IMPACTS 
ASSOCIATED WITH USE OF ANTIBIOTIC GROWTH PROMOTERS 
•	 Action Item(s): #49 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: The objective of this proposal is to use molecular epidemiologic 
approaches to determine whether eliminating the use of antibiotic growth promoters has 
adverse affects on public health, reduces the health of swine, and whether antibiotic 
growth promoters mediate their effects by alteration of the intestinal bacterial microflora. 
•	 2008 Update: Ongoing. Funded by CSREES, National Research Initiative (University of 
Minnesota). See CSREES website.
PROJECT TITLE: METAGENOMICS OF ANTIBIOTIC RESISTANCE   
•	 Action Item(s): #49 
•	 Project Type: New
•	 Agency: USDA 
•	 Description: Using metogenomics (and culture) approaches to evaluate the effects of 
feeding subtherapeutic (growth promoting) and therapeutic antibiotics on swine intestinal 
microbiota. The goal is to identify changes in microbial composition associated with 
performance enhancement. Once we identify how growth promotants work, then 
alternatives to antibiotics can be found that give the same effects. We are also looking at 
the changes in antibiotic resistance gene contents in swine exposed to one or more 
antibiotics in parallel. Finally, we will test whether or not growth promoting antibiotics still 
work in swine and use metagenomics to detect changes in intestinal microbiota to 
marketed probiotics 
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•	 2008 Update: In FY 2008 we tested an important hypothesis - that antibiotic sensitive 
commensal bacteria could block sow-to-piglet transmission of antibiotic resistant bacteria 
of the same species, thereby reducing the incidence of antibiotic resistance in the piglets.  
At ten days after weaning, only antibiotic sensitive M. elsdenii strains were recovered 
from the dosed piglets.  At 25 and 39 days after weaning, however, multiply antibiotic 
resistant M. elsdenii strains from the mother sow colonized and eventually predominated 
in the dosed piglets.  Control piglets (not dosed) were colonized with antibiotic resistant 
sow strains earlier.  One explanation for these results is that Megasphaera elsdenii
strains colonizing swine exhibit specificity for the host swine genotype.  Thus exogenous 
dosed strains cannot prevent sow-to-piglet transmission.  If this is more broadly true for 
intestinal commensal bacteria, then probiotic applications requiring colonization of animal 
or human by dosing non-specific probiotic bacteria are unlikely to be uniformly 
successful.
ACTION ITEM #50 
PROJECT TITLE: DISSEMINATION OF CEPHALOSPORIN RESISTANCE GENES 
•	 Action Item(s): #50 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Experimentally determine the frequency with which blacmy-2 and adjacent 
plasmid genes are transferred to previously susceptible e coli strains, and perform 
observational studies in calves and cows to determine the effects of ceftifur therapy on 
the frequency, diversity, and persistence of cmy-2 resistance in commensal e.coli
populations 
•	 2008 Update: Ongoing. Funded by CSREES, National Research Initiative (Washington 
State University). See CSREES website.
ACTION ITEM #52 
PROJECT TITLE: RAPID METHODS DEVELOPMENT 
•	 Action Item(s): #52 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Validated culture methods for foodborne pathogens in animal feeds.
•	 2008 Update: Completed development and instillation of cultural methods to be used in 
screening feeds and feed commodities for the presence of the Bacillus cereus group. 
CVM continues to screen feeds and feed commodities for the presence of antimicrobial 
resistant Enterococcus and E. coli. CVM continued to collaborate with USDA-Agricultural 
Marketing Service to determine DNA fingerprint patterns and antimicrobial susceptibilities 
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among Salmonella and E. coli isolates recovered from produce obtained from the 
microbiological data program plan.
ACTION ITEM #53 
PROJECT TITLE: NARMS RETAIL FOOD 
•	 Action Item(s): #53 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Monitor prevalence of antimicrobial resistant zoonotic pathogens and 
commensal organisms among foods of animal origin.
•	 2008 Update: NARMS retail was initiated in 2002, as of 2008, 9 FoodNet sites plus 
Pennsylvania are participating. The 2006 NARMS retail meat annual report was 
published in 2008 and can be found at 
http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/National 
AntimicrobialResistanceMonitoringSystem/ucm164662.htm. FDA just published the 2007 
Retail Meat Annual Report and is currently involved in publishing the 2008 annual report.   
ACTION ITEM #55 
PROJECT TITLE: ANIMAL PRODUCTION STUDIES 
•	 Action Item(s): #55 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Determine dynamics of resistance development in naïve animal 
populations exposed to antimicrobial agents.
•	 2008 Update: Completed animal studies focusing on the development and persistence 
of bacteria resistance after exposure to specific antimicrobials. Also, partnered with 
academic investigators at the University of Minnesota and Iowa State University in 
characterizing potential links between antimicrobial resistant E. coli recovered from 
foods and human extraintestinal pathogenic E. coli infections (e.g. UTIs, septicemia).
PROJECT TITLE: DEFINING THE ROLE OF SALMONELLA NEWPORT IN CONTAMINATED 
OYSTERS
•	 Action Item(s): #55 
•	 Project Type: Ongoing
•	 Agency: USDA 
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•	 Description: Research to test the ability of Salmonella to survive in oysters and to
track the source of Salmonella in surface waters.
•	 2008 Update: Ongoing. Funded by CSREES, National Research Initiative (University 
of Arizona). See CSREES website.
ACTION ITEM #58 
PROJECT TITLE: RISK ASSESSMENT 
•	 Action Item(s): #58 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Risk assessment: Conduct an analysis of the relationship between
emergence of streptogramin-resistant Enterococcus faecium (Synercid) in humans and 
use of streptogramins (virginiamycin) in food-producing animals. 
•	 2008 Update: Draft risk assessment published November 23, 2004; public comment 
period through February 25, 2005. The Center for Veterinary Medicine (CVM) conducted 
a thorough review and analysis of all the comments submitted to the Docket.  
Considerable attention was given to the potential impacts of suggested changes on risk 
estimates, particularly in light of new information in the scientific literature. However, 
there was insufficient basis to warrant revision of the original risk assessment. CVM 
continues to monitor the scientific literature, the results of surveillance studies, the usage 
patterns of Synercid (and other future streptogramin drugs) in hospital and health care 
settings, and other relevant data that may affect the findings of the risk assessment and 
will revisit the risk assessment at a time dictated by the availability of new data and 
scientific developments in streptogramin resistance.
PROJECT TITLE: ORDER PROHIBITING THE EXTRA-LABEL USE OF CEPHALOSPORIN 
ANTIMICROBIAL DRUGS IN FOOD-PRODUCING ANIMALS
•	 Action Item(s): #58 
•	 Project Type: New
•	 Agency:  FDA 
•	 Description:  Order prohibiting the extra-label use of cephalosporin antimicrobial drugs 
in food-producing animals. 
•	 2008 Update: FDA issued an order prohibiting the extra-label use of cephalosporin drugs 
July 3, 2008. The order is based on evidence that extra-label use of these drugs in food-
producing animals will likely cause an adverse event in humans and, as such, presents a 
risk to the public health. CVM received many substantive comments on the Order. Many 
comments felt that the scope of the Order was too broad and/or was not adequately 
justified. The Order was revoked on November 26, 2008, so that CVM could fully 
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consider the comments. CVM has completed its analysis of comments and expects to 
publish a revised Order in 2010.
ACTION ITEM #59 
PROJECT TITLE: AR USE BY VETERINARIANS 
•	 Action Item(s): #59 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Develop a Web-based decision support system for use by veterinarians to 
select and use antimicrobial agents appropriately. 
•	 2008 Update: Provided funding for development of Veterinary Antimicrobial Decision 
Support (VADS) System; 5 year contract awarded late 2001. The Veterinary Antimicrobial 
Decision System continues to be revised and improved. Feedback from users on the data 
used as well as modeling and interpretation methods are currently being solicited. VADS 
can be found at: http://vads.vetmed.vt.edu/Mission.cfm. 
ACTION ITEM #62 
PROJECT TITLE: ANTIMICROBIAL RESISTANCE TASK FORCE
•	 Action Item(s): #62 
•	 Project Type: Ongoing
•	 Agency: ARHQ, CDC, DoD, VA, EPA, FDA, NIH, USDA  
•	 Description: Annual Progress Report and Public Meeting. 
•	 2008 Update: 2001 - 2008, annual progress reports issued consisting of inventory of 
projects that address Action Plan items. Held eighth annual public meeting June 25, 
2008, Bethesda, MD. Task Force worked on reviewing information from December 2007, 
consultants meeting to discuss issues relating to revising the Action Plan. Task Force 
worked to revise the action plan. 
PROJECT TITLE: ANTIMICROBIAL RESISTANCE TASK FORCE ACTION PLAN UPDATE
•	 Action Item(s): #62 
•	 Project Type: Ongoing
•	 Agency: ARHQ, CDC, DoD, VA, EPA, FDA, NIH, USDA  
•	 Description: The Task Force is currently working on Revising and Updating The Action 
Plan to Combat Antimicrobial Resistance.  
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•	 2008 Update: On December 12 and 13, 2007, the Interagency Task Force on
Antimicrobial Resistance, held a consultants meeting in Atlanta, Georgia to obtain input 
for revising and updating “A Public Health Action Plan to Combat Antimicrobial 
Resistance.”  In addition to over fifty consultants from the United States, nine 
international consultants from Canada, Denmark, France, Germany, The Netherlands, 
and United Kingdom participated in the meeting. The consultants included experts from 
human and veterinary medicine, the pharmaceutical and diagnostics industries, animal 
husbandry industry, clinical microbiology, epidemiology, infectious disease and infection 
control specialists, and state and local public health departments. The consultants 
reviewed the 2001 Action Plan in detail and made a series of recommendations for the 
Interagency Task Force to consider. Following the meeting the Task Force reviewed 
input and worked to revise the Action Plan.  
PROJECT TITLE: CDC/KINDRED HOSPITALS Clostridium DIFFICILE INFECTION QUALITY 
IMPROVEMENT COLLABORATIVE 
•	 Action Item(s): #62 
•	 Project Type: New
•	 Agency: CDC
•	 Description: Long-term acute care (LTAC) hospitals care for medically complex patients 
requiring intensive care for prolonged periods of time. These patients are frequently 
exposed to multiple antimicrobials before and during their LTAC hospital stay and are at 
high risk for infections with multi-drug resistant organisms and C. difficile. The long-term 
goal of this project is to reduce CDI rates in Kindred LTAC hospitals by optimizing 
existing CDI prevention measures. The initial step will be to establish standardized 
surveillance for CDI in 7 volunteering Kindred LTAC hospitals and evaluate existing CDI 
control measures. This information will be used to identify appropriate prevention and 
control measures for each facility. 
•	 2008 Update: Protocol and plan for surveillance was developed and initiated in 7 LTAC 
hospitals. 
ACTION ITEM #63 
PROJECT TITLE: PREVENTION OF INFECTION CAUSED BY METHICILLIN OR OXACILLIN 
RESISTANT STAPHYLOCOCCUS AUREUS (PRIMO): RECURRENT CA-MRSA PREVENTION 
TRIAL
•	 Action Item(s): #63 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The Prevention of Infection caused by Methicillin or Oxacillin resistant 
Staphylococcus aureus or PRIMO study. A 2 x 2 phase iii open-label clinical trial of 
therapy for patients with recurrent methicillin resistant staphylococcus aureus infections: 
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topical nasal and body decolonization of household members versus standard of care, 
and environmental decontamination versus standard of care. 
•	 2008 Update: Enrollment continued through 2008 and is ongoing. As of July 30, 2009, 
enrollment was completed (goal of 350 participants successfully reached). Follow-up 
phase will continue through July 2010.     
ACTION ITEM #64 
PROJECT TITLE: INFLUENZA AND PNEUMOCOCCAL VACCINATIONS AS PERFORMANCE 
MEASURES 
•	 Action Item(s): #64 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: VHA has included the delivery of both influenza vaccination and 
pneumococcal vaccination to at-risk populations as a key performance measure for 
patient care.   
•	 2008 Update: For Federal Fiscal Year 2006, VHA introduced timing of antibiotics for 
community-acquired pneumonia for inpatients and is pursing measures for appropriate 
antibiotic choices, along with existing vaccination performance measures. See Action 
items # 7, 32, 47 and 48 above for specific results.  Ongoing.   
ACTION ITEM #65 
PROJECT TITLE: QUALITY ASSURANCE PROGRAMS
•	 Action Item(s): #65 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: The Office of Quality and Performance’s Performance Measurement
Program, which supports the VHA Strategic Plan, serves as a vehicle for effecting 
change in a balanced fashion. The Performance Plan operationalizes the premise that 
better quality, access, and satisfaction are often more efficient. Example, improved rates 
of inexpensive pneumococcal vaccinations may result in decreased antibiotic use.
Immunization rates are assessed through a contract chart review system and are part of 
managers’ perf. standards, and, therefore, used as part of the VHA quality-monitoring 
program. Excellent immunization rates in VHA have resulted from this program.   
•	 2008 Update: The VA Under Secretary for Health's hand hygiene memorandum was 
issued to VA medical facilities nationwide on 12/15/03. The study "Toward a Safety 
Culture" is in process. See Action items #7, 32, 47 and 48 above for results. 
PROJECT TITLE: NATIONAL MRSA PREVENTION INITIATIVE—BETA TEST SITES
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•	 Action Item(s): #65 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: For the National MRSA Prevention Initiative (noted above), the Office of 
Quality and Performance has sponsored support of 17 beta-testing sites for this initiative 
to determine if quality measures related any or all components of the bundle approach 
may be amenable to further analysis by quality monitors.
•	 2008 Update: In progress with evaluation beginning with initiation of beta-test sites in 
Summer 2006. Ongoing collaboration with the Centers for Diseases Control and 
Prevention (CDC). 
FOCUS AREA III: RESEARCH 
ACTION ITEM #67 
PROJECT TITLE: AR MECHANISMS OF S. PNEUMONIAE (ALASKA)
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: PCR methodologies are used to assist ongoing lab-based surveillance of 
invasive pneumococcal disease (IPD) in Alaska. We rapidly screen S. pneumoniae
isolates for genetic determinants of resistance; monitoring the emergence, spread, 
persistence, and decline of multidrug-resistance organisms by molecular-based typing 
capabilities to include multilocus sequence typing (MLST). 
•	 2008 Update: Serotype 19A has emerged as the most frequent cause of IPD in Alaska.  
Sequence type 199 remains the most frequent sequence type among 19A isolates and 
was present prior to the recent increase in serotype 19A disease among rural Alaska 
Native children. Recent identification of a multidrug-resistant sequence type 320 isolate is
of concern since it has emerged as the second most common clonal group in the rest of 
the U.S. 
PROJECT TITLE: EPIDEMIOLOGY OF CARBAPENEMASE-PRODUCING 
ENTEROBACTERIACEAE IN A HEALTHCARE SETTING
•	 Action Item(s): #67 
•	 Project Type: New
•	 Agency: CDC
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•	 Description: A cooperative agreement with Mount Sinai Hospital with sub-contract to 
New York University to study the transmission dynamics of carbapenemase-producing 
enterobacteriaceae in acute care hospitals. 
•	 2008 Update: 1) Data collection begat at both sites and is on-schedule 2) Supplemental 
funs were provided out of division budget to extend laboratory testing. 
PROJECT TITLE: PREVALENCE OF COLOIZATION AND INCIDENCE OF INFECTION WITH 
COMMUNITY-ASSOCIATED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN A 
LAREGE URBAN HIV OUTPATIENT CLINIC 
•	 Action Item(s): #67
•	 Project Type: New
•	 Agency: CDC, VA 
•	 Description: Skin and soft tissue infections with community-associated methicillin-
resistant Staphylococcus aureus (CA-MRSA) are an increasing problem among people 
living with HIV/AIDS. Fundamental aspects of the epidemiology of this condition, in 
particular asymptomatic carriage rates and risks for clinical disease, remain unknown.  
We are conducting a prospective cohort study at the Atlanta Veterans Affairs Medical 
Center (VAMC) to evaluate CA-MRSA carriage rates and risks for carriage and clinical 
disease. Approximately 700 patients (a maximum of 1100 patients) at the VAMC HIV 
Clinic will be recruited to provide nasal and groin swabs for S. aureus culture at a 
baseline visit and at two subsequent visits 6 and 12 months. At the baseline visit,
participants will complete a questionnaire to collect data about possible risk factors 
associated with CA-MRSA carriage and clinical disease, and clinical and demographic 
risk-related data will also be collected. All S. aureus isolates will be characterized by 
antimicrobial susceptibility, pulsed-field gel electrophoresis, and detection of toxin genes.  
Participants who develop clinical disease will complete an additional questionnaire to 
further characterize their course of illness and response to treatment.  
•	 2008 Update: 600 patients were enrolled, data was abstracted, and specimens were 
collected at baseline, 6 months and 12 months and processed. Preliminary analysis 
suggested that the prevalence of MRSA colonization is high in this cohort of HIV-infected 
adults compared with the general population. Addition of groin culture enhanced recovery 
over nasal swabs alone, and specifically enhanced detection of some MRSA strains. 
Prevalence of MRSA colonization at either site at baseline was 13%. Including groin 
swabs increased detection of MRSA colonization by 20%. 
PROJECT TITLE: PREVALENCE AND RISK FACTORS FOR COMMUNITY-ASSOCIATED
MRSA PNEUMONIA 
•	 Action Item(s): #67
•	 Project Type: New
•	 Agency: CDC
•	 Description: Study performed by the CDC-funded EMERGEncy ID Net to assess the 
prevalence of and risk factors for CA-MRSA pneumonia. Patients presenting to 12 
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network emergency departments and subsequently admitted to the hospital with S. 
aureus community-acquired pneumonia were enrolled and clinical, epidemiologic, and 
microbiologic data were collected. Isolates were characterized at CDC.
•	 2008 Update: Database was cleaned and finalized and data analysis initiated. 
PROJECT TITLE: PREVLAENCE OF COMMUNITY-ASSOCIATED MRSA INFECTION 
AMONG EMERGENCY DEPARTMENT PATIENTS WITH SKIN INFECTIONS, AND FACTORS 
ASSOCIATED WITH HOSPITAL ADMISSION AND ISOLATION DECISIONS
•	 Action Item(s): #67
•	 Project Type: New
•	 Agency: CDC
•	 Description: Study performed by the CDC-funded EMERGEncy ID Net to assess the 
prevalence of CA-MRSA among emergency department patients with skin infections and 
to evaluate factors associated with hospital admission and isolation decisions.
•	 2008 Update: 643 patients were enrolled and data collection was completed. Isolates 
were characterized at CDC. Data entry completed and database cleaning initiated. 
PROJECT TITLE: LABORATORY-BASED STUDIES ON THE MOLECULAR MECHANISMS
RESPONSIBLE FOR CEPHALOSPORIN RESISTANCE IN NEISSERIA GONORRHOEAE
•	 Action Item(s): #67 
•	 Project Type: New
•	 Agency: CDC
•	 Description: CDC/DSTDP will determine the Neisseria gonorrhoeae strain populations 
most likely to give rise to biological variants resistant to cephalosporin, and the rapidity 
with which they may emerge. To do this it is important to understand the genetic basis for 
such resistance and the biochemical mechanisms through which it is mediated. Studies 
on the prevalence of the penA mosaic allele in domestic gonococcal isolates will be 
conducted together with studies on the ability of any newly discovered gene variants that 
contribute to cephalosporin resistance to be transferred to additional strains of 
N.gonorrhoeae by DNA-mediated transformation. It is not clear whether or not known 
mutations in the TEM beta-lactamase gene that expand the substrate spectrum of the 
enzyme will confer significant levels of resistance in N. gonorrhoeae. It will also be 
important to determine if there exists a possibility for novel mutations in the bla gene that 
will confer cephalosporin resistance on beta-lactamase-producing N. gonorrhoeae and 
the frequency with which this can occur. The impact of known mutations introduced into 
the bla gene harbored by N. gonorrhoeae and by direct selection of cephalosporin 
resistance in PPNG strains with subsequent genetic analysis of the bla gene will be 
investigated. 
•	 2008 Update: Project planning initiated.
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PROJECT TITLE: DEFENSE THREAT REDUCTION AGENCY (DTRA) BIOTHREAT 
REDUCTION PROGRAM (BTRP)
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: DoD
•	 Description: The BTRP is a DTRA project to engage former soviet weapons scientists in 
public health activities and health related scientific research. The program concentrates 
on the states of the Former Soviet Union (FSU), especially the "stans". DTRA funds 
projects which develop collaborations between US scientists and FSU scientists to 
address critical questions about diseases caused specifically by biothreat agents but is 
expanding to other public health threats. 
•	 2008 Update: DTRA is funding the construction of a human and agriculture research 
institute in the Republic of Georgia. The plan is for the laboratory to become another DoD 
overseas facility with funding by GEIS, other DoD agencies and other US government 
agencies. The GEIS portion of the work will concentrate on disease surveillance including 
antimicrobial resistance. The Republic of Georgia lab is scheduled to be operational in 
2010.
PROJECT TITLE: DNA MICROARRAY PROFILING OF ANTIBIOTIC RESISTANCE GENES 
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Develop DNA microarray techniques and DNA chips for characterizing 
antibiotic resistance genes for multiple bacterial pathogens. 
2008 Update: Scientists from the Center for Food Safety and Applied Nutrition and the 
Center for Veterinary Medicine collaborated with researchers from the J. Craig Venter 
Institute in sequencing the genomes of 17 Salmonella serovars of public health 
importance. The strains chosen for genomic analysis were selected based on an
extensive examination of their potential to provide information needed for examining 
pathogenicity, transmission, origin, ecology, evolution, and dissemination of antimicrobial 
resistance. The DNA sequences were completed during 2008, and gene identification 
and labeling should be finished in FY 2009.
PROJECT TITLE: FATE AND DEGRADATION OF ANTIMICROBIALS, OXYTETRACYCLINE 
(OTC) AND SULFADIMETHOXINE-ORMETOPRIM (ROMET 30) FROM AQUACULTURE 
ENVIRONMENTAL SAMPLES
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: FDA 
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•	 Description: Isolate and characterize antimicrobial resistant bacteria from aquaculture 
and aquaculture products. 
•	 2008 Update: Sixty-three tetracycline-resistant E coli strains were isolated from the 
intestinal contents of 407 farm-raised catfish. PCR protocols were designed to amplify the 
various tetracycline resistant genes (tet) from the template DNA and tetB was determined 
to be the predominant gene. Sequence analysis of identified integrons demonstrated 
different gene cassettes conferring resistance to aminoglycosides and potentiated 
sulfonamides. 
PROJECT TITLE: DEVELOPMENT OF MICROARRAY CHIP FOR THE DETECTION OF 
ANTIBIOTIC RESISTANCE MARKERS
•	 Action Item(s):  #67 
•	 Project Type: New
•	 Agency: FDA 
•	 Description:  Develop a microarray chip for rapid characterization of antimicrobial
resistance genes present among foodborne bacteria.
•	 2008 Update: The Tn1546 transposon regions from seventeen vancomycin-resistant 
Enterococcus faecium isolates of human clinical origin were analyzed by PCR fragment 
length polymorphism, PFGE and sequence analysis. Several isolates were shown to 
have new arrangements of Tn1546 structural genes. Research is currently underway to 
determine potential associations of gene arrangements with decreased susceptibility of 
antimicrobials of human health significance.
PROJECT TITLE:  MOLECULAR CHARACTERIZATION OF SALMONELLA AND VIBRIO spp. 
ISOLATED FROM SEAFOOD 
•	 Action Item(s):  #67 
•	 Project Type: New
•	 Agency: FDA 
•	 Description: Characterize antimicrobial resistance Salmonella recovered from imported 
seafood.
•	 2008 Update: Fifty multiple antibiotic resistant strains of Salmonella spp. were isolated
from imported seafood. Multidrug resistance was observed among several serovars 
including S. Newport, S. Typhimurium and S. Lansing. Resistance was associated with
the presence of integrons containing gene cassettes conferring resistance to 
aminoglycosides and potentiated sulfonamides. 
PROJECT TITLE: SMALL BUSINESS INNOVATION RESEARCH AND TECHNOLOGY 
TRANSFER RESEARCH PROGRAM (SBIR/STTR)
•	 Action Item(s): #67 
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•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The SBIR/STTR program is an omnibus solicitation established under 
federal law that seeks to use small business to stimulate technological innovation, 
increase the participation of small business in federal R&D, and to increase private sector 
commercialization of technology development through Federal R&D. The annual set-
aside for agencies with extramural research budgets over $100M is 2.5%.   
•	 2008 Update: In 2008, NIH funded more than 1,800 research grants to small business, 
including a number that focused on antimicrobial resistance mechanisms and the 
development of novel vaccines, diagnostics and antimicrobial drugs for resistant 
pathogens. Examples of 2008 SBIR/STTR awards include: (1) Oral Prodrugs of 
Carbacephem Antibiotics Active Against Antibiotic-Resistant Bacteria, (2) Detection of 
Antibiotic Resistance Genes in Bacterial Agents of Hospital-Acquired Infections and (3) 
Rapid Affordable TB Drug Susceptibility Testing.      
PROJECT TITLE: RESEARCH, CONDITION, AND DISEASE CATEGORIZATION (RCDC) 
SYSTEM 
•	 Action Item(s): #67 
•	 Project Type: New
•	 Agency: NIH 
•	 Description: Recently, NIH has implemented a new computerized reporting process 
called Research, Condition, and Disease Categorization (RCDC), which all NIH institutes 
must now use to categorize and report funding in 215 research, condition, and disease 
categories, including antimicrobial resistance.  The NIH RePORTER
<http://projectreporter.nih.gov/reporter.cfm> (Research Portfolio Online Reporting Tool) is
a new web query tool within the RCDC system that allows the public to drill deeper into 
each RCDC category. RePORTER provides links to abstracts and other project-level 
data such as histories and start/end dates. It also features links to publications and 
patents associated with the research. The RCDC System can be accessed at the 
following link: http://www.report.nih.gov/rcdc/categories/. 
•	 2008 Update: Ongoing.
PROJECT TITLE: INVESTIGATOR-INITIATED RESEARCH GRANTS (R01) 
•	 Action item(s): #67 
•	 Project Type: New
•	 Agency: NIH
•	 Description: The Research Project Grant (R01) is the oldest and most frequently utilized 
NIH grant mechanism. The R01 provides support for health-related research and
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development based on the mission of the NIH. R01s can be investigator-initiated or can 
be in response to a program announcement or request for application.  R01 awards 
comprise the the largest overall NIH program, both in terms of number of awards and 
budget amount. 
•	 2008 Update: In 2008 NIH/NIAID awarded hundreds of R01 projects focused on
antimicrobial resistance mechanisms and the early development of vaccines, diagnostics 
and antimicrobial drugs for a broad range of resistant pathogens. Example of 
investigator-initiated R01 grants awarded in 2008 include: (1) Candida glabrata Pdr1: 
Master Regulator of Azole Resistance, (2) Design and mechanistic studies of mimics of 
antimicrobial peptides and (3) Design of New Antimicrobials. 
PROJECT TITLE: NIAID PRODUCT DEVELOPMENT PUBLIC/PRIVATE PARTNERSHIPS 
(RFA AI-06-033)
•	 Action item(s): #67 
•	 Project Type: New
•	 Agency: NIH
•	 Description: This Request for Applications calls attention to the vital role played by 
Public-Private Partnerships (PDPPP’s) in developing new products directed against the 
neglected tropical diseases.   
•	 2008 Update: Under this RFA, 4 new awards (U01) were made in 2007, two of which 
focus on antimalarial drug discovery and development, one of which focuses on new drug 
development for leishmaniasis, and one of which focuses on diseases caused by
trypanosomes. Support for these awards continued in 2008. 
COOPERATIVE RESEARCH PARTNERSHIPS FOR BIODEFENSE  
•	 Action Item(s): #67 
•	 Project Type: ongoing
•	 Agency: NIH 
•	 Description:  The purpose of this cooperative agreement program is to support 
discovery/design and development of vaccines, therapeutics, adjuvants and diagnostics for 
NIAID Category A, B and C priority pathogens and toxins. NIAID issues this RFA annually.  
Importantly, resistant pathogens are considered NIAID Catergory C pathogens and are 
therefore eligible for study under this initiative.  
•	 2008 Update:  In 2008, NIAID supported several awards with relevance to Antimicrobial 
Resistance, including: (1) Chemotherapeutics Against Multi-Drug Resistant Tuberculosis, (2) 
Response therapies for MDR-TB, and (3) Integrated Antimicrobial Drug Discovery Scheme for 
Multidrug Resistant Bacteria.
PROJECT TITLE: INVESTIGATOR-INITIATED SMALL RESEARCH GRANT AWARDS (R03) 
•	 Action Item(s): #67 and #72
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•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The R03 award supports small research projects that can be carried out in 
a short period of time, with limited resources. This is an important mechanism for 
attracting new investigators to a field of study and providing sufficient support to allow 
development of preliminary data that will enable successful long-term funding.
•	 2008 Update: Examples of awards made in FY2008 include: (1) Understanding a 
Mechanism of Antibiotic Resistance by Phosphorylation: Fosfomycin, (2) Biosynthesis of 
HSAF, an antifungal natural product with a novel mode of action and (3) Etiology, 
Epidemiology and Clinical Outcomes of Health Care Associated Pneumonia.
PROJECT TITLE: FOOD AND WATERBORNE DISEASES INTEGRATED RESEARCH 
NETWORK (FWDIRN)
•	 Action Item(s): #67, #70, #76, #77, and #78
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: NIAID's FWDIRN network includes multidisciplinary research on all food 
and waterborne pathogens (bacteria, viruses, and protozoa), as well as toxins, to 
facilitate the development and evaluation of products to rapidly identify, prevent, and treat 
food and waterborne diseases that threaten public health. The network includes 
Immunology (IRU), Microbiology (MRU), Zoonoses (ZRU) and Clinical (CRU) Research 
Units. The Network is supported by a Coordinating and Biostatistics Center.     
•	 2008 Update: Clinical activities within the FWDIRN in 2008 included: cell-mediated 
immunity studies from Salmonella typhi vaccine trials;  immunogenicity of tularemia live 
vaccine strain in humans; prime-boost study of the immunogenicity of Vi polysaccharide 
typhoid vaccine after priming by oral Vi+ S. typhi strain; phase I Study of the Safety and 
Immunogenicity of Recombinant Staphylococcal Enterotoxin B Vaccine (STEBVax) in 
Healthy Adults; evaluating the intestinal microbiome prior to and after dosing with an 
antibiotic, Ciprofloxacin; comparison of the efficacy and potential side-effects of several 
antibiotics in the treatment of Shiga toxin-producing Escherichia coli; and the 
development of small animal models that mimic human disease caused by 
Campylobacter and the life-threatening sequelae to infection by Shiga toxin-producing 
Escherichia coli, the hemolytic uremic syndrome (HUS). 
PROJECT TITLE: NIAID INTRAMURAL LABORATORY OF CLINICAL INFECTIOUS 
DISEASES, TUBERCULOSIS RESEARCH SECTION 
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: NIH 
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•	 Description: The Tuberculosis Research Section is an integrated group of chemists, 
clinicians, and microbiologists dedicated to improving the chemotherapy of tuberculosis. 
Projects in the section include evaluation and validation of drug targets, understanding
the mechanisms of resistance to specific drugs, and understanding the basic
mechanisms of pathogenesis at a molecular level. Research is also focused on 
understanding how current TB drugs work using the most modern technologies and using 
this information to develop new and improved therapies and therapeutic approaches.
•	 2008 Update: In 2008, section scientists reported on their determination of the mode of 
action of the candidate TB drug, PA-824. They found that PA-824 kills nonreplicating 
Mycobacterium tuberculosis by intracellular generation of nitric oxide (NO) and other 
reactive nitrogen species, which is the major cause of the anaerobic activity of these 
compounds. The scientists observed that NO generation during PA-824 metabolism is 
greatest when oxygen levels are low. This observation suggests how PA-824 may work 
against non-dividing M.tb. Science. 2008 Nov 28;322(5906):1392-5.  
PROJECT TITLE: NIAID INTRAMURAL LABORATORY OF CLINICAL INFECTIOUS 
DISEASES, CLINICAL MYCOLOGY SECTION 
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The Clinical Mycology Section conducts research to determine molecular 
mechanisms of azole resistance in clinical isolates of the pathogenic yeast, Candida 
glabrata. 
•	 2008 Update: In 2006, section scientists described a mechanism by which fluconazole 
resistance in Candida glabrata arises during therapy. In ten patients a single nucleotide 
mutation in the gene coding for the transcriptional regulator, CgPDR1, increased the 
transcription of two drug transporters and increased drug efflux so significantly that 
fluconazole susceptibility decreased at least four fold. Further study of this mechanism 
continues in 2008. 
PROJECT TITLE: NIAID INTRAMURAL LABORATORY OF HUMAN BACTERIAL 
PATHOGENESIS, PATHOGEN MOLECULAR GENETICS SECTION
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The Pathogen Molecular Genetics Section studies the pathogen-
polymorphonuclear neutrophil interface at both the cell and molecular levels to provide 
information critical to our understanding, treatment, and control of human diseases
caused by bacteria. The section's overarching goal is to develop and/or promote 
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development of enhanced diagnostics and better prophylaxis and therapeutics for 
pathogens such as community-associated methicillin-resistant S. aureus (CA-MRSA). 
•	 2008 Update: In 2008, section scientists continued to study the pathogenic role of  a 
bacterial toxin called PVL, epidemiologically linked to CA-MRSA outbreaks and the 
presumptive reason for its virulence (J Infect Dis 2008. 198:1166-1170; PLoS ONE 
2008.3:e3198). Also in 2008, section scientists reported results of a collaborative study 
showing that the USA300 group of CA-MRSA strains comprises nearly identical clones 
that have emerged from a single bacterial strain with extraordinary transmissibility (Proc 
Natl Acad Sci U S A. 2008 Jan 29;105(4):1327-32). They also reported new details about 
the complex mechanisms MRSA uses to avoid destruction by neutrophils.  
PROJECT TITLE: NIAID INTRAMURAL LABORATORY OF HUMAN BACTERIAL 
PATHOGENESIS, PATHOGEN-HOST CELL BIOLOGY SECTION 
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The Pathogen-Host Cell Biology Section studies the mechanisms of the 
formation of biofilms in chronic infections with staphylococci with a long-term objective to 
provide the scientific basis for the development of drugs interfering with these 
mechanisms. Such drugs would be useful in anti-staphylococcal therapy to both enable 
the immune system fight the infection and increase the efficiency of common antibiotics.  
•	 2008 Update: In 2008, section scientists compared the phylogeny and virulence of 
USA300 with that of closely related MRSA clones, discovering that the sublineage from 
which USA300 evolved is characterized by a phenotype of high virulence that is clearly 
distinct from other MRSA strains. 
PROJECT TITLE: NIAID INTRAMURAL LABORATORY OF MALARIA AND VECTOR 
RESEARCH, MALARIA GENETICS SECTION 
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: Section research addresses malaria drug resistance, antigenic variation, 
and disease virulence. Discoveries in these areas will support the development and 
evaluation of new diagnostic tools, antimalarial strategies, and candidate molecules for 
vaccines. Strains of malaria that are resistant to chloroquine have become a major 
problem and section scientists are seeking the exact resistance mechanism to support 
searches for new antimalarial compounds that can reverse or circumvent it. 
•	 2008 Update: Research is ongoing to characterize molecules that determine chloroquine 
and quinine responses in Plasmodium parasites; dissect structure-function relationships
of the P. falciparum chloroquine resistance transporter (CRT); and evaluate candidate 
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genes in a chromosome locus recently shown to affect the quinine response of P. 
falciparum. In 2008, section scientists reported on genome-wide compensatory changes 
accompanying chloroquine induced mutations in the CRT gene. Investigation of the 
genes involved is continuing (PLoS One. 2008 Jun 25;3(6):e2484). 
PROJECT TITLE: IMPACT OF DIET AND GUT MICROBIAL ECOLOGY ON FOODBORNE 
BACTERIAL PATHOGENS AND ANTIMICROBIAL RESISTANCE IN FARM ANIMALS
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: The project goal is to identify factors affecting persistence of antibiotic 
resistance genes and other genetic determinants among normal and pathogenic enteric
bacteria.   
•	 2008 Update: Demonstrated a collateral effect of a growth performance antibiotic widely 
used in the US, the quninoxaline antibiotic, carbadox. Sub-inhibitory carbadox 
concentrations in bacterial cultures induce both prophage-like Gene Transfer Agents 
carrying antimicrobial resistance genes and traditional prophages. Impact: This research 
provides important data on the use of sub-inhibitory concentrations of carbodox and its 
role in antimicrobial resistance induction. This study has also generated new knowledge 
about phage induction and may be useful for future interventions. We have found that low 
(sub-Mic) levels of the antimicrobial carbadox stimulate 100-fold increases in the in vitro 
transfer of natural resistance to the antibiotic tylosin.
PROJECT TITLE: SURVEILLANCE OF ANTIBIOTIC RESISTANCE IN NORMAL ENTERIC 
BACTERIA
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: The project goal is to determine tetracycline resistant genotypes, species 
identities, and resistance "baseline' levels of commensal bacteria in the swine intestinal 
tract. Current research aims to evaluate the transmissibility of resistance between 
Megaspaera elsdenii strains and other intestinal bacteria.   
•	 2008 Update: This was the first report of tetracycline gene class recombination. Studies 
showed that established M. elsdenii strains from swine that were never exposed to 
antimicrobials are multiply drug resistant, and that resistance genes can be transferred 
inter-strain at very high frequency. By genome sequencing, work demonstrated that 
resistance mobile elements in one M. elsdenii strain are identical to those in C. jejuni. 
Impact: These findings provide new knowledge implicating swine commensal bacteria not 
only as reservoirs of antimicrobial resistance for pathogens such as Campylobacter, but 
also as sites for the evolution of antimicrobial resistance. This research provides new 
directions for research in the role of commensals and antimicrobial resistance. We found 
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that Megasphaera elsdenii strains are multiply drug resistant.  Further, strains contain 
hybrid (recombinant) tetracycline resistant genes. Thus M. elsdenii is a potential site for 
evolution of antibiotic resistance as well as for the persistence of resistance in the swine 
intestinal tract.
PROJECT TITLE: TO ASSESS THE GENE VARIABILITY ASSOCIATED WITH RESISTANT 
VERSUS SUSCEPTIBLE STRAINS OF SALMONELLA, CAMPYLOBACTER, ENTERCOCCI
AND E. COLI
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: A microarray chip has been developed that can screen for almost 800 
resistance and virulence genes among the four bacterial species. Additional genes are 
being added for other bacteria. The microarray chip was also successfully tested on 
Listeria, another important food-borne pathogen. 
•	 2008 Update: Ongoing. Salmonella species resistant to multiple antibiotics frequently 
harbor plasmids or other mobile genetic elements that carry the resistance genes that 
can be spread to non-resistant bacteria. The DNA sequence of an 84.5-kb MR plasmid, 
pU302L, from S. Typhimurium U302, revealed 12 antibiotic resistance genes and 6 
genes involved in mercury resistance, as well as regions suggestive of multiple gene 
rearrangement events occurring during the evolution of the plasmid. Moreover, the DNA 
sequence of 4 small plasmids conferring antibiotic resistance in Salmonella strains were 
compared and were shown to be closely related to plasmids from E. coli and other 
pathogens that cause gastrointestinal illness. Impact: This sequence information was 
used to design probes for a microarray chip for typing and characterizing multi-resistance 
genes/plasmids. A DNA microarray to detect 100 resistance genes was successfully 
tested and has now been expanded to detect 775 resistance and virulence genes 
simultaneously.  
PROJECT TITLE: ASSESS THE EFFECTS OF TEMPERATURE ON THE SURVIVAL OF 
RESISTANT VERSUS SENSITIVE BACTERIA
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: A pan-susceptible and multiple-resistant strains were compared for their 
ability to survive following challenge of poultry exposed to various temperatures.
•	 2008 Update: Research has been conducted to look at the effect of temperature on 
various bacteria not only in animals, but also in culturing methods.
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PROJECT TITLE: DETERMINE THE EFFECT OF THREE FEED-BASED ANTIMICROBIALS
(APRAMYCIN, CARBADOX, AND TETRACYCLINE) ON THE DEVELOPMENT OF 
ANTIMICROBIAL RESISTANCE IN GENERIC E. COLI
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Study to determine the effect of three feed-based antimicrobials 
(apramycin, carbadox, and tetracycline) on the development of antimicrobial resistance in 
generic E. coli.
•	 2008 Update: Scientists determined the capability of a poultry feed additive, known as
flavophospholipol, to inhibit the spread of genetic information from one E. coli to another 
in living poultry. The studies used chicks inoculated with E. coli, and established that the 
additive did not prevent the bacteria from sharing genetic information. Impact: Although 
flavophospholipol demonstrated no useful biochemical actions, the work is important 
because it provides scientific data on feed additive interactions with poultry 
microorganisms. Ongoing work may be successful in identifying practical means to inhibit 
bacterial conjugation in animals and reduce the threat posed by the antibiotic resistance 
phenomenon. Resistance to tetracycline in E. coli varied widely by sample, group, and 
trial. However, a significant increase in the percentage of resistant isolates was observed
in piglets fed antimicrobials when compared to controls. Resistance to apramycin also 
increased in piglets when compared to controls. However, upon removal of apramycin, 
resistance in E. coli declined. Resistance to carbadox remained unchanged after feeding 
carbadox when compared to controls. Piglets fed low doses of antimicrobials 
demonstrated improved growth when compared to controls. These data are useful for 
veterinarians, pharmaceutical manufacturers, and scientists as they devise ways to limit 
the development of resistance to antimicrobials while maintaining animal health. 
PROJECT TITLE: CHARACTERIZE ANTIMICROBIAL RESISTANCE AND SPECIES OF 
CAMPYLOBACTER ISOLATED FROM DAIRY CATTLE 
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: In collaboration with scientists from USDA-APHIS-VS-CEAH, antimicrobial 
resistance was examined in Campylobacter isolates from US dairy cattle as part of a 
NAHMS study.
•	 2008 Update: Completed. Results indicate that a majority of the isolates were 
susceptible to the antimicrobials tested. Reporting of the results is ongoing in a variety of 
formats.
PROJECT TITLE: TO INCREASE RECOVERY OF CAMPYLOBACTER FROM VARIOUS 
SOURCES
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•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Because of the fastidious nature of Campylobacter, recovery from meat 
and other sources is difficult. We developed an enhanced method for recovering 
Campylobacter from chicken carcass rinsates by employing a centrifugation step of the 
rinsate prior to enrichment in culture media. This resulted in a >50% increase in the 
recovery of Campylobacter. This is significant in that previous methods were leading to 
the under-reporting of Campylobacter in samples. This work will be useful to scientists 
involved in Campylobacter research.
•	 2008 Update: Ongoing- Continual research on various Campylobacter sp. methods.
PROJECT TITLE: DETERMINE MOLECULAR GENETICS OF STREPTOGRAMIN 
RESISTANCE IN ENTEROCOCCI FROM ANIMALS
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: In this study, mechanisms of streptogramin resistance in enterococci from 
animals and the environment were investigated.  From 2000-2004, enterococci were 
isolated from poultry carcass rinsates, fruits, vegetables, retail meats, environmental 
rinsates, and from swine and cattle fecal samples collected on farms.   
•	 2008 Update: One Q/D resistance gene, vatD, which had not been found previously in 
enterococci from animals, was detected in three enterococcal isolates from the study.  
Two other Q/D resistance genes, vatB and vgaB, had never been previously reported in 
enterococci. To date, this is the first report of vatD from enterococci from animals in the 
U.S. and the first report of vatB and vgaB in enterococci. Ongoing in conjunction with 
NARMS. 
PROJECT TITLE: CHARACTERIZE AMINOGLYCOSIDE RESISTANCE AMONG 
ENTEROCOCCI ISOLATED FROM POULTRY 
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Aminoglycoside antimicrobials are of interest due to their use in both 
animals and humans.  
•	 2008 Update: In this study, resistance to aminoglycosides in enterococci from poultry 
samples was examined. High-level gentamicin, kanamycin, and streptomycin resistance 
was found in 23%, 41%, and 19% of the isolates, respectively. Of the ten aminoglycoside 
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resistance genes examined, five were identified in the isolates using PCR. Seven 
resistant E. faecalis isolates were negative for all genes tested suggesting that additional 
resistance genes may exist. Phylogenetic analysis revealed that the isolates were
genetically different with little clonality. Data from this study suggest that enterococci from 
poultry are diverse and contain potentially unidentified aminoglycoside resistance genes.  
This work will be useful to scientists involved in Enterococcus research as well as the 
industry as they develop and implement mitigation strategies. Ongoing in conjunction with 
NARMS.
PROJECT TITLE: TO CHARACTERIZE 3RD GENERATION CEPHALOSPORIN RESISTANT 
SALMONELLA FROM ANIMAL SOURCES   
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: We characterized the strains and resistance mechanisms of 3rd generation 
cephalosporin resistant Salmonella in the United States.
•	 2008 Update: Ongoing in conjunction with NARMS. CMY-2 is the most common 
mechanism of B-lactam resistance in salmonellae in the US. This is in contrast to Europe
where it is the Extended Spectrum Beta-Lactamase (ESBL). Isolates carrying the CMY-2 
gene are significantly more likely to multiple drug resistant, and that certain Salmonella 
serotypes were more likely to carry the resistance. Third generation cephalosporins are 
important antimicrobials used to treat severe infections in both humans and animals. The 
research resulted in a predictive diagnostic test for multiple drug resistant Salmonella.  
Turkeys, horses, cats and dogs are significantly more likely to have these isolates than 
cattle, swine, chicken and exotics. The multiple drug resistance identified was found to be 
encoded on a large transferable plasmid.
PROJECT TITLE: TO STUDY THE ABILITY OF RESISTANT STRAINS TO HAVE A 
COMPETITIVE PERSISTENCE ADVANTAGE
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Recently, Salmonella strains have arisen that are resistant to multiple 
antimicrobials including 3rd generation cephalosporins. The ability of those strains to be 
transmitted between hosts and under antimicrobial selective pressure is presently 
unknown.   
•	 2008 Update: Two Salmonella strains (one pan-susceptible and one resistant to 12 
antimicrobials used in the NARMS program) were compared by a natural transmission 
study in chickens in the presence of MIC levels of chlortetracycline (tet). The percentage 
of positive cloacal swabs from birds exposed to the resistant strain indicated that more 
birds were positive when tet treatment was administered. Conversely, cloacal swabs from
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the susceptible strain exposed birds indicated that more birds were positive in the
absence of tet treatment. The same results were observed for tissues at necropsy on 
D10. These results indicated that resistant strain did not have an increased 
transmissibility in the presence of tet and suggested that use of tet had a protective effect 
on tissue colonization. Ongoing as studies are being designed.  
PROJECT TITLE: ISOLATION AND CHARACTERIZATION OF METHICILLIN-RESISTANT 
STAPHYLOCOCCUS AUREUS (MRSA) FROM RETAIL PORK
•	 Action Item(s): #67 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: Retail pork products in the local Athens area are being collected and 
screened for MRSA. These isolates will be compared with human MRSA isolates
donated by a local hospital to determine if the MRSA from swine and retail pork products 
are genetically related to those from humans. The isolates from the various sources will 
be subjected to antimicrobial susceptibility testing and the antimicrobial resistance genes 
identified by PCR. Virulence genes from the isolates will also be identified using PCR, 
multi-locus sequence typing (MLST), and multiple variable number of tandem repeat 
(MLVA) analysis. Genetic comparisons will be accomplished using PFGE analysis.   
•	 2008 Update: Ongoing.
PROJECT TITLE: INTERACTION BETWEEN PROTOZOA AND RESISTANCE BACTERIA
AND ITS EFFECT ON ANTIMICROBIAL RESISTANCE 
•	 Action Item(s): #67
•	 Project Type: New
•	 Agency: USDA 
•	 Description: Protozoa in the environment are known to consume pathogenic bacteria 
and are believed to contribute to their survival and distribution. Understanding this 
relationship requires a method to locate and identify such protozoa. ARS scientists 
labeled a strain of disease-causing E. coli bacteria with a green fluorescent protein to 
identify and sort protozoa that ingest these bacteria. Application of this method to 
environmental samples should allow us to identify disease harboring protozoa and may 
aid in on-farm foodborne pathogen control. Research in FY 2008 is continuing in a 
broader scope to better understand the role of protozoa, pathogenic bacteria, and 
potentially antimicrobial resistance. For example, ARS scientists observed a rapid 
consumption of E. coli O157:H7 by protozoa in wastewater from dairy lagoons. These 
protozoa were characterized using 18S rRNA sequencing. An understanding of the 
biological and environmental factors responsible for the survival of E. coli O157:H7 will 
help in developing on-farm pathogen control strategies, and may help in the 
understanding of resistance persistence and transfer.
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•	 2008 Update: Salmonella spp. have a 44 gene integron structure, designated Salmonella
Genomic Island 1 (SGI1) that are multi-drug resistant. Research showed that SGI1 also 
promotes a hypervirulent phenotype of Salmonella residing in protozoa of the bovine 
rumen.  Furthermore, studies showed that Salmonella can acquire antibiotic resistance 
from co-existing bacteria in rumen protozoa. Elevated pathogenicity and acquisition of 
antibiotic resistance by multi-resistant Salmonella, such as DT104, are significant since 
DT104 is associated with increased cattle mortality and human morbidity. Impact: This 
research provides new knowledge about the potential interaction between antimicrobial 
resistance and virulence in Salmonella in cattle. These findings also begin to elucidate 
the role of protozoa in the increased pathogenicity of Salmonella and their potential role 
in antimicrobial resistance transference. Interventions focused on eliminating rumen 
protozoa may have an effect on Salmonella prevalence, virulence, and antimicrobial 
resistance.
PROJECT TITLE:  EVALUATION OF THE HYPOTHESIS THAT MYCOPLASMA HOMINIS 
INFECTION OF TRICHOMONADS CONTRIBUTES TO CLINICALLY RESISTANT 
TRICHOMONIASIS 
•	 Action Item(s): #67 
•	 Project Type: New
•	 Agency: CDC
•	 Description: A 2006 publication (Xiao, et al., Parasitol. Res. 100:123-130) suggested 
that when T. vaginalis parasites are infected by M. hominis, resistance to metronidazole 
and other nitroimidazole drugs is increased.  If true, this information provides both a 
potential marker and mechanism for combating antimicrobial resistant trichomoniasis.
•	 2008 Update: We did not find any evidence for increased prevalence of M. hominis in 
trichomonas isolates demonstrating clinical and/or in drug vitro resistance.  
ACTION ITEM #68 
PROJECT TITLE: DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEASES PROGRAM 
STAFF SERVE AS EXTERNAL CONSULTANTS OR LIAISON TO A VARIETY OF NATIONAL 
AND INTERNATIONAL TB-RELATED GROUPS
•	 Action Item(s): #68 
•	 Project Type: New
•	 Agency: NIH 
•	 Description: NIAID program staff members serve as external consultants or liaison to a 
variety of national and international TB-related groups. These collaborative activities 
inform NIAID’s strategic directions for the TB Program to assure maximum utilization of 
NIAID resources
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•	 2008 Update: NIAID staff engage with the following national groups: the US Federal TB 
task Force; the Advisory Council for the Elimination of Tuberculosis (ACET); CDC’s TB 
Clinical Trials Consortium and TB Epidemiologic Studies Consortium; the Infectious 
Disease Society of America and the American Thoracic Society. In addition, NIAID 
program staff are involved with these international groups: the STOP TB Vaccine
Partnership’ s Diagnostic, Vaccine, Drug Development and HIV/TB Working Groups; 
WHO/TDR; the International Union against Tuberculosis and Lung Disease (IUATLD); 
the Global Alliance for TB Drug Development (GATB);  the External Scientific Advisory 
Committee of the Medicines for Malaria Venture, a public-private partnership that fosters 
the accelerated development of new antimalarial compounds; the WHO Malaria Vaccine 
Advisory Committee; Aeras Global TB Vaccine Foundation; the Foundation for Innovative 
new Diagnostics; Lilly TB Drug Discovery Initiative; the Bill and Melinda Gates 
Foundation; the US-Indo Vaccine Action Program; and several European research 
consortia.
PROJECT TITLE: NIAID MDR/XDR TB RESEARCH AGENDA 
•	 Action Item(s): #68 
•	 Project Type: New
•	 Agency: NIH 
•	 Description: In early 2007, NIAID convened a special session of the National Allergy 
and Infectious Diseases Advisory Council to examine needs in tuberculosis research, 
especially for extensively resistant forms and in HIV-infected people. Invited were TB 
experts from academia, industry, public-private partnerships, international research 
organizations, and the public.  
•	 2008 Update: In June 2007, NIAID published the MDR/XDR TB Research Agenda at: 
http://www3.niaid.nih.gov/topics/tuberculosis/Research/PDF/MDRXDRTBResearchAgend 
a060607_tagged.pdf.
ACTION ITEM #69 
PROJECT TITLE: COMPREHENSIVE EXAMINATION OF THE ORGANIZATION AND 
FUNCTION OF THE NIH REVIEW PROCESS
•	 Action Item(s): #69 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The Infectious Diseases and Microbiology IRG review by the Expert 
Working Group was conducted from May – August 2001 and resulted in the development 
of a proposed set of guidelines and shared interests for new study sections.
•	 2008 Update: NIH's CSR established the Drug Discovery and Mechanisms of 
Antimicrobial Resistance (DDR) Study Section within the new Infectious Diseases and 
Microbiology Integrated Review Group (IRG). It reviews applications concerned with the 
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identification of novel antimicrobial agents, including agents that could be used in 
bioterrorism, with the prevention and treatment of infectious diseases; and with the study 
of the evolution, mechanisms, and transmission of resistance. DDR held its first meeting 
in June of 2004, and has met regularly thereafter. In FY2008, 245 applications were 
reviewed, of which 41 were awarded. 
ACTION ITEM #70 
PROJECT TITLE: COMPARATIVE HYBRIDIZATION OF C. DIFFICILE STRAINS FROM 
HUMAN AND ANIMAL HOST ORIGINS
•	 Action Item(s): #70 
•	 Project Type: New
•	 Agency: CDC, NIH 
•	 Description: NIH awarded development grants to Cornell University for creation of a C. 
difficile-specific microarray based on the two sequenced C. difficile genomes that are 
publicly available, and for the development of a C. difficile diagnostic array. CDC 
collaborated in development and testing of the microarrays by providing C. difficile strains 
of human and animal origin for genomic comparison, and by providing isolates of other 
Clostridium species for testing specificity of the diagnostic array.  
•	 2008 Update: Two microarrays were developed, one for investigation of C. difficile
genomics and one for C. difficile diagnosis.  Ref. J Bacteriol. 2009 Jun;191(12):3881-91. 
Epub 2009 Apr 17.
PROJECT TITLE: MICROBE PROJECT INTERAGENCY WORKING GROUP
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH, USDA, FDA, EPA, FDA 
•	 Description: The Microbe Project Interagency Working Group coordinates microbial 
genomics activities across Federal government agencies.  
•	 2008 Update: This working group continues to coordinate genomic activities across 
federal agencies, including those related to biodefense, and has also focused on issues
related to genomic data release and usage, as well as on bioinformatics and microbial 
sequencing efforts. 
PROJECT TITLE: THE TUBERCULOSIS RESEARCH MATERIALS AND VACCINE TESTING 
CONTRACT (COLORADO STATE UNIVERSITY)
•	 Action Item(s): #70 
•	 Project Type: Ongoing
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•	 Agency: NIH 
•	 Description: The contract provides TB research reagents to qualified investigators 
throughout the world, enabling them to work with consistent, high quality microbiological, 
immunological and genomic reagents, prepared from contagious and technically 
demanding mycobacterial pathogens.  
•	 2008 Update: This contract has significantly contributed to the selection of clinical 
vaccine candidates, several of which have recently entered human clinical trials and 
others of which are at various stages of preclinical development. In addition, research 
reagents from BSL3-grown mycobacteria, including specialized post-genomic materials, 
continue to be provided to researchers worldwide and are being used for drug, vaccine 
and diagnostic development. Contract staff collaborates with the Pathogen Functional 
Genomic Resource Center (PFGRC) for the production and dissemination of 
mycobacterial specific molecular reagents, with the NIH Tetramer Facility to provide 
mycobacterially relevant tetramers and with the Biodefense and Emerging Infections 
Research Resources Repository (BEI Resources) to broaden availability of research 
resources.
PROJECT TITLE: TUBERCULOSIS ANIMAL RESEARCH AND GENE EVALUATION TASK
FORCE (TARGET, JOHNS HOPKINS UNIVERSITY) 
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: This contract provides a selection of animal models that collectively 
reproduce the most critical features of human tuberculosis, as well as services to
evaluate M. tuberculosis and M. tuberculosis mutants in mice, guinea pigs, and hollow 
fibers. These models make it possible to assess mutant strains for virulence and the 
capacity to induce acute, latent, or progressive tuberculosis. Ultimately, they will facilitate 
the validation of novel drugs, vaccine and diagnostic targets. This contract also provides
transposon mutants either directly or through the tuberculosis research materials and 
vaccine testing contract (Colorado State University). 
•	 2008 Update: This contract continues to serve as a critical component in the process to 
validate putative therapeutic and preventive targets in TB in animal hosts. In addition, the 
contract continues to develop new models that probe the progression of natural infection 
and identify biochemical pathways that are most suitable for pharmaceutical intervention.  
PROJECT TITLE: NIAID PATHOGEN FUNCTIONAL GENOMICS RESOURCE CENTER 
(PFGRC)
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
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•	 Description: The PFGRC was established in FY2001 to provide and distribute to the 
broader research community a wide range of genomic and related resources and
technologies for the functional analysis of microbial pathogens and invertebrate vectors 
of infectious diseases. The PFGRC was expanded to provide the research community 
with the needed resources and reagents to conduct both basic and applied research on
microorganisms responsible for emerging and re-emerging infectious diseases and those 
considered agents of bioterrorism.  
•	 2008 Update: The number of organism-specific microarrays produced and distributed to 
the scientific community has increased to 33 in FY2008 and now includes arrays for 
viruses, bacteria, fungi, and parasites. The PFGRC has also developed the method and 
pipeline for generating organism-specific protein expression clones and has increased 
the throughput of the platform in 2008. Complete protein expression clone sets are now 
available for the following pathogens: Bacillus anthracis, Francisella tularensis, 
Helicobacter pylori, Human SARS coronavirus, Mycobacterium tuberculosis, 
Streptococcus pneumonia, Staphylococcus aureus, Vibrio cholera and Yersinia pestis. In 
addition, a clone set for Rickettsia prowazekii was generated in collaboration with one of 
NIAID’s Regional Centers of Excellence. Additional custom clone sets, which are made 
available upon request, have now been generated for more than 40 organisms, including 
human and avian influenza virus clone sets.   
PROJECT TITLE: SEQUENCING OF WHOLE PATHOGEN GENOMES 
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: NIAID has made significant investments in large-scale projects to sequence 
the genomes of medically significant bacterial, fungal, and parasitic pathogens. In 
addition, NIAID collaborates with other funding agencies to sequence larger genomes of 
protozoan pathogens such as the organism that causes malaria. A listing of currently 
active pathogen genome sequencing projects is available at: 
http://www.niaid.nih.gov/dmid/genomes/mscs/projects.htm 
The availability of microbial and human DNA sequences will open up new opportunities 
and allow scientists to examine functional analysis of genes and proteins in whole 
genomes and cells, as well as the host immune response and an individuals' genetic 
susceptibility to pathogens.
•	 2008 Update: In FY2008, NIAID supported large scale genome sequencing projects for 
approximately 40 different pathogens. New projects include additional strains of 
Influenza, Coronaviruses, Brucella (109 strains), E. coli (52 strains), West Nile Viruses 
(300 strains), Neisseria gonorrhorae (14 strains), Group A Streptococcus (81 strains), 
Staphylococcus aureus (57 strains), and filarial worms (3).
PROJECT TITLE: INFLUENZA GENOME SEQUENCING PROJECT
•	 Action Item(s): #70 
•	 Project Type: Ongoing
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•	 Agency: NIH 
•	 Description: This project puts influenza sequence data rapidly into the public domain, 
enabling scientists to further study how influenza viruses evolve, spread, and cause 
disease.  This project is a collaborative effort among NIAID, NCBI/NLM, CDC, St. Jude 
Children’s Research Hospital in Memphis and others, bringing together expertise in 
sequencing and bioinformatics, as well as expertise in human and avian influenza viruses 
to help NIAID prioritize, select and obtain strains.   
•	 2008 Update: As of June 15, 2009, 3717 human and avian isolates have been 





PROJECT TITLE: NIAID PATHOGEN GENOMICS WEBSITE
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The NIAID genomics website serves as a focal point to disseminate to the 
scientific community current information about NIAID’s microbial genomics research 
program and related activities, including information on funding opportunities, policies, 
application procedures, priorities for large-scale genome sequencing projects, press 
releases, and currently funded large-scale genome sequencing projects.
•	 2008 Update: Currently available to the scientific community: 
http://www3.niaid.nih.gov/topics/pathogenGenomics/.
PROJECT TITLE: NETWORK ON ANTIMICROBIAL RESISTANCE IN STAPHYLOCOCCUS 
AUREUS (NARSA) CONTRACT
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The network includes over two hundred domestic and international 
investigators made up of basic researchers, clinical laboratorians, epidemiologists, and 
infectious disease clinicians involved in staphylococcal and antimicrobial resistance 
research. NARSA supports sharing of information, bacterial strains and reagents, as well 
as an annual conference of NIH funded researchers. The 10th Annual NARSA 
Investigator’s Meeting was held on March 9 - 10, 2008 in Reston, Virginia.  The
repository has over two hundred strains of S. aureus including the first three identified 
VRSA isolates.  Additional information is available at www.narsa.net and 
http://www.niaid.nih.gov/dmid/antimicrob/
•	 2008 Update: In 2007, NIAID reissued a seven year contract, Network on Antimicrobial 
Resistance in Staphylococcus aureus (NARSA), to Eurofins Medinet, Inc. in Herndon, 
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VA. NARSA currently supports 425 registered users: 228 from academia, 128 from
industry, and 69 from government or other sectors. The repository houses 425 strains to 
date. 
PROJECT TITLE: POPULATION GENETICS ANALYSIS PROGRAM: IMMUNITY TO 
VACCINES/INFECTIONS
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The goal of this program is to identify associations between specific
immune response gene polymorphisms/genetic variations or polymorphisms in immune 
response genes and susceptibility to infection or response to vaccination with a focus on 
one or more of NIAID Category A-C pathogens and influenza.   
•	 2008 Update: Ongoing.
PROJECT TITLE: PROGRAM PROJECT GRANT “STRUCTURAL ORGANIZATION AND 
PROTEOMICS OF TB” 
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The goal of a global consortium, which involves over 70 laboratories in 12 
countries, was to determine and analyze the structures of over 400 functionally relevant 
Mtb proteins. Originally developed under a Center Grant, which ended in early FY 2006, 
consortium activities, as well as more scientifically targeted, collaborative programs for 
specific drug targets in Mycobacterium tuberculosis continue under a program project 
grant. 
•	 2008 Update: All data collated and produced by this consortium is publicly available 
online at www.webtb.org. Targeted studies of mycobacterial proteins relevant for drug
development are ongoing under this grant.  
PROJECT TITLE: STRUCTURAL GENOMICS OF PATHOGENIC PROTOZOA 
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The Structural Genomics of Pathogenic Protozoa project 
(http://depts.washington.edu/sgpp/) includes studies to derive the three dimensional 
structure of proteins deduced from the trypanosomatid and Plasmodium genomes. This 
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will be valuable information for future drug and vaccine discovery design, as well as for 
the discovery of new protein fold structures.  
•	 2008 Update: The overall goal of the project is to solve protein structures for diverse 
parasitic protozoa to aid in structure/function studies and drug design, emphasizing 
protein structures that differ significantly from the human enzyme while remaining 
conserved among parasitic protozoa. These studies are ongoing.   
PROJECT TITLE: NIAID MICROBIAL SEQUENCING CENTERS
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The Microbial Genome Sequencing Centers address NIAID’s need for 
sequencing of microorganism and invertebrate vectors of disease. The MGSCs provide 
rapid and cost efficient resources for production of high quality genome sequences of 
pathogens, including those considered agents of bioterrorism (NIAID category A-C 
priority list) and those responsible for emerging and re-emerging infectious diseases.  
Also eligible for sequencing at these centers are clinical isolates, non-pathogenic 
relatives of pathogenic organisms, and invertebrate vectors of disease. 
•	 2008 Update: These Centers are responding to the sequencing priorities of the scientific 
community and federal agencies. Filling in these sequence gaps facilitates basic 
understanding of microbes, forensic strain identification, and identification of targets for 
drugs, vaccines and diagnostics. See 
http://www.niaid.nih.gov/dmid/genomes/mscs/default.htm.
PROJECT TITLE: BIOINFORMATICS RESOURCE CENTERS
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: NIAID Bioinformatics Resource Centers are designed to develop, populate, 
and maintain comprehensive, relational databases to collect, store, display, annotate, 
query, and analyze genomic, functional genomic, structural and related data for 
microorganisms responsible for emerging and re-emerging infectious diseases and for 
those considered agents of bioterrorism. The center will also develop and provide
software tools.  
•	 2008 Update: Eight Centers were funded in FY04: 
http://www.niaid.nih.gov/dmid/genomes/brc/default.htm. In 2008, NIAID continued to 
support these centers. Ongoing activities include: development of publicly accessible 
BRC websites, improvement of public interfaces, and integration of a variety of genomic
data types, including gene expression, proteomics, host/pathogen interactions, and 
signaling/metabolic pathways data. Visit http://www.brc-central.org for additional 
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information. In FY2008, the National Microbial Pathogen Data Resource BRC (NMPDR 
http://www.nmpdr.org/) made available a computational server, RAST, which provides the 
scientific community with automated annotation of their bacterial genomes within 48 
hours of submission to NMPDR.
PROJECT TITLE: BIODEFENSE PROTEOMICS RESEARCH CENTERS
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: NIAID Proteomic Centers are intended to develop and enhance innovative 
proteomic technologies and methodologies and apply them to the understanding of the 
pathogen and/or host cell proteome for the discovery and identification of novel targets 
for the next generation of drugs, vaccines, diagnostics and immunotherapeutics against 
microorganisms considered agents of bioterrorism.
•	 2008 Update: Seven Centers were funded in 2004: 
http://www.niaid.nih.gov/dmid/genomes/prc/default.htm. In FY 2008 an additional 2 
SARS-CoV 3D protein structures were solved. As of FY2007 more than 7900 potential 
new pathogen targets and more than 11,700 potential host targets had been identified.  
During FY2008, more than 10,900 new potential pathogen targets and over 700 new 
potential host proteins were identified. In FY2009 24 protein interactions related to 
Salmonella pathogenesis were identified and several hundred human-pathogen 
interactions were identified for Bacillus anthracis, Francisella tularensis, Yersinia pestis 
and Vaccinia virus.
PROJECT TITLE: TUBERCULOSIS ANTIMICROBIAL ACQUISITION AND COORDINATING
FACILITY (TAACF)
•	 Action Item(s): #70 and #78
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: This contract was established to acquire compounds for screening against 
virulent Mtb, maintain a computerized chemical database of compound structures, 
coordinate and distribute compounds for evaluation in vitro and in an animal model, and 
report data to suppliers. The TAACF has contacted over 3,500 chemists throughout the 
world seeking candidate anti-TB compounds.    
•	 2008 Update: Over 87,235 compounds have been received from academic and private 
sector investigators, principally in the United States and Europe, with growing 
involvement of scientists from Africa, Asia, Australia, South America, and other 
geographic sites. The facility website is http://www.taacf.org/ where data and publications 
from this activity are posted. 
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PROJECT TITLE: HIGH-THROUGHPUT SCREENING CONTRACT WITH SOUTHERN
RESEARCH INSTITUTE
•	 Action Item(s): #70 and #78
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: This contract provides a high throughput screening capability to develop 
and implement biochemical, target-specific Mtb drug screening assays and to develop 
and implement Mtb metabolic stage-specific drug screening assays. 
•	 2008 Update: Selected molecular targets are being screened against large chemical 
libraries to identify new candidate antibiotics as potential additions to the combined 
regimen for treatment of tuberculosis, particularly to combat multidrug resistant strains. 
Assays have been developed and run for specific biochemical targets of active and 
persistent TB: inhA, DHFR, isocitrate lyase, pantothenate C, malate synthase, and Mtb 
growth inhibition. A diverse publicly available library of 100,000 compounds have recently 
completed screening against virulent M. tuberculosis. Data will be posted to the website 
for use by the research community. 
PROJECT TITLE: NIAID RESOURCES FOR RESEARCHERS 
•	 Action Item: #70, #78, and #80
•	 Project Type: New
•	 Agency: NIH 
•	 Description: NIAID provides a comprehensive set of services to facilitate efforts to 
develop the next generation of vaccines, diagnostics, and therapeutics. These services
make needed expertise as well as standardized, high-quality research materials and 
state-of-the art technologies available to eligible investigators worldwide. Provision of 
these pre-clinical and clinical services to drug development entities should stimulate the 
development of novel antimicrobial products by offsetting the risks inherent in 
antimicrobial development. 




PROJECT TITLE: NOVEL, ALL NATURAL CITRUS-BASED ANTIMICROBIALS FOR COST 
EFFECTIVE SALMONELLA REDUCTION DURING ORGANIC POULTRY PROCESSING 
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: USDA 
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•	 Description: Research to determine the in vitro activity (i.e.,MICs) of citrus oil fractions
for Salmonella spp., and to measure the effectiveness and economics of implementing 
this novel treatment in 2 process interventions.
•	 2008 Update: Ongoing research. Funded by CSREES, National Research Initiative 
(University of Arkansas). See CSREES website.
PROJECT TITLE: COMPARATIVE GENOMIC ANALYSIS OF SALMONELLA SEROTYPES 
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: A multi serotype Salmonella whole genome microarray has been obtained 
for this study. To determine the genetic elements responsible for these variations, 
Salmonella serotypes are analyzed by comparative genomic hybridization (CGH). 
•	 2008 Update: Research has revealed that bacterial stress in Salmonella induces 
mutations resulting in resistance to 5 different antibiotics. Studies were performed to 
evaluate the genetic expression patterns of a multiple antibiotic resistant isolate of 
Salmonella enterica derived during antibiotic exposure from a wild type strain. Many 
important genetic systems were modified in the mutant isolate compared to its parent 
strain. These included porins, lipopolysaccharides, efflux pumps, and global regulatory 
mechanisms. Impact: Elucidation of these genetic mechanisms that may contribute to 
antibiotic resistance will allow researchers to design and test better treatments, as well as 
determine alternative drugs or adjuvants, such as the efflux pump inhibitory chemicals. 
Comparative genomic hybridizations have been completed on 20 bovine associated 
Salmonella serotype Newport isolates and on 11 poultry associated serotype Kentucky 
isolates. Data analysis is proceeding.  
PROJECT TITLE: COMPARATIVE GENOMIC ANALYSIS OF CAMPYLOBACTER SUBTYPES
•	 Action Item(s): #70 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: To identify and trace Campylobacter isolates responsible for animal and 
human infections, a multi strain Campylobacter whole genome microarray has been 
obtained and is being used for comparative genomic hybridizations (CGH). 
•	 2008 Update: Ongoing. Genomic analysis has been done on several outbreak strains of 
Campylobacter spp and compared with animal samples. This has been in done with 
collaboration with Departments of Health and Agriculture. Additional analytic methods are 
being developed.
PROJECT TITLE: COMPARATIVE GENOMIC ANALYSIS OF LISTERIA SUBTYPES 
•	 Action Item(s): #70 
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•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: To identify and trace antimicrobial resistant Listeria monocytogenes from 
animals, food, and human sources, a Listeria whole genome microarray has been 
obtained and is being used for comparative genomic hybridizations (CGH).  
•	 2008 Update: Ongoing. Comparative genomic analysis has been done on Listeria
subtypes from foodborne outbreaks (animal, food, and human). Publication has occurred
and this data has been transferred to requesting agencies. 
ACTION ITEM #71 
PROJECT TITLE: COLLABORATION ON GENOMICS TECHNOLOGIES AND RESOURCES 
•	 Action Item(s): #71 
•	 Project Type: Ongoing
•	 Agency: NIH, DoD
•	 Description: NIAID continued its agreement with the Defense Advanced Research 
Project Agency (DARPA) in support of genomics efforts targeted at pathogens of 
potential bioterrorist threat.  
•	 2008 Update: Through this collaboration with DARPA large-scale genome sequencing 
projects for Brucella suis and Coxiella burneti have previously been completed.  In 2006 
sequenicng of a multi-drug resistant strain of plague from Madagascar was completed 
(see reference: Ravel et al., 2007, PLoS ONE, Issue 3:e309). In addition, DARPA 
provides funds for the Poxvirus Bioinformatics Resource Center
(http://www.poxvirus.org). This resource for the scientific community provides 
sequencing and functional comparisons of orthopox genes and the design and 
maintenance of a relational database to store, display, annotate, and query genome 
sequences, structural information, phenotypic data and bibliographic information.  It also 
serves as a repository of well-documented viral strains.
PROJECT TITLE: REAGENT DEVELOPMENT 
•	 Action Item(s): #71 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Facilitation of research through reagent development for the scientific 
community: Pertussis, H. influenzae, TB, influenza and S. pneumoniae. 
•	 2008 Update: WHO, Aeras Global Tuberculosis Foundation CBER collaboration - 
standard reagents for pre-clinical testing of new TB vaccines. Influenza reagents for live 
and inactivated influenza vaccine including products of reassortant influenza viruses with 
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high growth characteristics. Collaborative research with CDC and WHO supporting the 
development of vaccines against influenza virus, including the H5NI strain. Ongoing 
research project to develop nes pneumococcal reference serum.
ACTION ITEM #72 
PROJECT TITLE: RESEARCH SCHOLAR DEVELOPMENT AWARD (RSDA)(K22) 
•	 Action Item(s): #72 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The RSDA will provide support for postdoctoral fellows who are moving to 
assistant professor positions in an academic institution. The purpose of the RSDA is to 
ease the transition to an academic position by enabling the recipient to focus on the 
establishment of his/her research laboratory prior to submitting applications for grant 
support.  This is intended to establish new young investigators in needed fields, including
AR. 
•	 2008 Update: PAR 09-068 was released in December 2008 (see:
 
http://grants.nih.gov/grants/guide/pa-files/PAR-09-068.html).   

PROJECT TITLE: OTHER ONGOING TRAINING AND RESEARCH FELLOWSHIP AWARDS 
•	 Action Item(s): #72 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: NIAID continues to support young scientists and clinical investigators 
through National Research Service Awards and various types of career development 
awards, including: Mentored Research Scientist Award (K01), Independent Scientist 
Award (K02), Mentored Clinical Scientist Development Award (K08), Mentored Patient 
Oriented Research Career Development Award (K23), Mid-career Investigator Award in 
Patient Oriented Research (K24) and NIH Pathway to Independence Award (K99). 
•	 2008 Update: Examples of projects awarded in 2008 include: (1) Epidemiology of 
resistant bacteria in acute-care and long-term care facilities, (2) Social Networks and the 
Spread of Influenza and other Nosocomial Infections and (3) A longitudinal Study of CA­
MRSA Nasal Colonization in College Sports Participants.  
PROJECT TITLE: NIH EXPLORATORY/DEVELOPMENTAL RESEARCH GRANT AWARD 
(R21)
•	 Action Item(s): #72 
•	 Project Type: Ongoing
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•	 Agency: NIH 
•	 Description: The R21 is intended to encourage exploratory and developmental research 
projects by providing support for the early and conceptual stages of these projects.  This 
is an important mechanism for attracting new investigators to a field of study and 
providing sufficient support to allow development of preliminary data that will enable 
successful long-term funding. 
•	 2008 Update: In 2008 NIH awarded a number of R21 projects focused on antimicrobial 
resistance mechanisms and the early development of vaccines, diagnostics and 
antimicrobial drugs for a broad range of resistant pathogens.  Examples of R21 projects 
awarded in 2008 include: (1) Impact of Fluoroquinolone resistance on Pseudomonas
virulence and patient outcome, (2) Impact of ARV Chemoprophylaxis on Emergence and 
Spread of HIV Drug Resistance and (3) High throughput screening for anti-fungal drugs 
that inhibit mRNA polyadenylation. 
ACTION ITEM #73 
PROJECT TITLE: NIH SUPPORT FOR CONFERENCES AND SCIENTIFIC MEETINGS 
•	 Action Item(s): #73 
•	 Project Type: New
•	 Agency: NIH 
•	 Description: The purpose of the NIH Research Conference Grant Program (R13 and 
U13) is to support high quality conferences/scientific meetings that are relevant to the 
scientific mission of the NIH and to the public health. A conference/scientific meeting is 
defined as a gathering, symposium, seminar, scientific meeting, workshop or any other 
organized, formal meeting where persons assemble to coordinate, exchange, and 
disseminate information or to explore or clarify a defined subject, problem, or area of 
knowledge.  
•	 2008 Update: The following conference grants enabling scientific meetings on topics of 
relevance to antimicrobial resistance were awarded in 2008: (1) Pathogenesis and
Control of Emerging Infections and Drug Resistant Organisms, (2) Computer-Aided Drug 
Design and (3) International conference on Gram-Positive Pathogens.
PROJECT TITLE: ANTIBIOTIC RESISTANCE CONFERENCE
•	 Action Item(s): #73 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: USDA-CSREES and Ohio State University co-sponsored the conference on 
“Food Safety and Public Health Frontier: Minimizing Antibiotic Resistance Transmission 
through the Food Chain”, which brought together experts from academia, industry and 
federal agencies to provide a balanced and scientific review on antibiotic resistance.  
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Over 20 senior experts shared their most up-to-date discoveries and vision on antibiotic 
management through oral presentations, and over 80 attendees participated in the 
ensuing open discussion. A conference report detailing recommendations for future 
research on antibiotic resistance is under development. 
•	 2008 Update: Ongoing research. Funded by CSREES, National Integrated Food Safety 
Initiative (Ohio State University). See CSREES website. 
ACTION ITEM #74 
PROJECT TITLE:  PHARMACOLOGICAL APPROACHES TO COMBATING ANTIMICROBIAL 
RESISTANCE (R01) TARGETED INITIATIVE (RFA-AI-07-025) 
•	 Action Item:  # 74 and #67
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: This solicitation invited Research Project Grant (R01) applications from 
institutions/organizations proposing to apply pharmacokinetic and pharmacodynamic 
principles to studies on the prevention of emergence of antimicrobial drug resistance. 
This initiative is also intended to stimulate and strengthen collaborations between
antimicrobial pharmacologists and infectious disease researchers to provide a 
synergistic, integrated approach that will form the basis for future clinical management of 
antimicrobial drug resistance.
•	 2008 Update: Examples of awards made under this RFA include: (1) PK-PD of 
combination antituberculosis therapy for suppression of drug-resistance, (2) Resistance 
Suppression for Pseudomonas aeruginosa using Novel Combination Therapy Modeling 
and (3) Pharmacologic Approaches to Combating Resistance to Antimalarial 
Compounds.
PROJECT TITLE: PHARMACOKINETICS AND PHARMACODYNAMICS ANIMAL MODEL
CONTRACT
•	 Action Item(s): #74 and #70 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: This contract, awarded in June 2004, provides a resource to determine 
basic pharmacology and efficacy characteristics of new chemical entities in order to best 
evaluate candidate compounds as potential new drugs for tuberculosis and other 
infections. This contract will allow NIAID to provide critical support for investigator-
initiated drug discovery, to stimulate private sector sponsorship of new drugs, to perform 
comparison (or confirmatory) studies from different sponsors, and to provide information 
for selection of antimicrobial drug candidates for design of clinical studies. This contract 
will serve as the central facility for evaluation of novel compounds for physical, 
pharmacokinetic, and pharmacodynamic properties. 
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•	 2008 Update: Investigations of products from companies such as Sanofi-Aventis have 
led to renewed interest in research and development of rifapentine for tuberculosis.  
Pharmacokinetic evaluations of new drug combinations are planned to address regimens
for treatment of drug resistant TB. Of note, data on new drug combination regimens from 
this preclinical research contract has informed and guided the development of new 
protocols for clinical trials (TB Trials Consortium) coordinated by the CDC. Publications of 
improved drug combinations may serve as a model of regimens to shorten therapy, 
thereby reducing the potential of treatment interruptions leading to resistant TB. 
ACTION ITEM #75 
PROJECT TITLE: INVESTIGATION OF FLUOROQUINOLONE RESTRICTION FOR CONTROL 
OF CLOSTRIDIUM DIFFICILE IN A HOSPITAL SETTING 
•	 Action Item(s): #75 
•	 Project Type: New
•	 Agency: CDC
•	 Description: The emergence of the NAP1 epidemic strain of C. difficile appears to have 
been driven largely by fluoroquinolone overuse in healthcare settings. We investigated an 
outbreak in a healthcare setting that implemented a complete ban on all fluoroquinolone 
antibiotics in an attempt to control and outbreak in their hospital caused by the 
NAP1strain. All C. difficile toxin-positive stools from the time period before, during and 
after the outbreak were cultured for C. difficile, and isolates from each time period were 
characterized by PFGE, characterization of the pathogenicity locus, PCR for binary toxin, 
and antimicrobial susceptibility testing. 
•	 2008 Update: Organism recovery and isolate characterization completed. Patients 
infected with the NAP1 epidemic strain were more likely to have received a 
fluoroquinolone than those patients infected with other strains. Ref:  Infect Control Hosp 
Epidemiol. 2009 Mar;30(3):264-72.
PROJECT TITLE: DIVISION OF AIDS CLINICAL TRIALS   
•	 Action Item(s): #75 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: Numerous trials are underway related to prevention and treatment of HIV­
TB co-infected patients as well as monitoring for TB resistance: R. Chaisson, Johns 
Hopkins University, “Novel TB Prevention Regimens for HIV-Infected Adults” in South 
Africa. C. Whalen, Case Western Reserve, “Randomized, Phase II Study of Punctuated 
Antiretroviral Therapy for HIV Infected Patients with Active Pulmonary Tuberculosis and 
CD4 count > 350 cells/mm3.” Sok Thim, “A Cambodian Clinical Research Network for 
HIV/TB” (CIPRA). AIDS Clinical Trials Group (ACTG) 5221 "A strategy study of 
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immediate versus deferred initiation of ART for AIDS disease-free survival in HIV-infected 
persons treated for TB with CD4<250 cells/mm3".   
•	 2008 Update: These studies will help inform standard of care for optimizing treatment of 
HIV-TB co-infected individuals.    
PROJECT TITLE: TUBERCULOSIS RESEARCH UNIT (TBRU) 
•	 Action Item(s): #75 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The TBRU contract was recompeted in 2007 and awarded again to Case 
Western Reserve University. Development of surrogate markers of disease and human 
protective immunity will continue. In addition, activities under this contract will now focus 
more closely on preventive strategies for TB, to complement therapeutic approaches.   
Activities of the TBRU are coordinated with other major organizations involved in TB 
research, including the CDC, USAID, FDA, WHO, Aeras Global TB Vaccine Foundation 
and IUATLD. Study sites for the current TBRU are in Cape Town, South Africa and 
Kampala, Uganda. 
•	 2008 Update: Information about ongoing TBRU supported studies can be found at: 
http://www.tbresearchunit.org.  
PROJECT TITLE: BACTERIOLOGY AND MYCOLOGY STUDY GROUP (BAMSG) AND 
BACTERIOLOGY AND MYCOLOGY BIOSTATISTICAL AND OPERATIONS UNIT (BAMBU)
•	 Action Item(s): #75 
•	 Project Type: Completed 
•	 Agency: NIH 
•	 Description: The BAMSG and BAMBU support clinical trials against fungal and resistant 
bacterial infections. The BAMSG was awarded to the University of Alabama in 2001. A 
reserve fund to support orphan studies that cannot be funded through industrial sponsors 
is available through the BAMSG contract.  
•	 2008 Update: All studies have been completed. The results of the BAMSG study can be 
found in the following publication: Pappas PG et. al, Clinical Infectious Diseases 2009; 
48:1775–83.   
PROJECT TITLE: VACCINE AND TREATMENT EVALUATION UNITS (VTEUS)
•	 Action Item(s): #75 
•	 Project Type: Ongoing
•	 Agency: NIH 
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•	 Description: The VTEUs are a network of university research hospitals across the 
United States that conduct Phase I, II, and III clinical trials to test and evaluate vaccine 
and therapeutic candidates for infectious diseases. Through these sites, researchers can 
quickly carry out safety and efficacy studies of promising vaccines in children, adult, and 
specific high-risk populations. The results of these trials may have a profound effect on 
public health here and abroad. Through numerous studies at the VTEUs, researchers 
have tested and advanced vaccines for malaria, tuberculosis, pneumonia, cholera, and 
whooping cough. In the last 6 years alone, NIAID has supported more than 110 clinical 
trials through the VTEUs.
•	 2008 Update: “Phase I Studies of the Safety and Immunogenicity of Primary and
Secondary BCG Vaccination Delivered Intradermally, Orally, and by Combined Routes of 
Administration in Healthy and Previously Immunologically Naïve Volunteers” was initiated 
in 2008. Enrollment is underway.   
PROJECT TITLE: CLINICAL TRIALS AT MASAN NATIONAL TUBERCULOSIS HOSPITAL IN 
SOUTH KOREA 
•	 Action Item(s): #75 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: NIAID intramural researchers are collaborating with colleagues at Masan 
National Tuberculosis Hospital in South Korea to study drug-resistant TB, new therapies, 
and markers of hypoxia in lung tissue. As part of a consortium of scientists jointly funded 
by the Bill and Melinda Gates Foundation and the Wellcome trust under the Grand 
Challenges in Global Health Program, the researchers have also initiated a Phase II trial 
of metronidazole with an extensive investigation of surrogate drug efficacy endpoints in 
partnership with the Novartis Institute for Tropical Diseases in Singapore and scientists at 
the National University of Singapore. 
•	 2008 Update: A natural history clinical research protocol, initiated in 2006 at the Masan 
National Tuberculosis Hospital in South Korea, has enrolled more than 700 volunteers in 
an effort to understand factors that contribute to MDR-TB. In addition, this patient cohort 
has allowed an examination of the occurrence of XDR (eXtensively Drug Resistant) 
disease in patients who have failed chemotherapy completely. In 2008, the scientists 
described risk factors and treatment outcomes among 26 XDR-TB patients enrolled in the 
study (Clin Infect Dis. 2008 Jan 1; 46(1):42-9.). A trial of metronidazole therapy for 
pulmonary tuberculosis initiated in 2007 has enrolled nearly 30 volunteers.  IRB and US 
and Korean FDA approvals have been received for a new protocol “A Phase 2a, 
Randomized, Two Arm, Open-label, Clinical Trial of the Efficacy of Linezolid Combined 
with Antituberculous Therapy in Subjects with Extensively Drug-Resistant (XDR) 
Pulmonary Tuberculosis.” 
PROJECT TITLE: PREVENTION OF GROUP B STREPTOCOCCAL (GBS) DISEASE 
CONTRACT
•	 Action Item(s): #75 
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•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: NIAID continues to support research on the prevention of GBS disease 
through a five year multidisciplinary contract awarded late in 2002 to the Channing 
Laboratory, Brigham and Women’s Hospital. This collaborative multidisciplinary effort is 
focused on clinical studies in selected populations to further understand GBS infection 
and on studies of the host immune response.
•	 2008 Update A clinical trial to evaluate the impact of a GBS vaccine on GBS colonization 
has been completed and the final study report is under development. 
PROJECT TITLE: RANDOMIZED CLINICAL TRIAL EVALUATING EFFICACY OF 
GENTAMICIN/AZITHROMYCIN AND GEMIFLOXACIN/AZITHROMYCIN COMBINATION 
THERAPIES AS A SALVAGE REGIMEN FOR UNCOMPLICATED UROGENITAL 
GONORRHEA
•	 Action Item(s): #75 
•	 Project Type: Ongoing 
•	 Agency: CDC, NIH
•	 Description: A randomized clinical trial to determine the efficacy of each of two 
combination antimicrobial regimens for the treatment of uncomplicated gonococcal 
infection (Regimen A = gentamicin plus azithromycin, Regimen B = gemifloxacin plus 
azithromycin). For each regimen, 250 patients with cervical or urethral gonorrhea will be 
enrolled in participating STD clinics in 4 geographically diverse areas. Efficacy of each 
regimen will be assessed as the proportion of enrollees with a positive gonococcal culture 
at enrollment who are negative by culture at 12-18 days after treatment. 
•	 2008 Update: Protocol has been reviewed and approved by NIH Office of Clinical 
Research Affairs and Office of Regulatory Affairs, and is under review by the CDC and 
site institutional review boards. 
PROJECT TITLE: EMERGENCE OF HEPATITIS B VIRUS MUTANTS IN HIV AND HBV CO­
INFECTED WOMEN TREATED WITH LAMUVIDINE 
•	 Action Item(s): #75
•	 Project Type: New
•	 Agency: CDC, Ministry of Public Health, Thailand
•	 Description: Between 2005 and 2007, 217 HIV-infected women received GPOvir, 
containing zidovudine, 3TC and nevirapine (NVP), for 48 weeks to evaluate the impact of 
previous NVP exposure on clinical and virologic responses. From these patients, the 
prevalence and emergence of HBV mutations are being evaluated. 
•	 2008 Update: Baseline serologies completed. 
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PROJECT TITLE: CHARACTERIZATION OF CHANGES IN THE HBV GENOME CARRIED BY
PATIENTS WITH CHRONIC HEPATITIS B AND RECIPIENTS OF ORTHOTOPIC LIVER 
TRANSPLANTATIONS
•	 Action Item(s): #75
•	 Project Type: New
•	 Agency: CDC, University of Michigan Medical Center
•	 Description: Serum samples collected serially from patients enrolled in the NIH HBV 
Orthotropic Liver Transplantation Study (n=50) and from hepatitis B patients receiving 
antiviral treatment at the Liver Clinic, University of Michigan (n=50) are characterized to 
determine if they carry HBV with drug-resistant mutations in the reverse transcriptase 
region of the HBV polymerase. They are then sent to CDC for whole-genome 
characterization of HBV including that of HBV quasispecies constituents, and for studies
into changes in antibody affinity and secretion of HBsAg. 
•	 2008 Update: Baseline sequencing completed.
PROJECT TITLE: CLINICAL TRIAL FOR COMMUNITY-ACQUIRED METHICILLIN­
RESISTANT STAPHYLOCOCCUS AUREUS (CA-MRSA) INFECTIONS
•	 Action Item(s): #75 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: These studies are to define the optimal outpatient treatment with skin and 
soft tissue infection in areas where prevalence of CA-MRSA is high. The efficacy of off-
patent antimicrobials such as clindamycin and trimethoprim/sulfamethoxazole will be 
evaluated. 
•	 2008 Update: Two contracts were awarded in 2007: one to University of California San 
Francisco entitled “Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-
Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused
by Community-Associated Methicillin-Resistant Staphylococcus aureus” and one to Olive 
View University of California Los Angeles entitled “Strategies using Off-Patent antibiotics 
for Methicillin-Resistant Staphylococcus aureus” (“STOP MRSA”) – a multi-center, 
randomized, double-blind clinical trial. Enrollment for these studies began in 2008. 
PROJECT TITLE: A LONGITUDINAL STUDY OF CHLOROQUINE AS MONOTHERAPY OR IN 
COMBINATION WITH ARTESUNATE, AZITHROMYCIN OR ATOVAQUONE-PROGUANIL TO 
TREAT MALARIA IN CHILDREN IN BLANTYRE 
•	 Action Item(s): #75 
•	 Project Type: New
•	 Agency: NIH 
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•	 Description: NIAID is supporting a longitudinal study of chloroquine as monotherapy or 
in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria in 
children in Blantyre, Malawi.  These studies are needed to identify the pharmacokinetic
and pharmacodynamic properties of drug combinations that will deter resistance and 
prolong the useful therapeutic life of the next generation of antimalarial drug 
combinations.  
•	 2008 Update: The trial is ongoing; results expected in 2009.  
PROJECT TITLE: PHASE I CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST 
INFECTIOUS DISEASES (REQUEST FOR PROPOSALS RFP-NIH-NIAID-DMID-08-06) 
•	 Action Item(s): #75 
•	 Project Type: New
•	 Agency: NIH 
•	 Description: The purpose of this program is to provide a dedicated resource to assess 
the safety of investigational therapeutic products for a variety of infectious diseases. 
Using this resource, investigators may submit proposals for Phase I clinical trials to their 
scientific Program Officers.  
http://www3.niaid.nih.gov/LabsAndResources/resources/dmid/phasetherap/
•	 2008 Update: The solicitation for this program was issued in 2007. In 2008, contracts 
were awarded to DynPort Vaccine Company (with a clinical site at the Quintiles Phase I 
Unit in Overland Park, Kansas) or Clinical Research Management (with clinical sites at 
Johns Hopkins University in Baltimore and Case Western Reserve University in 
Cleveland, Ohio). The process of selecting clinical projects to be conducted at the study 
sites from the research community also began in 2008, and resulted in the launch of a 
Phase Ib study evaluating a promising new anti-TB drug, SQ109 in 2009.
PROJECT TITLE: TARGETED CLINICAL TRIALS TO REDUCE THE RISK OF ANIMICROBIAL 
RESISTANCE 
•	 Action Item(s): #75 
•	 Project Type: New
•	 Agency: NIH 
•	 Description: This Broad Agency Announcement (BAA-NIAID-DMID-NIHAI2008025)
targets infectious diseases where improved treatment strategies could reduce the risk of 
antimicrobial resistance and preserve the effectiveness of existing antimicrobials. A 
central goal of this solicitation is to target disease areas experiencing the greatest
antimicrobial selective pressure, and within these areas, develop strategies that test the 
safety and effectiveness of different therapeutic approaches/regimens that reduce the 
probability of the emergence of drug resistance by minimizing unnecessary drug 
exposure.
























Last revised: December 29, 2009 
•	 2008 Update: The solicitation for proposals under this BAA was released in April of 2008.  
Contracts will be awarded in 2009. 
PROJECT TITLE: AIDS CLINICAL TRIALS GROUP
•	 Action item(s): #75
•	 Project type: ongoing
•	 Agency: NIH
•	 Description: The ACTG was initially established in 1987 to broaden the scope of the 
AIDS research effort of the National Institute of Allergy and Infectious Diseases (NIAID). 
The ACTG established and supports the largest Network of expert clinical and 
translational investigators and therapeutic clinical trials units in the world, including sites 
in resource-limited countries. These investigators and units serve as the major resource 
for HIV/AIDS research, treatment, care, and training/education in their communities.
•	 2008 Update: Numerous clinical trials testing novel therapeutics and novel combination 
therapies, as well as their relationship to the emergence of resistant HIV strains, are 
ongoing.  For more information, visit www.aactg.org/.
PROJECT TITLE: VA RESEARCH UPDATE
•	 Action Item(s): #75 
•	 Project Type: Ongoing
•	 Agency: VA
•	 Description: Such topics as spread of resistance in nursing homes, the relationship of 
resistance to staffing levels, and work practices (organization) as they relate to antibiotic 
resistance are all part of VA investigators’ portfolios and are topics unlikely to be studied
in the private sector.  VA investigators continue to have an extensive and expanding 
portfolio in antimicrobial resistance research.
•	 2008 Update: Overall Medical Service research funding for projects associated with 
antimicrobial resistance increased 26% from FY 2005 to FY 2006, with both an increase 
in the number of funded projects and the number of sites receiving funding. For FY 2007 
the budget for accepted research projects is a 29% increase over the monies spent on 
directed-antimicrobial research from FY 2006; the depth and breadth of funded projects 
remains varied. For FY 2008, funding remained stable with a continued medical service 
research portfolio of breadth and depth. Proposed funding for FY 2009 also remains 
stable with a diverse portfolio of projects. 
ACTION ITEM #76 
PROJECT TITLE: DETECTION AND EPIDEMIOLOGY OF CARBAPENEMASE-PRODUCING 
GRAM-NEGATIVE BACTERIA
•	 Action Item(s): #76
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•	 Project Type: New
•	 Agency: CDC
•	 Description: Carbapenemase-producing gram-negative bacilli harbor a mobile broad-
spectrum β-lactamase, which constitute a serious treatment and infection control
concern. Studies were conducted at CDC to (1) evaluate current susceptibility testing 
methods for detection of carbapenemase-mediated resistance, (2) develop and evaluate 
novel methods for detection of carbapenemase-mediated resistance, and (3) describe the 
molecular epidemiology of the resistant isolates to understand mechanisms of 
transmission and to develop prevention strategies.
•	 2008 Update: (A) A study was conducted to evaluate commonly used antimicrobial 
susceptibility testing methods for detection of carbapenemase-mediated resistance. 
Many methods failed to detect resistance and strategies to overcome these limitations 
were recommended. These results were published in a clinical microbiology journal. (B) A 
multicenter evaluation of a phenotypic assay for detection of carbapenemase-mediated 
resistance was performed. This study was designed for placement of the phenotypic test 
in an international susceptibility testing guideline. (C) Studies were initiated to examine 
the molecular epidemiology of carbapenemase-producing Enterobacteriaceae. 
PROJECT TITLE: DETECTION AND EPIDEMIOLOGY OF EMERGING ANTIMICROBIAL 
RESISTANCE IN STAPHYLOCOCCUS AUREUS
•	 Action Item: #76
•	 Project Type: New
•	 Agency: CDC
•	 Description: To improve detection and prevention of emerging antimicrobial resistance 
in S. aureus, studies were conducted to (1) evaluate commonly used methods for 
detecting antimicrobial resistance, (2) develop and evaluate novel methods for detection 
of resistance, and (3) describe the molecular epidemiology of resistant isolates to 
develop effective prevention strategies.
•	 2008 Update: (A) A study was conducted to evaluate commonly used susceptibility 
testing methods for detection of vancomycin intermediate S. aureus. (B) Studies were 
initiated to validate a disk diffusion test to detect resistance to mupirocin, an antimicrobial 
agents used for nasal MRSA decolonization of patients. (C) A plasmid-associated with 
transfer of vancomycin resistance between Enterococcus and S. aureus was identified 
and a surveillance study was conducted to identify the prevalence and geographic 
distribution of Enterococcus with these plasmids. This information will be used to predict 
and prevent vancomycin resistance in S. aureus. (D) Surveillance isolates if USA300, the 
epidemic strain of MRSA which commonly causes community MRSA infection in the U.S. 
were examined for the presence of new or emerging antimicrobial resistance. An
epidemiological study was conducted to describe isolates and patients infected with 
these isolates. 
PROJECT TITLE: COMPARISON OF METHODS FOR STRAIN TYPING OF (METHICILLIN­
RESISTANT) STAPHYLOCOCCUS AUREUS
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•	 Action Item(s): #76 
•	 Project Type: New
•	 Agency: CDC
•	 Description: PFGE, the method used routinely at CDC to type isolates from healthcare­
associated infections, has significant limitations. Sequence-based typing methods, 
including spa typing and the T500 PCR-mass spectroscopy assay, will be evaluated for 
utility in investigating outbreaks and staphylococcal evolution, and for cost, ease of use, 
and reproducibility. Goals are to determine concordance of results obtained with different 
methods, and to establish a plan for transitioning MRSA strain typing to the most robust 
and reliable method.  
•	 2008 Update: Project planned, timeline established, earliest testing in progress.  
PROJECT TITLE: EVALUATION OF THE SPECTRACELL INSTRUMENT FOR STRAIN 
TYPING OF HEALTHCARE-ASSOCIATED PATHOGENS, MRSA AND ACINETOBACTER
BAUMANII
•	 Action Item(s): #76
•	 Project Type: New
•	 Agency: CDC
•	 Description: PFGE, the method used at CDC to type MRSA strains, has limitations for 
the strain typing of certain organisms, and is time-intensive and expensive to perform. 
The recently developed SpectraCell instrument uses RAMAN spectroscopy to directly 
assay intact bacterial cells, requiring approx. 1 min per isolate. Goals are to determine 
concordance of results obtained with different methods, and to establish a plan for 
transitioning strain typing to the most robust and reliable method. 
•	 2008 Update: Project planned, timeline established, MRSA testing started. 
PROJECT TITLE: ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) PRACTICES IN SIX 
STATES: RESULTS OF THE NATIONAL LABORATORY SYSTEM (NLS) ASSESSMENT 
•	 Action Item(s):  #76 
•	 Project Type: New
•	 Agency: CDC 
•	 Description: In collaboration with CDC, six states performed an initial assessment of 
AST practices. This effort was a part of the NLS cooperative agreement (CoAg) initiative 
to integrate clinical laboratories into public health testing. The CoAg partners, Wisconsin, 
Nebraska and Montana led the effort. Montana worked in collaboration with other states 
in the Northern Plains Consortium (North Dakota, South Dakota, and Wyoming). All 
laboratories performing AST in each state were asked to participate; the response rate 
was 76.5% (231/302). The assessment included information on demographics, methods 
used, practices, training, and knowledge of CLSI recommendations for AST practices.  
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Subsequently, the states conducted targeted training and offered resources for ongoing 
AST consultation.  
•	 2008 Update: The descriptive results reflected the demographics of the region: the 
majority of the participant laboratories were from non-profit hospitals having fewer than 
200 beds, although other lab- types were represented. The mean annual testing volume 
was 2528; median was 898. Only 62% of respondents obtained CLSI guidelines annually.  
Of nine practice- based questions, only 47.2% of the laboratories answered more than 
half of the questions correctly. The participants cited the need for more training and 
consultation with state public health laboratories.  As a result of this assessment, other 
NLS initiative activities, and the recognized need for stronger and ongoing interaction 
between clinical laboratories and public health laboratories, the states involved have 
established networks to provide ongoing collaboration and consultation on AST. Using 
the results of this assessment, the participating states have conducted targeted training
based upon the needs of laboratories within their state or network. A follow-up post-
intervention assessment is being conducted this year (2009), with plans to compare the 
results.   
PROJECT TITLE: NEW DIAGNOSTICS FOR HIV DRUG RESISTANCE SCREENING
•	 Action Item(s): #76
•	 Project Type: New 
•	 Agency: CDC
•	 Description: The CDC DHAP Laboratory continues to develop and assess methods with 
improved sensitivity and cost-efficiency for testing drug resistance markers in HIV. One 
goal is that these methods eventually could be used to augment national HIV drug
resistance surveillance to better estimate transmitted drug-resistant HIV. 
•	 2008 Update: A seminal Laboratory Branch paper on the prevalence and clinical impact 
of transmitted drug resistance at low levels was published in 2008 (Johnson et al., PLoS 
Medicine). As a result, as of 2008, two international public health laboratories (in London 
and Tokyo) have adopted the sensitive resistance tests, and other sites in Thailand and 
Africa have expressed an interest in acquiring the method. Development and evaluation 
of new tests for other mutations and subtypes continues.
PROJECT TITLE: PARTNERSHIPS TO IMPROVE DIAGNOSIS AND TREATMENT OF 
SELECTED DRUG-RESISTANT HEALTHCARE-ASSOCIATED INFECTIONS (RFA-AI-06-036) 
•	 Action Item(s): #76 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The purpose of the initiative is to support the development of rapid 
diagnostics capable of identifying specific bacterial strains and drug resistant phenotypes
and treatment for the following healthcare-associated pathogens: Clostridium difficile, 
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Pseudomonas, Acinectobacter, Klebsiella, Serratia, Proteus, Enterobacter and 

Stenotrophomonas. Four cooperative agreements (U01) were awarded in 2007.
 
•	 2008 Update: In 2008, NIAID continued to support the following projects: (1) Tailoring
Novel Therapeutics for Emerging Drug-Resistant C. Difficile Colitis, (2) Sensor 
Technology for Rapid Microbial Identification and Susceptibility Testing, (3) 
Resequencing microarray for rapid detection & antimicrobial resistance profiling and (4) 
Development of an antimicrobial peptide therapeutic for Pseudomonas infections. 
PROJECT TITLE: FACTORS AFFECTING MICROBIAL ECOLOGY OF PATHOGEN 
COLONIZATION AND AR ACQUISITION 
•	 Action Item(s): #76 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: An automated ribotyping system is being used at ARS to identify, 
characterize and monitor gut bacteria isolated by us and others; information obtained 
from this use is being maintained in the Gastrointestinal Microflora Ribotype Database 
(GMRD). Molecular typing methods (e.g. ribotyping, denaturing-gradient gel 
electrophoresis (DGGE), and DNA sequencing) are being used to distinguish bacterial 
strains inhabiting the gastrointestinal tract with even greater precision and to determine
genetic alterations occurring within these bacteria. This database is being used by
scientists worldwide to develop a more thorough understanding of the effects of sub-
therapeutic antibiotic administration and other stressors on the ecology of the gut 
microflora. 
•	 2008 Update: Ongoing. The database continues to be updated. 
PROJECT TITLE: DEVELOP A MULTIPLEX PCR METHOD FOR IDENTIFYING THE MOST
PREVALENT CLINICAL AND ANIMAL DERIVED SEROTYPES OF SALMONELLA
•	 Action Item(s): #76 
•	 Project Type: Ongoing
•	 Agency: USDA 
•	 Description: A new typing technique based on genomics is being developed that detects 
genes specific for Salmonella serotypes by multiplex PCR. 
•	 2008 Update: This assay can identify the top 31 serotypes isolated which represent 75% 
of all clinically isolated Salmonella. The technique has been adapted to a high-throughput 
platform by incorporation of capillary analysis of the multiplex PCR products, allowing the 
determination of up to 90 isolates in a day with very little hands on time. The technique 
requires little training, no specific anti-sera, and works in standard DNA sequencing 
instruments. This method continues to be modified and validated.
ACTION ITEM #77 
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PROJECT TITLE: VACCINE RESEARCH 
•	 Action Item(s): #77 and #81
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Research in support of the development and appropriate use of vaccines in 
humans to: 1) prevent viral infections, i.e. influenza, RSV; 2) prevent common bacterial 
infections i.e. S. pneumoniae, non-typable Haemophilus influenzae, group B 
streptococcus, N. gonorrhoeae, N. meningitidis. 3) Prevent bacterial infections caused 
by potential bioterror agents including Bacillus anthracis and Yersinia pestis.
•	 2008 Update: Fifteen ongoing research projects support development of vaccines for the 
organisms listed. 
PROJECT TITLE: STAPHYLOCOCCAL VACCINE GROUP
•	 Action Item(s):  #77 and #81
•	 Project Type: New
•	 Agency:  FDA 
•	 Description: Conduct research and provide guidance for the evaluation of multiple 
proposed vaccine candidates to advance the public health effort to develop effective 
vaccines to prevent staphylococcal disease.
•	 2008 Update:  Research program initiated involving several investigators with expertise 
in Gram-positive bacterial genetics, animal modeling of infectious diseases, protein 
chemistry, and assay design and development. Under this program investigators will 
generate purified, recombinant forms of S. aureus vaccine candidates, as well as develop 
immunoassays to investigate vaccine-induced immune responses. 
PROJECT TITLE: VACCINE RESEARCH - PNEUMOCOCCAL CONJUGATE VACCINE
•	 Action Item(s): #77 and #81
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Conduct research and provide guidance to support licensure of additional 
pneumococcal vaccines (various products under IND). Collaborative research project to 
develop pneumococcal reference sera. Provide expertise and guidance to facilitate 
development and licensure of new pneumococcal vaccines.
•	 2008 Update: Research regarding serologic assessment of response to vaccines
ongoing. Collection and testing of serum for new reference completed resulting in 15,333 
lyophylized 6 ml vials. Protocol for collaborative study to bridge new reference to existing 
reference under development. 
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PROJECT TITLE: VACCINE DEVELOPMENT - TB 

•	 Action Item(s): #77, #80, and #81
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Conduct research in support of the development of vaccines to prevent 
colonization, infection, and transmission of tuberculosis. Provide expertise and guidance 
to facilitate development and licensure of TB vaccines. 
•	 2008 Update: Current projects investigate the following vaccine candidates in mouse 
model of tuberculosis: novel recombinant BCG vaccines, combination DNA vaccines, 
multigene DNA constructs, attenuated live vaccines and subunit vaccines. These 
vaccines are also being tested using prime-boost strategies and post-exposure models.  
Collaborations include the Albert Einstein College of Medicine and the University of 
Maryland.  Participated in meetings and workshops to address clinical trial design and 
development plans (Geneva, Tanzania). 
PROJECT TITLE: MENINGITIS VACCINE PROJECT (MVP)
•	 Action Item(s): #77, #80, and #82
•	 Project Type: Ongoing
•	 Agency:  FDA 
•	 Description:  MVP is a combined WHO Program for Appropriate Technology in Health 
(PATH) project to develop affordable meningococcal conjugate vaccines for Africa. 
•	 2008 Update: CBER-PATH Cooperative Research and Development (CRADA) resulted 
in development of novel efficient conjugation technology and technology transfer to 
Serum Institute of India. Vaccine currently in phase 2-3 trials in Africa. Additional CBER 
research supporting immunologic assays to evaluate vaccine efficacy. This consortium of 
public, private, and non-profit organizations, and a philanthropic organization (the Gates 
Foundation) will develop a vaccine that is critically needed in Africa. 
PROJECT TITLE: DRUG THERAPY
•	 Action Item(s): #77 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Research: novel targets for drug therapy (to avoid resistance).
•	 2008 Update: Two ongoing projects that examine the mechanisms of development of 
HIV drug resistance.
PROJECT TITLE:  FACILITATION OF MALARIA VACCINE DEVELOPMENT 
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•	 Action Item(s): #77, #80, #81 and #82
•	 Project Type: New
•	 Agency: FDA 
•	 Description: Conduct research in support of the development of vaccines to prevent 
malaria. Provide expertise and guidance to facilitate development and licensure of 
malaria vaccines.
•	 2008 Update:  Research resulted in: development of a novel TB-malaria co-infection 
model, and identified potential bio-markers of cerebral malaria.  Participated in an
NIAID/Malaria Vaccine Initiative meeting on human challenge models.  Participation in 
the EC/EMVI/WHO EURHAVAC Workshop “Safety Harmonisation in Pre-Licensure 
Clinical Trials” Brussels October 2008.
PROJECT TITLE: BACTERIAL RESPIRATORY PATHOGEN RESEARCH UNIT (BRPRU) 
•	 Action Item(s): #77 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: This project supports bacterial pre-clinical and clinical studies for the 
diagnosis, prevention, and management of selected human bacterial respiratory 
pathogens.   
•	 2008 Update: The contractor is currently pursuing clinical studies to evaluate vaccines 
for non-typeable Haemophilus influenzae organisms using a human challenge model, as 
well as vaccines against Group B Streptococci in a phase I trial. Additional studies 
include the development of candidate vaccines against Pseudomonas and Moraxella. 
PROJECT TITLE: THE TUBERCULOSIS RESEARCH MATERIALS AND VACCINE TESTING 
CONTRACT (COLORADO STATE UNIVERSITY)
•	 Action Item(s): #77 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: The contract provides exploratory and preclinical evaluation of promising 
new TB vaccine candidates in state of the art animal models and as such continues to 
provide critical resources for the interface between fundamental and applied science.   
•	 2008 Update: This contract has significantly contributed to the selection of clinical 
vaccine candidates, several of which have recently entered human clinical trials and 
others of which are in various stages of preclinical development. In addition, research 
reagents from BSL3-grown mycobacteria, including specialized post-genomic materials, 
continue to be provided to researchers worldwide and are being used for drug, vaccine 
and diagnostic development. Contract staff collaborates with the Pathogen Functional 
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Genomic Resource Center (PFGRC) for the production and dissemination of 
mycobacterial specific molecular reagents, with the NIH Tetramer Facility to provide 
mycobacterially relevant tetramers and with the Biodefense and Emerging Infections 
Research Resources Repository (BEI Resources) to broaden availability of research 
resources.
PROJECT TITLE: PHASE I AND II MALARIA VACCINE TRIAL IN MALI
•	 Action Item(s): #77 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: NIAID, in collaboration with Walter Reed Army Institute of Research 
(WRAIR), GlaxoSmithKline Biologicals, U.S. Agency for International Development 
(USAID), the University of Maryland School of Medicine Center for Vaccine Development 
(Md/CVD), and the University of Bamako, Mali, completed two Phase I trials in Mali of 
novel candidate vaccines that target the blood-stage of malaria parasites. 
• 2008 Update: Final analysis of the trials will be completed in 2009.  
PROJECT TITLE: PHASE I MALARIA VACCINE TRIALS IN USA 
•	 Action Item(s): #77 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: Phase I Malaria vaccine trials in USA
•	 2008 Update: NIAID has undertaken two Phase I dosage-escalation trials of two novel 
candidate malaria vaccines at the Baylor College of Medicine, Vanderbilt University, and 
Stanford University. Enrollment is ongoing in the Vanderbilt and Stanford trials, and data 
from the Baylor trial are being analyzed.
ACTION ITEM #78 
PROJECT TITLE: TB TRIALS CONSORTIUM (TBTC) 
•	 Action Item(s): #78 and #75
•	 Project Type: Ongoing
•	 Agency: CDC 
•	 Description: The TBTC is an investigator-driven collaboration involving TB control 
programs, academic medical researchers, and CDC whose mission is to conduct 
programmatically relevant clinical research on TB control and prevention. TBTC designs 
and executes clinical trials of TB treatment and prevention at sites on 4 continents. Trials
are designed both to increase the effectiveness of current regimens and to identify new 
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agents. Collaboration with the commercial sector is common. TBTC trials have identified 
new regimens, clarified risk factors for development of drug resistance, and assessed 
regimens used to treat drug resistant TB.  Growing collaborations exist with the 
commercial sector, the not-for-profit private sector (GATB, MSF, TAG) and the public
sector (FDA, NIAID).   
•	 2008 Update: Study 30 - In 2008, in collaboration with investigators at the University of 
KwaZulu Natal in Durban, South Africa, we developed a protocol, manual of operations
and case report forms for TBTC Study 30 (A phase I/II pilot study for evaluation of low-
dose, once-daily linezolid plus optimized background therapy (OBT) versus placebo plus
OBT for the treatment of multi-drug resistant tuberculosis). We submitted an 
investigational new drug (IND) application to use linezolid in the treatment of resistant 
tuberculosis and received approval from the U.S. Food and Drug Administration (FDA).  
The protocol was also approved by CDC and local IRBs. Linezolid was donated by Pfizer 
Pharmaceuticals and a blinded placebo was created by Bilcare Pharmaceutical Services.  
The South African Medicines Control Council, a regulatory body similar to the U.S. FDA, 
required eight months to review and approve this protocol. This delayed the 
commencement of enrollment well into 2009. This study has now begun enrolling. It will 
include the evaluation of the potential development of resistance to tuberculosis during 
treatment and whether the mycobacterial isolate's baseline sensitivity to linezolid, as 
measured by the minimum inhibitory concentration, impacts the effectiveness of linezolid.     
PROJECT TITLE: SUBMISSION OF COMPOUNDS FOR IN VITRO EVALUATION 
•	 Action Item(s): #78 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: Staff has selected for evaluation more than 10,000 compounds, based on
their chemical structure, from the National Cancer Institute (NCI) chemical repository of 
over 500,000 compounds. Of these compounds, many have shown initial in vitro activity 
against a wild-type Mtb strain, and some have promising in vitro activity against isoniazid
(INH)-resistant strains.  A large part of this effort is conducted under an interagency 
agreement with the Health Resources and Services Administration at the National 
Hansen’s Disease Programs Center. 
•	 2008 Update: Efficacy evaluations in animal models of TB are being conducted on 
selected compounds. Novel chemical classes have been identified with in vitro activity 
against wild-type and drug-resistant strains. Follow-up of compound is continuing. 
FOCUS AREA IV: PRODUCT DEVELOPMENT 
ACTION ITEM #80 
PROJECT TITLE: EVOLUTION OF HIV DRUG RESISTANCE MUTATIONS IN ANIMAL 
MODELS
•	 Action Item(s): #80 
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•	 Project Type: Ongoing
•	 Agency: CDC
•	 Description: The DHAP Laboratory Branch focuses on the development of improved 
diagnostics for HIV drug resistance surveillance, laboratory investigations on the clinical 
implications of drug resistant HIV, and studies in monkey models of drug resistance 
emergence and evolution during chemoprophylaxis and microbicide interventions.  
Studies also address the development of improved diagnostics for HIV drug resistance 
surveillance.
•	 2008 Update: We have successfully generated and characterized SIV/HIV chimeric 
viruses that are resistant to the HIV reverse transcriptase inhibitors FTC and TDF 
(combined=Truvada). We are currently evaluating in macaques if the effectiveness of 
chemoprophylaxis and microbicide interventions may be compromised by drug-resistant 
viruses. We are also continuing to monitor for drug resistance in macaques infected 
during pre-exposure prophylaxis with Truvada as a measure of drug resistance risk for 
human trial failures. 
PROJECT TITLE: SUPPORT PARTNERSHIPS TO PROMOTE DEVELOPMENT OF PRIORITY 
AR PRODUCTS
•	 Action Item(s): #80 
•	 Project Type: Ongoing
•	 Agency: NIH 
•	 Description: NIAID brings together leading scientists to share capabilities and expertise 
in new drug discovery. 
•	 2008 Update: NIAID, Eli Lilly and Company, the Infectious Disease Research Institute, 
and others have begun a not-for-profit partnership announced in June 2007 to promote 
discovery of new TB drugs especially for resistant cases 
(www3.niaid.nih.gov/topics/tuberculosis/Research/lilly.htm/). 
ACTION ITEM #81 
PROJECT TITLE: EVALUATION OF RESOURCE-LIMITED COUNTRY-FRIENDLY SAMPLE 
COLLECTION
•	 Action Item(s): #81 
•	 Project Type: New
•	 Agency: CDC
•	 Description: To meet the needs of HIV DR surveillance and monitoring, the HIV DR 
laboratory in the International Laboratory Branch (ILB) has focused on evaluating sample 
collection devices that can be utilized in resource-limited countries. The laboratory 
developed a broadly sensitive in-house genotyping assay using dried blood spots (DBS).  
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•	 2008 Update: By applying this assay, the laboratory has assisted 5 PEPFAR countries to 
conduct HIV DR surveys. Survey results ensured policy maker and physicians that the 
scaling up of antiretroviral therapy in countries under PEPFAR has not caused the 
widely-spread development of HIV DR, as had been feared. By utilizing DBS for 
resistance testing, this method not only made HIV DR surveillance a reality in PEPFAR 
countries, it also reduced the cost by almost 50%.
ACTION ITEM #82 
PROJECT TITLE: CHALLENGES IN EVALUATION AND LICENSING OF NEW
PHEUMOCOCCAL VACCINES- WHO SPONOSRED WORKSHOP 
•	 Action Item(s): #82 
•	 Project Type: New
•	 Agency: FDA 
•	 Description: Develop consensus regarding standardized approaches for evaluation and 
licensure of new pneumococcal vaccines with added serotype coverage. 
•	 2008 Update: 2008 meeting in Ottawa and subsequent workshop in London UK with 
WHO and EMEA representatives to develop standards for immunologic evaluation of new 
pneumococcal vaccines.  Updates to the WHO recommendations published at 
http://www.who.int/biologicals/meetings/areas/vaccines/pneumococcal/en/index.html. 
Meeting report prepared for publication in Vaccine.
PROJECT TITLE: REGULATORY REQUIREMENTS – INDUSTRY AND SCIENTIFIC 
COMMUNITY 
•	 Action Item(s): #82 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Clarify FDA regulatory requirements to both industry and the scientific 
community. 
•	 2008 Update: 1) Presented regulatory requirements for AR tests at the Professional and 
IVD Industry Roundtable meetings twice yearly. Discussed obstacles/issues that might 
exist in technology transfer; 2) CDRH assisted device manufacturers in the most efficient 
way to get an alternative method for detecting vancomycin resistance in S. aureus to 
market; 3) preliminary stages of eSubmission for AST devices to promote a faster more 
efficient means of presenting data for a 510(k) review process; 4) 4/10/06 FDA published 
guidance document to ensure the safe & effective use of in vitro diagnostics for detecting
novel influenza A; 5) 2/3/06 FDA cleared new assay submitted by CDC for the detecting 
human infection with H5 Avaian Flu virus; 6) other approvals:10/18/06 MASTALEX­
MRSA rapid test for confirming Methicillin Resistant Staph aureus;12/12/06, Smart GBS 
Dx System rapid DNA test for detecting Group B strep in pregnant women; 2/14/07 
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ImmunoCard STAT EHEC rapid test for detecting Shiga toxins 1 & 2 produced by E.coli 
in stool to aid in the diagnosis of diseases caused by enterohemorrhagic E.coli (EHEC). 
PROJECT TITLE: GUIDANCE TO INDUSTRY:  ACUTE BACTERIAL OTITIS MEDIA - 
DEVELOPING ANTIMICROBIAL DRUGS FOR TREATMENT 
•	 Action Item(s): #82 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: This document provided guidance on the development of drugs for acute 
bacterial otitis media, a less serious, self-limited infection. Emphasis was placed on the 
importance of conducting meaningful clinical trials that adequately support approval.  
Overuse of antibiotics in infections such as these leads to the development of resistance.
•	 2008 Update: Draft guidance published 1/17/2008. 
PROJECT TITLE: PANDEMIC INFLUENZA VACCINE 
•	 Action Item(s): #82 
•	 Project Type: Ongoing
•	 Agency: FDA 
•	 Description: Regulatory and research activities to support development, licensure and 
rapid widespread availability of vaccines for pandemic influenza.
•	 2008 Update: Multiple INDs under review for vaccines against potential pandemic 
influenza virus strains H5N1, H7N3, and H9N2.  December 2008: CBER co-chaired and 
participated in a Public Workshop “Adjuvants and Adjuvanted Preventative and 
Theraputic Vaccines for Infectious Disease Indications.  September 2008: CBER ­
sponsored meeting “Rapid Methods for Detecting Mycoplasma Contamination in the 
Manufacture of Vaccines, Including Pandemic Influenza Vaccines and other Biological 
Products.  Vaccines and Related Products Advisory Committee meeting in February 
2009 to address pediatric clinical development of novel Pandemic Vaccines.  February 
2008 Vaccines and Related Biological Products Advisory Committee Pandemic and Pre-
Pandemic Clinical Development Issues
PROJECT TITLE: GUIDANCE TO INDUSTRY- UPDATING LABELING FOR SUSCEPTIBILITY 
TEST INFORMATION IN SYSTEMIC ANTIBACTERIAL DRUG PRODUCTS AND 
ANTIMICROBIAL SUSCEPTIBILITY TESTING DEVICES 
•	 Action Item(s): #82 
•	 Project Type: New
•	 Agency:  FDA 
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•	 Description: This document provides guidance to industry on how to periodically update 
susceptibility test interpretive criteria, susceptibility test methods, and quality control 
parameters in drug product labeling. Drug labeling that is updated in this regard is critical 
in encouraging appropriate use of antibacterial drug products.
•	 2008 Update:  Draft guidance published in June 2008. 
PROJECT TITLE: ACUTE BACTERIAL EXACERBATIONS OF CHRONIC BRONCHITIS IN 
PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: DEVELOPING 
ANTIMICROBIAL DRUGS FOR TREATMENT
•	 Action Item(s): #82 
•	 Project Type: New
•	 Agency: FDA 
•	 Description: This document provides guidance to industry on the development of drugs 
for the treatment of ABECB. Special emphasis is placed on clinical trial design. In 
particular, the need for informative trials that adequately differentiate the effect of the test 
drug vs. placebo. Such information will allow for one to weigh the benefits of therapies for 
this condition against the risks.
•	 2008 Update: Published in draft in August 2008.
PROJECT TITLE: ADVISORY COMMITTEE TO DISCUSS THE CLINICAL TRIAL DESIGN 
FOR DEVELOPING DRUGS FOR SKIN AND SKIN STRUCTURE INFECTIONS
•	 Action Item(s): #82 
•	 Project Type: New
•	 Agency: FDA 
•	 Description: This meeting focused on clinical trial designs for the development of drugs 
for skin infections.
•	 2008 Update: Meeting was held in November 2008. 
